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Thesis Abstract 
Section 1 describes a systematic literature review examining quantitative correlates of stigma 
in adults with epilepsy living in Western countries.  To identify relevant literature, four 
academic databases (PsycINFO, CINAHL, PubMed, and Scopus) were systematically 
searched using key terms related to stigma and epilepsy.  The findings of the review 
suggested that stigma can be predicted by demographic, illness-related, and psychosocial 
factors; although associations were found to be highly culturally-specific.  Detrimental effects 
of stigma included both physical health, including effective management of the condition, 
and psychological wellbeing, including difficulties such as depression and anxiety.  These 
findings suggested that culturally-informed educational initiatives and therapeutic 
interventions which aim to address stigma in people with epilepsy (PWE) are needed. 
Section 2 describes a research study examining the extent to which self-compassion can 
predict depression, anxiety, and resilience in PWE, when controlling for other important 
demographic and illness-related variables.  Adults with epilepsy were invited to take part in a 
survey either online or in epilepsy or neurology clinics.  Data were then analysed using 
hierarchical multiple regression models.  In this sample of PWE, self-compassion was found 
to significantly predict lower depression and anxiety and higher resilience when other 
significant sociodemographic and illness-related variables had been taken into account.  
These findings indicated that self-compassion is an important factor in determining 
psychological outcomes for PWE, providing preliminary support for the use of compassion-
focused approaches in this population. 
Section 3 provides a critical appraisal of the thesis.  This includes a summary of the main 
findings; a discussion of some of the key decisions, challenges, and professional issues 
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identified during the research process; a consideration of potential future research arising 
from the findings; and personal reflections on the process of undertaking the work.  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Highlights 
• The present study examined correlates of stigma in people with epilepsy (PWE) in Western 
populations 
• Thirty-three research papers reporting findings from 25 quantitative studies were identified 
• Stigma was found to be associated with demographic, illness-related, and psychosocial factors 
• Predictors of stigma were highly culturally-specific 
• Negative outcomes of stigma included poorer physical health and psychological wellbeing, 
including greater depression and anxiety 
Abstract 
Objectives 
The aim of this review was to identify quantitative correlates, predictors, and outcomes of stigma in 
adults with epilepsy living in Western countries.  
Methods 
To identify relevant literature, four academic databases (PsycINFO, CINAHL, PubMed, and 
Scopus) were systematically searched using key terms related to stigma and epilepsy.   
Results 
Thirty-three research papers reporting findings from 25 quantitative studies of correlates of stigma 
in epilepsy were identified.  The findings suggest that stigma can be predicted by demographic, 
illness-related, and psychosocial factors; although associations were found to be highly culturally-
specific.  Outcomes of stigma in people with epilepsy (PWE) were replicated more consistently 
across cultures and its impact was significant.  Detrimental effects included both physical health, 
including effective management of the condition, and psychological wellbeing, including 
difficulties such as depression and anxiety.   
Implications 
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Educational initiatives and therapeutic interventions which aim to address stigma in PWE are 
recommended; however, these need to be culturally-informed to ensure that they are valid and 
effective. 
Keywords 
Epilepsy; stigma; neurological conditions; chronic illness; mental health 
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1. Introduction 
1. 1 Stigma in chronic illness 
Stigma has been defined as a phenomenon in which a person is discredited or rejected by society 
because of a particular attribute, in a way that spoils their normal identity [1].  Within this seminal 
definition, stigma is described as constituting a gap between a person’s “virtual social identity”, 
assumptions about how an individual ought to be, and their “actual social identity”, the attributes an 
individual possesses in reality.  Such discrepancies can be precipitated by “external deformations” 
such as physical disabilities and diseases, “deviations in personal traits”, such as being unemployed 
or becoming addicted to drugs, and “tribal stigmas” based on, for example, ethnic group or 
nationality [1].  Various authors have since elaborated on, or provided alternatives to, Goffman’s 
work to produce definitions of stigma that incorporate a range of salient factors.  An influential 
definition by Jones et al. [2] developed Goffman’s description of the relationship between 
“attributes and stereotypes” by defining stigma as a “mark” (attribute) that links a person to 
undesirable characteristics (stereotype).  Crocker, Major, and Steele [3] similarly went on to 
describe stigma as the possession (or believed possession) of an attribute or characteristic that 
conveys a social identity that is devalued in a particular social context.  In a more recent review of 
stigma conceptualisation [4], Link and Phelan argue that significant variations in stigma definitions 
have been apparent due to the varied circumstances in which the concept applies and the various 
disciplines involved in its study (e.g. psychology, sociology, anthropology).  The authors of this 
paper go on to offer a more unified definition of stigma which derives elements from previous 
work, including Goffman and Jones, and incorporates novel elements including discrimination, 
stating that “stigma exists when elements of labelling, stereotyping, separating, status loss, and 
discrimination co-occur in a power situation that allows these processes to unfold” [4]. 
People with chronic illnesses or health conditions are often subjected to stigma that is enacted by 
others who do not have the condition through rejecting or discrediting behaviours, which can lead 
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to attempts at concealment [5-7].  Furthermore, even where stigma is not enacted externally, this 
may be “felt” internally [8].  A person’s beliefs about their own condition can help lead to a place of 
acceptance, or alternatively to self-stigmatising appraisals which affect self-esteem, self-efficacy, 
and coping; this has been studied most comprehensively in mental health populations [9-11].   
1.2 Epilepsy 
Epilepsy is a chronic neurological condition in which a person experiences recurrent episodes of 
abnormal electrical brain activity known as seizures [12].  Clinical manifestations of seizure activity 
are complex, depending on a wide range of underlying physical factors and affecting people with 
epilepsy (PWE) in a variety of ways; seizures can affect sensory, motor and autonomic function, 
consciousness, emotional state, memory, cognition, and behaviour [13].  Seizures can be broadly 
categorised as either “focal” (or partial), involving just one area of the brain, or “generalised”, 
involving all areas of the brain, with or without loss of consciousness [14], although different 
classification systems have been a matter of debate [15].  Seizures typically last a few seconds or 
minutes; some seizures involve convulsions, characterised by rhythmic jerking or shaking 
movements, whereas others can cause people to become unresponsive, vacant, or confused [16].  
The condition can be life-threatening and there is a risk of sudden unexplained death in epilepsy 
(SUDEP), where a person with the condition dies without warning and with no obvious medical 
cause [17].  Seizures can happen at any time, including when a person is asleep [18], and can lead 
to physical injury or death [19].  Whilst awareness of such risks has improved, these are not always 
communicated to people with the condition [20].  There can be a number of possible causes of 
seizures including genetic influence, head trauma, brain conditions such as strokes or tumours, 
infectious diseases, prenatal injury, and developmental disorders; although epilepsy has no 
identifiable cause in about half of those with the condition [21].   
Epilepsy affects millions of people globally.  In England, between 362,000 and 415,000 people are 
estimated to have epilepsy, although 5-30% may have an incorrect diagnosis and two-thirds of 
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people with active epilepsy have the condition controlled effectively with anti-epileptic drugs [22].  
In Europe, there are an estimated 2.5 million adults with active epilepsy, or 6-7 in every 1000 
people, with around 20-30% having more than one seizure per month [23].  In the United States 
(US), around 2.4 million adults are currently diagnosed with the condition [24]. 
1.3 Stigma in epilepsy 
Informed by the work of Goffmann [1], Scambler and Hopkins [25] described how stigma can 
manifest in PWE in their “Hidden Distress Model of Epilepsy”, which differentiated between “felt” 
and “enacted” stigma [26].  The model can be broadly operationalised into three areas: the sense of 
felt sigma that people experience when being confronted by a diagnosis and as a result feeling the 
need to conceal their illness; the impact of this concealment in relation to others being unaware of 
their epilepsy; and the disruption that this felt stigma can cause, which can be even greater than 
when stigma is enacted externally [27].  Examples of enacted stigma in relation to epilepsy include 
derogatory language being used to describe a person’s epilepsy or seizures, or a person being 
blamed for having epilepsy or seizures, or a person being avoided as a result of their condition.  In 
contrast, PWE may experience felt stigma if they feel embarrassed about their condition or 
associated physical limitations, or if they feel left out of social events when there is no objective 
evidence to support this belief.
1.4 Historical context of epilepsy-related stigma 
The cultural and epidemiological understanding of epilepsy, and therefore the stigma attached to it, 
has varied significantly over time.  Some of the earliest evidence of a medical understanding of the 
condition emerged in ancient Greece; in 400 BC Hippocrates described epilepsy as a disease of the 
brain and argued that it should be treated with drugs and diet, rather than magic [28].  However, 
early Christian beliefs reverted to biblical notions of PWE being possessed, and historical Islamic 
remedies included the use of amulets and stones [29].  Such stigmatising beliefs continued for 
several hundred years; in the 15th century seizures were widely viewed as a characteristic of 
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witchcraft and seen as infectious [30].  However, during the period of Enlightenment in the 18th 
and 19th century, the Hippocratic concept was resurrected, with preeminent figures of the time such 
as John Hughlings Jackson (1835-1911) describing seizures as medical phenomenon that can “alter 
consciousness, sensation, and behaviour” [31].  Despite advancements, in the 20th Century the 
condition was treated predominantly as a dangerous and infectious disease, and PWE were 
commonly held in asylums or confined to discrete epilepsy communities [32]. 
1.5 Present context of epilepsy-related stigma 
Public myths and misconceptions of epilepsy endure [33].  Misconceptions are often reinforced by 
the use of derogatory language and negative or erroneous media representations [34], and PWE 
continue to face social and legal barriers in the UK and other Western countries, underpinned by the 
longstanding stigma associated with the condition [35].  In the UK, it was illegal for PWE to marry 
until as late as 1970 [30].  To protect the rights of PWE in England, Scotland, and Wales, epilepsy 
has been included in the Equality Act [36], and in Northern Ireland in the Disability Discrimination 
Act [37].  However, despite legislative protections, PWE continue to be discriminated against in the 
UK, for example in regard to employment and driving [38]. 
Stigmatising negative attitudes towards epilepsy, underpinned by misconceptions of the condition 
and often enacted as discrimination, continue to impact on those living with the condition, although 
these have diminished over time [39,40].  This may be due in part to an increased understanding of 
the causes and nature of epilepsy and large-scale campaigns designed to raise awareness and 
understanding of epilepsy and to promote education and research.  Such campaigns include the 
Global Campaign Against Epilepsy [41] and the Collaborative Research on Epilepsy Stigma Project 
[42], designed to inform the development of culturally appropriate approaches to reducing stigma 
and discrimination of epilepsy in the developing world.   
A significant focus of these campaigns was on reducing stigma in developing countries, which 
reflects a cultural divide in terms of prevalence and strength of misconceptions of epilepsy 
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identified in research across Western and non-Western populations .  For example, a relatively 1
recent study of myths and misunderstandings about epilepsy in a rural community in Nigeria found 
that, of the people interviewed, only 12% attributed epilepsy to a brain disorder, with 81.4% 
attributing it to witchcraft, 49.8% to destiny, and 26.8% to demonic possession [43].  Similarly, in a 
survey of first-year medical students in Zambia, 80% said that they would not allow their children 
to marry someone with epilepsy; the majority viewed it as mental illness and some believed that 
PWE cannot have normal intelligence [44].  Such beliefs are commonplace in some cultures and are 
likely to be highly stigmatising to PWE in these communities. 
In contrast, whilst misperceptions and misunderstanding continues to exist in the West [45-47], a 
broader acceptance of medical causes of illness, alongside public awareness campaigns such as 
those introduced by the US Epilepsy Foundation in 2001 [48], mean that such extreme and 
stigmatising beliefs are unlikely to be reflected by the majority of the population compared to those 
identified in research from non-Western samples.  Despite this, misconceptions still exist in the 
West and research is needed to better understand stigma in this context [40].   
1.6 Existing reviews of stigma and epilepsy 
There has been significant interest in stigma, epilepsy, and factors relating to quality of life (QOL) 
in PWE over the last 15 years.  In 2002, Morrell completed a narrative review of stigma and 
epilepsy in the US and Europe; she concluded that PWE frequently have to cope with stigma and 
that this was likely to continue until perceptions of the illness improved [49].  In the same year, a 
review of stigma and QOL in PWE concluded that those with the condition unquestionably face 
difficulties as a result of stigma and that for some this can lead to high levels of distress [38].  A 
further review in 2008 explored the frequency and nature of stigma towards epilepsy [50]; here, 
stigma was found to be associated with incomplete seizure control and poor psychosocial outcomes; 
 Utilising definitions of “Western” and “non-Western” populations is pragmatic in research terms but flawed 1
in real terms as it relies on arbitrary geographical and cultural distinctions.  Further reference will be made to 
issues of cultural categorisation in the method and discussion sections. 
LITERATURE REVIEW 1- !9
the authors advocated further research to help understand the origins of stigma in epilepsy and how 
to decrease its impact.  An updated review of illness-related stigma, the stigma experiences of PWE, 
and the beliefs and attitudes of other target groups was also completed by Jacoby [51].  This 
narrative review, incorporating literature from countries across the world, highlighted the 
importance of sociodemographic characteristics on negative attitudes; the author suggested that 
more research is required to better understand the nature of this relationship.  Jacoby and colleagues 
have also discussed stigma and quality of life elsewhere [52].  More recently a systematic review 
was published synthesising the literature on misconceptions of epilepsy held by people without the 
condition in Western countries [40]; the authors concluded that misconceptions of the illness remain 
prevalent but that there is a limited literature on stigma reduction strategies in these settings.  
Despite the number of reviews exploring stigma, epilepsy, and QOL, these have typically provided 
narrative accounts of the available literature incorporating a range of research questions using 
mixed methods.  However, to date no focused systematic review of quantitative studies examining 
correlates of stigma in epilepsy has been published.  
1.7 Justification for a review 
In summary, epilepsy is a common neurological condition that can affect people in many different 
ways.  Whilst medical treatments for epilepsy have advanced, stigma around the condition has been 
shown to persist over time [53].  Perceptions of epilepsy may have improved in recent years, 
particularly in the West, as a result of health promotion campaigns.  However, despite an increased 
awareness of the causes and effects of epilepsy, misconceptions that underpin stigma of the 
condition have not been eradicated, even in the Western world [40].  Previous reviews have 
described the frequency and nature of stigma towards epilepsy, examined misconceptions within the 
general population, and discussed issues related to stigma and QOL.  However, in light of more 
recent public health initiatives which have aimed to shift social perceptions of the illness, an 
updated review is needed.   
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There are currently no systematic reviews that have explicitly examined the quantitative evidence of 
correlates of stigma in adults with epilepsy.  An up-to-date account of the research in this area using 
systematic review principles will shed light on the factors associated with this important 
relationship.  The review will add to existing research by identifying, synthesising, and appraising 
the available evidence of the current state of felt and enacted stigma experienced by adults with 
epilepsy.  Given the disparity between Western and developing countries in relation to research, 
health promotion, and education, the review will focus on research from Western countries.  
Specifically, the review will identify predictors and outcomes associated with stigma for adults in 
this population.  It is hoped that the findings will help to inform the future direction of interventions 
aimed at reducing the prevalence and impact of stigma in PWE. 
2. Methods 
2.1 Research aims 
The primary aim of this review was to identify quantitative correlations, predictors, and outcomes 
of stigma in adults with epilepsy.  A further aim of the review was to consider the implications of 
the findings and identify the need for further research. 
2.2 Inclusion and exclusion criteria  
As highlighted above, stigma in epilepsy is highly culturally-dependent [54].  Given the cultural 
sensitivity of the phenomenon, the focus of the review was limited to studies published in Western 
countries.  As in previous research [40], this was defined as research from countries in North and 
South America, Europe, and Australia.  Where countries could not easily be defined as either 
Eastern or Western, inclusion was considered on individual merit.  This was underpinned by 
existing research into epilepsy perceptions; for example, studies from Turkey - a country which 
straddles continental Europe and Asia - were included in the review, as research has shown that, 
whilst discrimination against PWE exists in the country, there is generally a good understanding of 
the condition amongst the general population [55].   
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In order to understand the current status of stigma and epilepsy, the focus of the review was also 
narrowed to include only studies published after the year 2000, to coincide with the development of 
educational campaigns (e.g. [41,42]).  The focus was also on correlates of stigma in adults; 
therefore studies looking at child and adolescent populations were excluded.  In order to gain an 
empirical measure of the nature of the predictors and outcomes associated with stigma and epilepsy, 
the search was narrowed to focus only on studies that included quantitative measures of stigma and 
epilepsy, therefore qualitative studies were excluded from the review.  The following inclusion and 
exclusion criteria were therefore developed to identify relevant published, peer-reviewed articles 
from database searches. 
2.2.1 Inclusion criteria 
• Studies that have quantitatively measured correlates of stigma in adults with epilepsy using (a) 
validated measure(s) of stigma 
• Studies focusing on adult populations (ages ≥ 16 years) 
• Studies published in Western countries (North America, South America, Europe, and Australia) 
• Studies published after 2000 
• Studies available in English 
2.2.2 Exclusion criteria 
• Studies using qualitative methods 
• Studies examining misconceptions of epilepsy or perceptions of epilepsy stigma in the general 
population 
• Studies including participants who have had seizures but do not have a diagnosis of epilepsy 
These search parameters were chosen to provide a homogenous sample that would allow a clear 
picture to be obtained in relation to the current state of stigma in adults with epilepsy in a culturally 
specific context.   
2.3 Description of systematic search process 
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In order to ensure that the search process was undertaken systematically, and to reduce the chance 
of missing relevant studies, an academic librarian was consulted to provide independent advice 
about the search strategy.  To achieve a comprehensive search of the literature, four databases were 
identified: PsycINFO, CINAHL, PubMed, and Scopus.  Search terms were developed to include the 
two main concepts under review: stigma and epilepsy.  Two key search terms were used: “epilepsy” 
and “stigma”.  Use of the truncation symbol in the context of “stigma*” to include suffixes such as 
“stigmatising” and “stigmatised” was discounted as it was felt that this would likely result in a more 
cumbersome search which would not yield additional relevant papers.  Keyword searches including 
the terms “stigma”, “social stigma”, “labelling”, “stereotyped attitudes”, “stereotyping”, combined 
with the term  “epilepsy”, were completed in databases where this functionality was available (e.g. 
Thesaurus in PsychINFO, CINAHL Headings, and Medical Subject Headings [MeSH] in PubMed).  
This was then combined with a free text search of the “abstract” or “title and abstract” fields to 
identify additional articles missed by index searches.  The articles identified across databases were 
entered into the referencing software, Endnote, and duplications were removed.  Articles were then 
filtered and excluded by title, abstract, or full-text according to their relevance to the research 
question, methodology, date and location of publication, and sample population.  Reference lists of 
included papers were also searched for additional relevant articles.  An overview of the search 
strategy, including the number of articles identified at each stage, is provided in Figure 1.  A 
detailed summary of the results of searches by database is provided in Appendix A. 
[Figure 1 here] 
Once all relevant articles had been identified, the findings were compared and contrasted using a 
narrative synthesis.  This approach was chosen as it allowed for a meaningful integration and 
discussion of the available evidence.  Due to the heterogeneity of research identified in the review, 
which included a variety of measures and analyses used for different purposes and in different 
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populations, which would make it difficult to meaningfully synthesise findings numerically, a meta-
analysis was not undertaken. 
2.4 Appraisal of methodological quality 
To assess the methodological quality of studies included in the review, a quality appraisal tool for 
observational studies adapted from the Agency for Healthcare Research and Quality was used [56].  
This comprised an eight-point checklist of key methodological considerations which researchers 
should take into account and report in studies of this type, including issues relating to sample 
selection, measures, data handling, and analysis.  Studies were rated on each item and assigned an 
overall score to indicate an appraisal of the methodological quality.  To ensure the reliability and 
validity of appraisal ratings, a sub-sample of six papers was chosen at random and peer inter-rated; 
discrepancies were minor and final ratings were agreed by consensus. 
3. Results 
3.1 Synthesis of reviewed studies 
An overview of the studies identified for inclusion in the review, including key elements of the 
design, sample, results, and authors’ conclusions, is provided in Table 1.  Correlation coefficients 
(Pearson’s r) are also presented in Table 1, where available, as an accessible and widely used 
measure of effect size [57]. 
[Table 1 here] 
3.2 Study characteristics 
Following the search procedure described above, 33 research papers were identified, reporting 
findings from 25 quantitative studies of stigma in epilepsy.  The total number of research 
participants across all of the studies included in the review was 16,942 adults with epilepsy.  An 
additional 238 adults without a diagnosis of epilepsy were recruited as controls.  Participant ages 
ranged from 16-98 years.  Research was identified from countries in North and South America, 
Europe, and Australia.  There were 12 papers from the US, five from Bulgaria, four from Turkey, 
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three from the UK, three from countries across Europe, two from Australia, one from the 
Netherlands, one from Croatia, one from Mexico, and one from Canada.  Of the studies identified, 
30 were cross-sectional in design and three incorporated longitudinal methods.  Two studies 
compared findings to controls without epilepsy.  Eight papers used only correlational analyses and 
25 included regression analyses. 
3.3 Measures 
The papers identified in the review used 10 different standardised measures of stigma.  Fifteen 
papers used the “Jacoby 3-Item Measure of Stigma” [8], which was the most widely used measure 
in the review.  Twelve papers used the “Modified Parent Stigma Scale”, also referred to as the 
“Epilepsy Stigma Scale (ESS)” [58].  Of the remaining studies, individual papers used the “Felt 
Stigma Scale” [59], the “Perception of Stigma of Epilepsy Scale (PSE)” [60], the “Revised Stigma 
Scale” [61], the “Stigma Scale” [62], the “Stigma Scale for People with Intellectual 
Impairment” [63], and stigma items derived from the “Child Asthma Scale” [64].  
3.4 Scope of the research 
The identified studies examined correlations, predictors, and outcomes of stigma in adults with 
epilepsy.  Statistical data regarding epilepsy epidemiology or stigma prevalence was not addressed 
in this review.  Similarly, descriptive accounts of stigma experiences in PWE, which are typically 
the domain of qualitative research designs, were also beyond the scope of the review.  Whilst the 
majority of research was cross-sectional in design, and therefore directionality of effect or causation 
could not determined, researchers typically framed their findings in relation to what they viewed as 
predictors or outcomes of stigma within the target population. 
3.5 Summary of quality appraisal 
Overall, the methodological quality of studies in the review was satisfactory, with a mean score of 
5.5 out of 8, although this ranged from 2.5 to 7 indicating variability of quality across studies.  Most 
studies provided clear descriptions of participant samples, including details of inclusion/exclusion 
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criteria and how participants were recruited.  Details of statistical analyses were generally provided 
and appropriate for the type of study.  Consideration of confounding data was also widely taken into 
account, with the majority of studies using regression analyses to adjust for demographic or clinical 
factors likely to be correlated with outcomes.  However, the appraisal revealed a number of 
common issues.  Power calculations as a means of determining and justifying sample size were 
reported in only two studies.  Validity of standardised measures was frequently referred to in 
relation to findings of previous studies; however reliability coefficients (e.g. Cronbach’s alpha) 
were rarely calculated for present studies, therefore validity and reliability could not be fully 
assumed [65].  Details of missing data and how these were handled by researchers was also rarely 
reported; again this limits confidence that data was obtained and presented in a way which 
minimises bias.  An overview of the outcomes of the methodological quality appraisal is provided 
in Table 2. 
[Table 2 here] 
3.6 Summary of main findings  
3.6.1 Demographic, illness, and psychosocial correlates and predictors of stigma 
Twenty studies examined correlations or predictors of stigma in PWE.  Findings could be broadly 
categorised according to demographic, illness-related, and psychosocial variables found to be 
correlated with, or to predict, stigma. 
3.6.1.1 Demographic variables 
 3.6.1.1.1 Socioeconomic factors 
Several socioeconomic factors were identified as important.  Yeni, Tulek, and Bebek identified a 
negative correlation between income and stigma [66].  Income was also found to predict lower 
stigma when other variables had been taken into account [67,68].  In a further regression study, 
Smith et al. found that people who were disabled or unemployed with greater seizure worry were 
more likely to report higher levels of stigma when adjusting for other variables (e.g. self-efficacy, 
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social support, and race) [69].  Yeni, Tulek, and Bebek also identified a negative correlation 
between education and stigma [66].  In correlational studies comparing patients from clinics in “low 
and high sociodemographic communities”, participants from low socioeconomic status 
backgrounds were found to report higher felt stigma [70,71]; although when psychosocial variables 
including QOL, depressive symptoms, and social support were entered into a regression model, 
these differences were found not to be significant [71].  These findings indicate that socioeconomic 
status may not in itself significantly affect stigma but that other related psychosocial variables may 
be of greater importance. 
3.6.1.1.2 Cultural factors 
The impact of cultural factors was also identified.  In a large-scale continental study examining the 
relationship between stigma and health system performance across 10 European countries, 
including a sample of over 5,000 PWE, Baker et al. found country of origin to significantly 
contribute to variance in reported levels of stigma in regression analyses [54].  For example, 
Spanish participants reported significantly lower levels of stigma than participants in France.  The 
authors suggested that cultural differences may be due to a range of factors, including sociocultural 
bias against epilepsy, cultural norms, the structure of the health system, and the existence of high 
profile public figures with the condition who may act as role models, although they suggested that 
more research is needed.  Brigo et al., reporting on the same data, identified a trend towards 
negative correlation between stigma and overall health system performance and health expenditure 
per capita; however, this association was non-significant [72]. 
3.6.1.1.3 Personal factors 
Personal factors were also identified as potentially contributing to variance in stigma.  When taking 
into account other clinical and demographic variables using regression analyses, Baker et al. 
identified that being married significantly predicted lower levels of stigma, alongside six other 
important illness-related and psychosocial variables [54].  Bautista, Shapovalov, & Shoraka 
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replicated this finding [67].  Younger age was also found to be correlated with higher stigma in 
some studies [67,73,74]; this was found to independently predict lower levels of reported stigma 
when other variables had been taken into account in regression analyses [61].  In contrast, however, 
several studies using regression analyses did not find age to significantly predict stigma 
[66,68,71,75,76].  Gender was also found to be uncorrelated with stigma [68,71,75,77].  It has been 
suggested that such findings may be due in part to overarching negative social attitudes, particularly 
in developing countries, which can cause other factors to “recede into the background” [77]. 
3.6.1.2 Illness-related variables 
3.6.1.2.1 Seizure type and severity 
Eidhin and McLeavey found seizure type and severity to correlate significantly with stigma [78], 
although significant flaws were identified in their methodology.  Baker also found seizure type 
(generalised seizures) to contribute to variance in stigma outcomes in regression analyses [79]; 
however, the authors of this paper stressed that the relevant contributions of these findings 
depended on the country of origin of those surveyed, highlighting the importance of cultural 
differences in determining the impact of illness-related variables on stigma.  In regression analyses, 
Baker et al. found epilepsy-related injuries to significantly contribute to scores of stigma but not 
seizure type [54].  Viteva found no correlation between stigma and seizure severity [77]. 
3.6.1.2.2 Seizure frequency 
Dilorio et al. found the number of seizures experienced during the past year to significantly predict 
stigma in regression analyses [68], and this was replicated in Croatian and UK studies using 
regression models which found number of seizures to date to significantly predict stigma [61,73].  
Yeni et al. also identified positive correlations between seizure frequency and stigma [80].  
Furthermore, Baker’s large-scale study in European countries found greater seizure frequency to be 
the most consistent cross-cultural predictor of higher levels of reported stigma in regression 
analyses [79].  However, these findings were partially in contrast to those of a large-scale study by 
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Baker et al., which found that whilst seizure frequency significantly correlated with measures of 
stigma, these variables did not predict significant variance in stigma when entered into a regression 
model alongside other variables [54].  Aydemir, Kaya, Yıldız, Öztura, and Baklan (2016) also found 
that number of seizures did not significantly predict stigma in regression analyses [75], and Viteva 
found no correlation at all between stigma and seizure frequency [77]. 
3.6.1.2.3 Epilepsy onset 
The age of epilepsy onset (i.e. longer duration of epilepsy) was found to significantly correlate with 
stigma [80] and to contribute to higher scores of stigma in several regression studies[54,68,79].  
However, cultural variations were again identified [54].  In another regression study, Smith et al. 
(2009) found that those with later seizure onset were more likely to report lower levels of stigma 
but only when they were experiencing a higher quality of care [69].  In contrast, Aydemir, Kaya, 
Yıldız, Öztura, and Baklan did not find duration of epilepsy to significantly predict stigma in 
regression analyses [75]. 
3.6.1.2.4 Epilepsy treatment 
Aydemir, Kaya, Yıldız, Öztura, and Baklan found that taking a greater number of epilepsy 
medications was correlated with increased stigma [75].  Yeni et al. also identified positive 
associations between the use of epilepsy medication and stigma [80].  However, in contrast, Viteva 
found no correlation between stigma and prescribed treatment [77].  Observed associations may be 
due in part to iatrogenic effects of treatments.  When taking into account other illness-related 
variables in regression analyses, adverse events and side effects relating to the use of anti-epileptic 
drugs were found to significantly predict stigma [61,81].  Aydemir, Özkara, Canbeyli, and Tekcan 
also examined the effects of epilepsy surgery by comparing participants who had already received 
surgery to those who were awaiting surgery using t-tests [82].  The authors found no significant 
differences in the pre- and post-surgery groups, which they argued might have been due to the long-
term effect of being labelled as “epileptic”, even if epilepsy has gone into remission.  It is also 
LITERATURE REVIEW 1- !19
possible that for some people stigma related to refractory epilepsy (e.g. seizures) was replaced by 
stigma related to surgery (e.g. visible scarring), although this was not included in analyses. 
3.6.1.3 Psychosocial variables 
3.6.1.3.1 Psychological factors 
Psychological and emotional factors which were found to predict higher levels of reported stigma in 
regression analyses included feelings about life and perceived impact of epilepsy [54], lower self-
efficacy [68,69], lower patient satisfaction [68], feeling more socially restricted, and poor overall 
global QOL [61].  Social anxiety was also found to predict stigma in regression analyses, over and 
above depression and other types of anxiety [76].  Cognitive factors which were found to predict 
stigma variance in regression models included concerns related to social life and future occupation 
[75], negative outcome expectancies for seizures [68], and perception of the role of genetics in 
determining the condition [83].  Although previous research describes important differences 
between felt and enacted stigma [27], authors of the studies identified did not typically differentiate 
between the two; although in one study enacted stigma was found to predict felt stigma, with those 
experiencing discrimination, insults, threats or attacks reporting higher levels of the felt stigma [74].  
Behavioural factors were also found to be important.  After controlling for demographic and clinical 
variables including age, gender, duration of epilepsy, number of seizures, and number of 
medications using regression analyses, Aydemir, Kaya, Yıldız, Öztura, and Baklan found 
concealment of epilepsy to significantly predict felt stigma [75].  Similarly, the use of behavioural 
disengagement, a coping strategy whereby a person intentionally decreases the amount of effort 
needed to deal with a stressful situation, was also found in regression analyses to be independently 
associated with higher reported stigma [67]. 
3.6.1.3.2 Relational factors 
Social support was found to be important.  In a correlational study, participants with greater social 
support reported significantly lower stigma [66].  Furthermore, social support was found to 
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significantly predict lower stigma even when other sociodemographic variables had been taken into 
account in regression analyses [71].  To ascertain whether participants’ social cognitive skills and 
their ability to understand the thoughts, intentions, beliefs, and emotions of others contributed to 
feelings of stigma, Noble, Robinson, and Marson compared “theory of mind” and stigma measures 
using regression analyses [84]; these were found to share little variance, regardless of participant 
seizure status, indicating that the model has little utility in understanding epilepsy stigma. 
3.6.1.3.3 Knowledge and access to information 
Access to understandable information was also found to be important.  Correlational studies 
identified negative associations between knowledge and attitudes towards epilepsy (increased 
knowledge and more positive attitudes) and stigma [66,80].  After taking into account demographic 
and clinical variables using regression analyses, Baker also found knowledge of epilepsy to 
negatively predict stigma [79].  Similarly, difficulties in understanding written information, which 
may limit access to epilepsy knowledge, were found to predict higher levels of stigma in regression 
analyses [67]. 
3.6.2 Stigma as a predictor and correlate of wellbeing 
Seventeen studies examined correlations between stigma and condition management, physical 
health or psychological wellbeing, with 11 studies then going on to use more complex models (e.g.. 
regression or mediation) where stigma was a predictor of physical and psychological wellbeing. 
3.6.2.1 Physical wellbeing and condition management 
Chesaniuk, Choi, Wicks, and Stadler found that higher perceived stigma was correlated with lower 
medication adherence; mediation analyses revealed this association to be explained largely by 
information, motivation, and behavioural skills [85].  Similarly, using path analysis Dilorio, Shafer, 
Letz, Henry, and Schomer found stigma to be indirectly related to medication self-management 
through its association with self-efficacy [86].  The association between stigma and lower self-
efficacy was supported by a correlational study by Yeni et al., who found participants reporting 
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higher levels of stigma to be more likely to hide their condition from others and more likely to seek 
help from non-medical sources such as “mystics” [66].  In a regression study, Dilorio, Shafer, Letz, 
Henry, and Schomer found stigma to predict seizure severity [87], which they argued may be 
related to poor self-management or help-seeking behaviours; although it is possible that people who 
experience more seizures may be more likely to experience greater discrimination.  Stigma was also 
found to be negatively correlated with social support [88] and epilepsy outcomes, including being 
identified as a significant predictor of “concerns about the social impact of epilepsy”, alongside 
seizure severity in regression analyses [62].  These findings may help to explain those identifying 
positive correlations between seizure severity and social support and stigma discussed above 
[69,78], and brings into question the causal direction of these relationships.  In contrast to other 
studies, Elliott, Jacobson, and Seals did not find stigma to predict self-efficacy or epilepsy self-
management in regression analyses [89].  The authors of this study identified age and ethnicity as 
the only predictors of these variables, highlighting the potential importance of demographic and 
cultural factors in determining health outcomes alongside stigma.  
3.6.2.2 Psychological wellbeing and QOL 
There was also evidence that stigma can affect psychological wellbeing and QOL.  In several 
studies, stigma was positively correlated with depression and anxiety [66,70,71,77,86,87,88].  
These findings were supported by a longitudinal study completed by Reisinger and Dilorio, in 
which stigma was found to be the third most important predictor of depression following 
employment status and social support, after controlling for demographic and seizure-related 
variables using regression analyses [90].  Similarly, in another regression study stigma was found to 
predict depression and anxiety when gender, age, and epilepsy-related variables had been controlled 
for [91].  Viteva also found that stigma correlated with affective and obsessive compulsive disorders 
(defined by the authors as “mental status impairment”) [77].   
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In addition to depression and anxiety, Viteva found stigma to negatively correlate with QOL [92]. 
Regression studies also found stigma to predict poor health-related quality of life (HRQOL), 
reduced psychosocial function, and lower “emotional wellbeing” when other variables had been 
accounted for [93,94].  Similarly, in regression analyses Suurmeijer, Reuvekamp, and Aldenkamp 
found perception of stigma to be the fourth strongest predictor of low QOL after psychological 
distress, loneliness, and adjustment and coping; this association was significant regardless of 
participants’ physical status [95].  Eidhin and McLeavey also found stigma to be significantly 
correlated with lower perceived acceptance of the condition, with participants with higher stigma 
feeling less cared for and less valued by others [78]. 
4. Discussion 
4.1 Key findings 
The findings of the review suggest that stigma is a complicated construct to understand in the 
context of PWE and is associated with a range of important factors.  A number of demographic 
variables were found to be associated with stigma, although these findings were not replicated 
across all studies.  Being married, higher income, and higher age were found to be associated with 
lower levels of stigma.  These findings may be explained by the protective value that each of these 
variables has in relation to stigma.  Being in a stable relationship may help to protect or mitigate 
against social rejection and the identification of an individual as “discredited” or having a “spoiled 
identity”, as per Goffman’s definition of stigma [1], through the social support offered by spouses 
[96].  This may help in part to explain why people who have stronger social relationships, including 
those that are married, have better health outcomes than those who are isolated or in relationships 
that are strained [97].  There is also evidence that those with access to greater financial resources 
and social support may be better able to cope with adversity [98,99].  Financial resources may be 
particularly relevant to PWE if it helps them to overcome limitations, for example paying for taxis 
may help to mitigate against the impact of being unable to drive and lead to feeling more included.  
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Older age has also been associated with increased resilience, which may be due to the development 
of coping skills and emotional regulation abilities [100]; this may again help to protect against the 
negative impact of externally-enacted stigma associated with the condition. 
The review also highlighted differences in relation to illness-related variables.  Findings in relation 
to seizure type and severity were mixed.  Some studies found these factors to be associated with 
increased stigma whilst elsewhere the finding was not replicated.  Regression analyses revealed that 
other illness-related variables such as age of epilepsy onset (lower age associated with higher 
stigma), number of seizures to date (greater number associated with higher stigma), and injuries 
associated with epilepsy, may be more important.  Seizure frequency, whilst found to be associated 
with stigma, may also be less important in predicting stigma than the duration and impact of the 
condition.  This fits in with wider health research which suggests that chronic illnesses can have a 
cumulative negative impact on psychological wellbeing [101], and can shift illness into the 
forefront of awareness [102].  For example, short-term illnesses may be easier to cope with than 
those experienced over a longer-period of time due to repeated exposure to negative health-related 
events, including experiences of discrimination by others.  The cumulative number of seizures 
experienced may also increase the number of negative reactions from others (enacted stigma) and 
an increased perception of self as “externally deformed” (felt stigma), as per Goffman’s work [1] 
and Scambler’s Hidden Distress Model [26].  This longer-term exposure to seizures and negative 
reactions from others may also lead to an over-identification with the condition, exacerbated by 
negative language or labelling.  The effect of labelling was demonstrated in an influential Brazilian 
study which reported experimental evidence that the term “epileptic” evoked more negative 
attitudes than the term "person with epilepsy" [103].  However, these findings have not been 
consistently replicated in other populations such as the UK and have been subject to criticism [104]. 
The findings of the review also suggested that the impact of illness-related variables on stigma can 
vary by country of origin, and therefore appeared to be, to a significant degree, culturally-specific.  
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Stigma in epilepsy is highly culturally-dependent [54] and this has been highlighted in previous 
research; for example, a recent cross-continental comparative study of PWE found Swedish 
participants to report significantly lower levels of stigma than PWE in Iran; the researchers argued 
that this was likely due to differences in medical treatment and educational exposure [105].  These 
cultural differences informed the rationale to narrow the focus the review on countries of Western 
origin, however there was still considerable heterogeneity identified across studies of different 
geographical origin.   
One possible explanation relates to the impact of overall health system performance and health 
expenditure; the hypothesis being that higher expenditure will result in lower stigma as a result of 
greater understanding of the condition and better support systems.  A PWE with greater seizure 
frequency and severity in a country where seizures are not well understood may be subject to 
greater stigma with lower support than someone experiencing the same level of seizure frequency 
and severity in a country where the condition is better understood.  However, Brigo et al. found 
that, whilst there was a trend towards negative associations between expenditure and stigma, 
findings related to these variables were non-significant [72].  This suggests that general investments 
in public health systems do not necessarily lead to improvements in stigma-related epilepsy.  To 
achieve this, the authors argue, funds need to be directed specifically towards epilepsy awareness 
and stigma-reduction programmes.  Whilst public myths and misconceptions remain even in 
countries of higher socioeconomic status where educational campaigns have been launched 
[33,106], the negative impact of stigma on social identity in PWE can be greater in resource-poor 
countries [7].  Concealment of the condition in these countries is also likely to be higher [107], and 
issues of language and legality may increase the risks of stigma further [104].  It is therefore 
important that stigma reduction efforts are viewed as important and are culturally-informed [103]. 
Further variance in stigma can be explained by psychosocial factors.  Knowledge of epilepsy, and 
the ability to access this, was universally found to be associated with lower stigma.  Knowledge of 
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epilepsy is also an important factor in optimising control of seizures [108]; this may impact further 
on stigma and help to explain some of the geographical differences in stigma identified in different 
countries.  Unsurprisingly, therefore, feelings of control and mastery over the condition were found 
to be negatively associated with perceptions of stigma.  Where PWE reported lower feelings of self-
efficacy or a deterministic view of the condition, or where they identified concerns about their 
ability to effectively manage their illness, to access support, or to cope in the future, stigma was 
higher.  Such beliefs may also lead to maladaptive and avoidant coping strategies, such as 
concealment of the condition or behavioural disengagement with its management, which were 
found to increase stigma [67,75].  This could furthermore serve to reinforce a lack of social support, 
condition management, and perceived ability to cope, completing a vicious cycle that provides a 
fertile ground for perceived stigma in PWE.  In this case, stigma may be seen as self-perpetuating, 
and again fits in with Scambler’s “Hidden Distress Model of Epilepsy”, in which a person feels 
stigmatised, conceals their condition from others, and feels increasingly distressed [26].  Therefore, 
in addition to wider societal educational campaigns, therapeutic interventions at an individual level 
are also likely to be important. 
The findings associated with outcomes of stigma were more straightforward and perhaps less 
surprising.  Higher levels of stigma were associated with a reduced sense of self-efficacy, lower 
motivation, and compromised condition management, characterised by lower medication adherence 
and poor epilepsy outcomes, including increased seizure severity.  As previously identified, 
however, it was not possible to determine causal directions and it is likely that these relationships 
are strengthened in both directions.  The psychological impact was also found to be significant.  
Stigma was found universally to be associated with or to predict depression and anxiety, even when 
other variables had been taken into account.  This was in contrast to a review of earlier studies 
which found only one out of three studies to predict stigma [109], suggesting that the emotional 
impact of stigma may have changed over time.  Stigma was also found to predict lower QOL and 
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was associated with other psychological difficulties including lower “emotional wellbeing” and 
perceived acceptance by others, and a greater incidence of obsessive compulsive disorders.  Clearly, 
therefore, the impact of stigma on both physical and psychological wellbeing is significant, and 
warrants greater attention through research and targeted public health initiatives. 
4.2 Implications and recommendations 
The findings of the review suggest that, in addition to demographic and illness-related variables, 
psychosocial factors are likely to be particularly important in determining stigma.  These are likely 
underpinned by knowledge about the condition, social support, and a perception that the care 
system, and in turn society, takes an understanding view of epilepsy and its management.  
Insufficient awareness of epilepsy can result in a range of negative consequences, therefore public 
campaigns to address educational deficits have been advocated [48,110].  In the UK, this has been 
reflected by clinical guidelines that explicitly outline the responsibility of healthcare professionals 
to educate others about epilepsy as a means of reducing stigma [22], and a large number of 
awareness campaigns launched by charities [111,112].  Where such campaigns have been 
introduced, there has been some evidence of effectiveness [113].  However, there is some evidence 
that attitudes over the last 10 years may actually have worsened [114].  This may be explained in 
part by technological advances such as online social networking platforms like Twitter, where 
derogatory communications about epilepsy and seizures are common, and where stigma may be 
being fuelled by the propagation of negative attitudes towards the condition [115].   
Societal values that can lead people to feel stigmatised and to conceal health conditions such as 
epilepsy can also extend to the law [116], therefore further research is needed to ensure that legal 
structures serve to protect, rather than stigmatise, people with the condition.  In the current political 
climate, where division between different social and cultural groups is being made increasingly 
explicit, interventions which aim to reduce the stigma of people in minority health populations and 
increase compassion for those who are seen as “different” are now more important than ever.  PWE 
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who feel stigmatised by others are more likely to feel depressed and anxious [e.g. 90]; they may 
also feel less accepted and valued by others [78].  Psychologists and other professionals working 
with PWE and their families should therefore help to give those they work with a voice, and to 
promote the view that epilepsy is a manageable, socially acceptable, condition that should not 
differentiate them negatively from others.  Psychological therapies may also be beneficial in 
reducing perceived stigma.  There is some evidence that psychological approaches such as 
acceptance and commitment therapy (ACT [117]) and compassion focused therapy (CFT; [118]) 
can help to increase psychological flexibility and reduce internalised health-related stigma [119].  
Self-compassion has also been found to mediate the relationship between internalised self-stigma 
and depression; it has been suggested that self-compassion may provide a buffer against the 
negative impact of stigma that is experienced externally and then internalised [120].  Narrative 
therapy may also be beneficial in shedding light on alternative perspectives and helping PWE to 
develop new narratives about themselves [121].  In light of these recommendations, psychologists 
working in health settings arguably have a key role to play in tackling stigma at a wider societal 
level as part of their widening influence in public health initiatives [122]. 
4.3 Limitations and recommendations for further research  
One of the most significant limitations of this review was that it relied heavily on cross-sectional 
surveys gathering data via self-report measures.  The first limitation of this type of research is that it 
is not possible to determine causation [123].  For example, where higher seizure severity was found 
to be associated with greater stigma, severe seizures may have led to increased stigma or increased 
stigma may have led to more severe seizures, perhaps mediated by self-efficacy or condition 
management.  Relationships in this context may therefore be bidirectional with one factor 
reinforcing another; from the research identified in the review it was possible to infer but not 
confirm this.  Cross-sectional designs have also been criticised for assuming that variables remain 
stable over time and for therefore failing to address chronological variability, leading to biased 
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estimates and incorrect inferences [124].  Further research should aim to incorporate longitudinal 
methods to help determine causation and chronological variation.  The second issue with this type 
of research is that, whilst an appropriate tool in this context, findings derived from self-report 
measures are open to bias [125].  They are also sensitive to culture [126], therefore the use of such 
measures in different countries requires careful consideration. 
The specific tools used to measure stigma in the studies identified can also be brought into question.  
A large number of studies used a three-item measure of stigma originally used in a study of stroke 
patients [127], adapted for use in PWE by Jacoby [8].  Although this measure has been validated for 
use in this population [8,128], the measure is basic and may not detect subtle but important nuances 
such as “felt” versus “enacted” stigma.  Further research should aim to use more detailed 
measurement tools and incorporate alternative sources of information such as clinical observations 
and case studies.  A further limitation is that whilst much of the background literature on stigma in 
epilepsy differentiates between felt and enacted stigma as independent constructs, this was rarely 
discussed or addressed by researchers.  This may be a significant omission as, for example, subtle 
differences in others’ language may be perceived as stigmatising by a person with epilepsy even 
where this is not intentionally or objectively enacted [129].  Current research fails to address this 
nuance of experience and this has implications for practice.  For example, evidence of enacted 
stigma may point towards a need to direct change at public health level, whereas felt stigma may 
require support and interventions at an individual level. 
A final limitation related to the challenges associated with determining inclusion and exclusion of 
studies on the basis of Western versus non-Western populations.  Whilst the decision to differentiate 
was pragmatic and informed by an aim to address a defined research question, it is important to 
acknowledge that the “othering" - and potential stigmatising - of different social, cultural, and 
geographic groups may be perceived as in direct contrast to the spirit of this review.  This is an 
LITERATURE REVIEW 1- !29
entirely unintended consequence of the limited scope of the work, which a further review or 
reviews in other populations would help to address. 
4.4 Conclusions 
The findings of this review suggest that stigma in PWE may be predicted by demographic, illness-
related, and psychosocial factors, with the latter explaining a large degree of variance.  However, 
findings varied significantly by country of origin.  This suggests that stigma is, to a significant 
degree, culturally determined.  As stigma is a social construct, this may be unsurprising; however it 
may present challenges to campaigners and legislators attempting to reduce stigma and its impact at 
an international level.  What appears to be important, however, is fostering education and 
understanding of the condition, both in PWE and in the general population.  The outcomes of 
stigma appear significant and more universal; its impact relates to both physical health, including 
management of the condition, and psychological wellbeing, including difficulties such as 
depression and anxiety.  It is therefore important that healthcare providers, legislators, policy-
makers, and citizens take steps to try and address these issues.  Psychologists, who understand 
research and can influence others at individual and systemic levels, may be particularly well-placed 
to support these agendas.  Whilst the evidence suggests that stigma of epilepsy remains prevalent, 
this is almost certainly to a significantly lesser degree in the West than in some developing areas of 
the world, particularly in rural areas where the condition is often still referred to in terms of 
demonic possession or a spiritual affliction.  We may therefore already be able to see a positive 
influence of education and understanding.  However, given the continued prevalence of stigma, 
perpetuated by historically and culturally-determined myths and misconceptions, and the impact it 
can have on PWE, we need to continue to invest in research and structures that can help to tackle 
stigma of epilepsy both now and in the future. 
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No significant difference was 
found relative to stigma levels 
between pre- and post-SAH 
groups (p=.82). In fact, a high 
level of stigma was observed 
in only 6 (14.7%) of the 
patients, suggesting that 






































































Concealment of epilepsy 
(β = .43, p < .001), concerns 
related to social life (β = .27, 
p < .001), and concerns 
related to future occupation 
(β = .26, p < .001) were found 
as the predictors of felt 
stigma after controlling for 
demographics (age and 
gender), and clinical variables 
(duration of epilepsy, number 
of seizures, and number of 
medications).
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A multivariate analysis 
identified impact of epilepsy 
(β = .43, p < .0001), age of 
onset (β = .09, p < .0001), 
country of origin, feelings 
about life (β = .05, p < .001), 
and injuries associated with 
epilepsy (β = .05, p < .01) as 
significant contributors on 
scores on the stigma scale. 
Whereas seizure type and 
frequency were significantly 
correlated with scores on the 
stigma scale, results of the 
multiple regression showed 
that neither seizure frequency 
nor seizure type accounted for 
a significant amount of the 































































in 1997, data 
on health 
expenditure 





















We found a nonsignificant 
trend towards negative 
correlation between the 
epilepsy-related stigma 
percentage and the overall 
health system performance 
(r=-0.16; p=0.57), the health 
expenditure per capita in 
international dollars (r=-0.24; 
p=0.4), and the Economist 
Intelligence Unit's quality-of-















































e, the Impact 
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After taking into account 
demographic and clinical 
variables, a number of factors 
were predictive of stigma, 
including seizure frequency, 
knowledge of epilepsy, 
duration of epilepsy, and 
seizure type. The relative 
contributions of these factors 
varied depending on the 
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Using multiple linear 
regression, marital status 
(being single) (β = -4.027, 
p=.01), being poorer, 
indicated by higher 
QOLIE-10 scores (β = .45, 
p< .01), difficulties 
understanding written 
information (β =-2.19, p=.
03), and the use of 
behavioural disengagement 
(β =2, p=.01) were 
independently associated with 
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Stigma, along with self-
efficacy, depression, social 
support, desire for control, 
and outcome expectations, 
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clinic (N = 
238 ; age = 
18+ years, 
























































Reported levels of stigma 
were higher in low SES than 
in high SES (p<0.0001), and 
all psychosocial variables 
were associated with stigma, 
including depression severity 
(p<0.0001), knowledge of 
epilepsy (p=0.006), quality of 
life (p<0.0001), social 
support (p<0.0001), and self-
efficacy (p=0.0009). Stigma 
was statistically significantly 
associated with quality of life 
in the low SES group and 
with depression severity and 






















age = 45 
years)
Revised 














Feelings of stigma were 
significantly associated with 
age </= 50 years, younger age 
of epilepsy onset, more than 
50 seizures to date, 
generalised tonic-clonic 
seizures, and a shorter 
seizure-free period. Multiple 
stepwise regression showed 
number of seizures to date as 





















USA N = 140 









































related stigma was associated 
with lower medication 
adherence (r = −0.18, p=.05). 
Higher stigma was associated 
with lower levels of 
information (r = −0.28, p b .
05), motivation (r = −0.55, p 
b .05), and behavioural skills 
(r = −0.41, p b .05). 
Adherence information, 
motivation, and behavioural 
skills explained nearly all of 
the association between 
perceived stigma and 
adherence: the total effect of 
perceived stigma on 
adherence (c = −0.18, p b .05) 
was reduced to a direct effect 
near 
zero (c = 0.06, p = .48) when 
accounting for the indirect 
effects through information, 




















(age = 18+ 
years, mean 
age = 38.6 
years)
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Stigma was positively 
correlated with depression 
(r=0.39, p<0.01) and 
negatively associated with 
social support (r=-0.65, 
<0.001). Stigma was not 
significantly correlated with 
perceived criticism, 
emotional involvement, self-
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Participants who reported 
higher levels of perceived 
stigma also reported lower 
levels of self-efficacy to 
manage epilepsy (r=−0.431); 
more negative outcome 
expectancies related to 
treatment (r=−0.213) and 
seizures (r=0.652); and lower 
levels of medication 
management (r=−0.200), 
medication adherence 
(r=0.202), and patient 
satisfaction (r=−0.190 to 
−0.350). However, they 
reported more positive 
outcome expectancies related 
to information management 
(r=0.159). In regression 
analysis, income, age at first 
seizure, seizures during the 
past year, lower self-efficacy, 
negative outcome 
expectancies for seizures, and 
less patient satisfaction 
explained 54% of the 
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Stigma was directly related to 
self-efficacy and depressive 
symptoms. Stigma was 
indirectly related to 
medication self-management 
through its association with 
self-efficacy. These results 
suggest that those who feel 
highly stigmatised because of 
their epilepsy are less 
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Stigma was a “potentially 
significant predictor” of self-
efficacy (F=3.643, 
p<0.057) 
but this was less important 
than self-management, 
depressive symptoms and 
seizure severity. The inverse 
relationship found between 
perceived stigma and self-
efficacy in this study suggests 
that those who harbour 
negative thoughts about 
epilepsy also feel less 
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Stigma was correlated with 
depression at baseline, 3- and 
6-month follow-up (r=.425, .
343 and .371, respectively, 
p<.001). The three major 
factors that predicted 
depressive symptoms at each 
time point (when controlling 
for demographic and seizure-
related variables) were 
employment status, social 
support, and stigma. The third 
main predictor of depressive 
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depressive symptoms, stigma 
and sometimes regimen-
specific support and QOL. 
Psychosocial variables 
measured 3 months prior to 
QOL were entered into a 
hierarchical multiple linear 
regression model, revealing 
that depressive symptoms, 
stigma and social support can 










USA N = 94 
epilepsy 
patients in 
the US (age 
= 19-78 
years, mean 




































The Liverpool Stigma Scale 
did not predict any of the 
dependent variables (self-



















































































Social anxiety positively 
correlated with felt stigma 
(r=.48, p<.001). This 
relationship remained 
significant after controlling 
for depression (p<.001). 
Social anxiety significantly 
predicted the variance in 
stigma above and beyond age, 
anxiety, impact of epilepsy, 
seizure frequency, and 



















(age = 60+ 
years, mean 
age = 67.59 
years). 
Control 


































In the HRQOL regression, 
stigma contributed 
significantly to prediction of 
HRQOL (sr2 = .21). A greater 
perception of stigma was 
strongly related to poor 
quality of life and reduced 
psychosocial function. Less 
stigma and lower frequency 
of seizures uniquely 
contributed to the overall 
prediction of better health-
related quality of life. 
Overall, the predictors of 
stigma and seizure frequency 
together accounted for 54% 
of the variability in health-




























































Seizure severity was 
significantly correlated with 
perception of stigma (r=.37, 
p<.01). A significant negative 
correlation were found 
between perceived stigma and 
















N = 503 


































Feelings of stigma held a 
negligible, negative, and 
nonsignificant association 
with ToM performance (r=-.
02 and -.05). The ToM model 
for understanding epilepsy 































































correlations between anxiety 
and depression and social and 
personal aspects of stigma. 
Social aspects of stigma 
significantly predicted 
depression and anxiety (B=.
34 and .32, respectively, p<.
01) when gender, age and 
epilepsy-related variables had 
been controlled for. Social 
aspects of stigma had the 
strongest effect on anxiety, 
followed by the effectiveness 
of current control on seizures. 
Those who take more 
epilepsy drugs experienced 
greater stigma as a result and, 
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Felt stigma was higher among 
individuals who were aged >/
=60 years, were unemployed, 
reported epilepsy-related 
discrimination, or had 
seizures within the last year 
or >100 seizures in their 
lifetime. Adjusting for other 
variables, ESS scores in 
people with epilepsy were 
significantly higher among 
those who perceived genetics 
played a "medium" or "big" 
role in causing epilepsy in the 
family than in others (3.4 vs. 













USA N = 244 
adults with 
epilepsy in 
























After adjustment for the other 
variables in the final model, 
only three combinations were 
significantly related to 
perceived stigma. Reported 
levels of stigma were 
associated with interactions 
of seizure worry and 
employment status (disabled 
or unemployed with higher 
seizure worry=higher stigma), 
self-efficacy and social 
support (higher scores=lower 
stigma), and quality of care 
and age at seizure onset 
(higher quality of care and 

















































































Perception of stigma in 
epilepsy was negatively 
correlated with QOL (r=0.17, 
p<.01). In decreasing order of 
importance, psychological 
distress, loneliness, 
adjustment and coping, and 
stigma perception (B=.17, p=.
4) appeared to contribute 
most significantly to the 
outcome QoL as judged by 
the patients. themselves, 

































































Those who felt highly 
stigmatised were significantly 
younger than those who did 
not report feeling stigmatised; 
they were also more likely to 
have a previous or current 
neurological disorder (25.0% 
vs 14.1%), less likely to be 
married (47.9% vs 60.2%), 
more likely to have already 
experienced four or more 
seizures (86.5% vs 60.7%), 
more likely to have no formal 
educational qualifications on 
leaving school (52.7% vs 
37.1%), and more likely to be 
unemployed (69.0% vs 
47.6%). Gender, seizure type, 
presence of a neurological 
deficit, and social class were 
not associated with degree of 
felt stigma. A multivariate 
linear regression 
demonstrated that scores on 
the AEP, mastery scale, and 
ABNAS, poor overall global 
QOL, age < 50 years, more 
than four seizures at baseline, 
sand feeling more socially 
restricted were significant 
























= 164; age 
= 18-65 
years, mean 



























No correlation was found 
between stigma and age and 
gender, education, marital 
status, employment, seizure 
frequency and severity, 
prescribed treatment, or 
anxiety (Р > 0.05). A 
moderate correlation was 
found between depression 
and stigmatisation frequency 
and severity (r=.40, Р< .01). 
A mild correlation was found 
between mental status 
impairment and 
stigmatisation. Mental status 
impairment was associated 
with a more frequent and 























































Perceived stigma had a 
negative impact on QOL (T-
score 47.8), including all sub-
scales of QOLIE-89, with the 
exception of “change in 
health” and “sexual 
relations”. Patients with 
refractory epilepsy reporting 
stigmatisation most 
commonly had very low and 
low scores on the sub-scales 
“health perceptions” (82.9%), 
“emotional well-
being” (71.5%), 
“memory” (63.4%) and 
“health 
discouragement” (62.5%). 
There was a negative 
correlation of all QOLIE-89 




































































GEOS-35 total scores were 
associated with seizure 
frequency and severity, 
stigma, depression, and 
anxiety. On multivariate 
regression analysis predictors 
of the GEOS-35 total score 
were anxiety, seizure severity, 
and stigma Р < 0.001 
(F = 14.66). Regarding 
GEOS-35 sub-scales, on 
multivariate regression 
analysis seizure severity and 
stigma were predictors of 
“concerns about social 














































































The experience of insults and/
or threats and attacks because 
of participants’ health 
problems was more frequent 
in cases with moderate 
intellectual impairment 
(χ2 = 5.17, P < 0.05). 
Participants who gave a 
greater number of positive 
answers about experienced 
discrimination or insults and/
or threats and attacks reported 
a more pronounced perceived 
stigma (F=19.30, P<0.001 
and F=12.91, P<0.001, 
respectively). Perceived 
stigma and the experience of 
insults and/or threats and 
attacks proved to be 
predictors of discrimination 
on multivariate regression 


















































Perceived stigma was 
observed in 64.71% of the 
study participants. There was 
a significant association 
between perceived stigma and 
the total LAEP score (p < 
0.05, F = 13.71). Patients who 
reported AEs had an 
increased risk of perceiving 
stigma compared to those 
who did not experience AEs. 
A significant correlation 
between perceived stigma and 
the presence of neurological 
and psychiatric AEs (p < 
0.001, r = +0.60) and a mild 
correlation between perceived 
stigma and the presence of 
nonneurological AEs (p < 
0.01, r = +0.20) were verified. 
In a multivariate regression 
analysis the only predictors of 
perceived stigma were AED 
polytherapy and the presence 






















































































Significant correlations were 
obtained between stigma and 
attitude towards epilepsy 
(r=−.267, p=.026), anxiety 
and depression (r=.283, p=.
018, r=.282, p=.018), QOL 
epilepsy effects (r=−.255, p=.
























of stigma, the 
Multidimensi











































Education (χ2=8.23, p=.016), 
income (χ2=9.735, p=.008), 
age at onset (r=−0.183, p=.
01), seizure frequency in 
previous year (χ2=9.26, p=.
01), social support (r=−.3, p=.
001), and knowledge and 
attitudes towards epilepsy 
(r=−.18, p=.012, r=-.152, p=.
034) were significant factors 
determining scores on the 
stigma scale. It was also 
determined that stigma was 
associated with seeking non-
medical help (Z=3.60, p=.
001), disclosure of the 
diagnosis (Z=2.59, p=.01), 
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Appendices 
Appendix A. Literature review database search history 
PsycINFO 
Search terms: “epilepsy”, “stigma” (abstract field) 
Thesaurus terms: “Stigma”, “Labelling”, “Stereotyped attitudes”, “Epilepsy” 
Combined Thesaurus and free text search completed on 10/11/2016 - 391 results 
Limited to papers since 2000 - 350 results 
Limited to academic journals - 317 results 
CINAHL 
Search terms: “epilepsy”, “stigma” (abstract field) 
CINAHL Headings: “Stigma”, “Labelling”, “Stereotyped attitudes”, “Epilepsy” 
Combined CINAHL Headings and free text search completed on 10/11/2016 - 77 results 
Limited to papers since 2000 - 70 results 
Limited to academic journals - 50 results 
Pubmed 
Search terms: “epilepsy” and “stigma” (title/abstract field) 
Medical Subject Headings [MeSH]: “Epilepsy” and “Social Stigma” 
Combined Mesh and free text search completed on 10/11/2016 - 527 results 
Limited to papers since 2000 - 482 results 
Scopus 
Search completed: 11/11/16 
Search terms: “epilepsy” and “stigma” (title/abstract field) 
Free text search completed on 08/11/2016 - 834 results 
Limited to papers since 2000 - 737 results 
Total = 1,586 
Total Endnote de-duplicated = 1,280 
Total hand de-duplicated = 872 
Total excluded by title = 594 
Total screened by abstract = 278 
Articles excluded by abstract = 230 
Excluded by relevance = 179 
Excluded by methodology = 28 (34) 
Excluded by sample = 9 (13) 
Excluded by location = 14 
Articles excluded by full-text = 15 
Sample (non-Western, child/adolescent, or non-epilepsy) = 4 
LITERATURE REVIEW 1- !64
Methodology = 6 
Date of publication = 3 
Excluded by unavailable in English = 2 
Additional articles identified from reference list searches = 0 
Articles examining “outcomes” = 13 
Articles examining “predictors” = 20 
Total articles identified for inclusion in the review = 33 
Appendix B - Copy of notes to contributors for selected journal: Epilepsy & Behaviour 
Article structure 
Subdivision - numbered sections  
Divide your article into clearly defined and numbered sections. Subsections should be numbered 1.1 
(then 1.1.1, 1.1.2, ...), 1.2, etc. (the abstract is not included in section numbering). Use this 
numbering also for internal cross-referencing: do not just refer to 'the text'. Any subsection may be 
given a brief heading. Each heading should appear on its own separate line. 
Introduction  
State the objectives of the work and provide an adequate background, avoiding a detailed literature 
survey or a summary of the results. 
Material and methods  
Provide sufficient detail to allow the work to be reproduced. Methods already published should be 
indicated by a reference: only relevant modifications should be described. 
Results  
Results should be clear and concise. 
Discussion  
The Discussion section should explore the significance of the results of the work, not repeat them. 
Results and Discussion should be separate and may be organized into subheadings. Avoid extensive 
citations and discussion of published literature. 
Conclusions  
The main conclusions of the study may be presented in a short Conclusions section, which may 
stand alone or form a subsection of a Discussion or Results and Discussion section. 
Essential title page information  
• Title. Concise and informative. Titles are often used in information-retrieval systems. Avoid 
abbreviations and formulae where possible. 
• Author names and affiliations. Please clearly indicate the given name(s) and family name(s) of 
each author and check that all names are accurately spelled. Present the authors' affiliation 
addresses (where the actual work was done) below the names. Indicate all affiliations with a lower-
case superscript letter immediately after the author's name and in front of the appropriate address. 
Provide the full postal address of each affiliation, including the country name and, if available, the 
e-mail address of each author. 
• Corresponding author. Clearly indicate who will handle correspondence at all stages of refereeing 
and publication, also post-publication. Ensure that the e-mail address is given and that contact 
details are kept up to date by the corresponding author. 
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• Present/permanent address. If an author has moved since the work described in the article was 
done, or was visiting at the time, a 'Present address' (or 'Permanent address') may be indicated as a 
footnote to that author's name. The address at which the author actually did the work must be 
retained as the main, affiliation address. Superscript Arabic numerals are used for such footnotes. 
Please note that proprietary names for drugs should not be used in the article title. 
Abstract  
A concise and factual abstract is required. The abstract should state briefly the purpose of the 
research, the principal results and major conclusions. An abstract is often presented separately from 
the article, so it must be able to stand alone. For this reason, References should be avoided, but if 
essential, then cite the author(s) and year(s). Also, non-standard or uncommon abbreviations should 
be avoided, but if essential they must be defined at their first mention in the abstract itself. 
Graphical abstract  
Although a graphical abstract is optional, its use is encouraged as it draws more attention to the 
online article. The graphical abstract should summarize the contents of the article in a concise, 
pictorial form designed to capture the attention of a wide readership. Graphical abstracts should be 
submitted as a separate file in the online submission system. Image size: Please provide an image 
with a minimum of 531 × 1328 pixels (h × w) or proportionally more. The image should be 
readable at a size of 5 × 13 cm using a regular screen resolution of 96 dpi. Preferred file types: 
TIFF, EPS, PDF or MS Office files. You can view Example Graphical Abstracts on our information 
site. 
Authors can make use of Elsevier's Illustration and Enhancement service to ensure the best 
presentation of their images and in accordance with all technical requirements: Illustration Service. 
Highlights  
Highlights are a short collection of bullet points that convey the core findings of the article. 
Highlights are optional and should be submitted in a separate editable file in the online submission 
system. Please use 'Highlights' in the file name and include 3 to 5 bullet points (maximum 85 
characters, including spaces, per bullet point). You can view example Highlights on our information 
site. 
Highlights are mandatory for Original Reports and Reviews only. They are optional but encouraged 
for all other article types. 
Keywords  
Immediately after the abstract, provide a maximum of 6 keywords, using American spelling and 
avoiding general and plural terms and multiple concepts (avoid, for example, 'and', 'of'). Be sparing 
with abbreviations: only abbreviations firmly established in the field may be eligible. These 
keywords will be used for indexing purposes. 
Abbreviations  
Define abbreviations that are not standard in this field in a footnote to be placed on the first page of 
the article. Such abbreviations that are unavoidable in the abstract must be defined at their first 
mention there, as well as in the footnote. Ensure consistency of abbreviations throughout the article. 
Acknowledgements  
Collate acknowledgements in a separate section at the end of the article before the references and 
do not, therefore, include them on the title page, as a footnote to the title or otherwise. List here 
those individuals who provided help during the research (e.g., providing language help, writing 
assistance or proof reading the article, etc.). 
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Formatting of funding sources  
List funding sources in this standard way to facilitate compliance to funder's requirements: 
Funding: This work was supported by the National Institutes of Health [grant numbers xxxx, yyyy]; 
the Bill & Melinda Gates Foundation, Seattle, WA [grant number zzzz]; and the United States 
Institutes of Peace [grant number aaaa]. 
It is not necessary to include detailed descriptions on the program or type of grants and awards. 
When funding is from a block grant or other resources available to a university, college, or other 
research institution, submit the name of the institute or organization that provided the funding. 
If no funding has been provided for the research, please include the following sentence: 
This research did not receive any specific grant from funding agencies in the public, commercial, or 
not-for-profit sectors. 
Units  
Follow internationally accepted rules and conventions: use the international system of units (SI). If 
other units are mentioned, please give their equivalent in SI. 
Math formulae  
Please submit math equations as editable text and not as images. Present simple formulae in line 
with normal text where possible and use the solidus (/) instead of a horizontal line for small 
fractional terms, e.g., X/Y. In principle, variables are to be presented in italics. Powers of e are often 
more conveniently denoted by exp. Number consecutively any equations that have to be displayed 
separately from the text (if referred to explicitly in the text). 
Footnotes  
Footnotes should be used sparingly. Number them consecutively throughout the article. Many word 
processors can build footnotes into the text, and this feature may be used. Otherwise, please indicate 
the position of footnotes in the text and list the footnotes themselves separately at the end of the 
article. Do not include footnotes in the Reference list. 
Artwork 
Electronic artwork  
General points 
• Make sure you use uniform lettering and sizing of your original artwork.  
• Embed the used fonts if the application provides that option.  
• Aim to use the following fonts in your illustrations: Arial, Courier, Times New Roman, Symbol, or 
use fonts that look similar.  
• Number the illustrations according to their sequence in the text.  
• Use a logical naming convention for your artwork files.  
• Provide captions to illustrations separately.  
• Size the illustrations close to the desired dimensions of the published version.  
• Submit each illustration as a separate file. 
A detailed guide on electronic artwork is available. 
You are urged to visit this site; some excerpts from the detailed information are given here. 
Formats 
If your electronic artwork is created in a Microsoft Office application (Word, PowerPoint, Excel) 
then please supply 'as is' in the native document format.  
Regardless of the application used other than Microsoft Office, when your electronic artwork is 
finalized, please 'Save as' or convert the images to one of the following formats (note the resolution 
requirements for line drawings, halftones, and line/halftone combinations given below):  
EPS (or PDF): Vector drawings, embed all used fonts.  
TIFF (or JPEG): Color or grayscale photographs (halftones), keep to a minimum of 300 dpi.  
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TIFF (or JPEG): Bitmapped (pure black & white pixels) line drawings, keep to a minimum of 1000 
dpi.  
TIFF (or JPEG): Combinations bitmapped line/half-tone (color or grayscale), keep to a minimum of 
500 dpi. 
Please do not:  
• Supply files that are optimized for screen use (e.g., GIF, BMP, PICT, WPG); these typically have a 
low number of pixels and limited set of colors;  
• Supply files that are too low in resolution;  
• Submit graphics that are disproportionately large for the content. 
Color artwork  
Please make sure that artwork files are in an acceptable format (TIFF (or JPEG), EPS (or PDF), or 
MS Office files) and with the correct resolution. If, together with your accepted article, you submit 
usable color figures then Elsevier will ensure, at no additional charge, that these figures will appear 
in color online (e.g., ScienceDirect and other sites) regardless of whether or not these illustrations 
are reproduced in color in the printed version. For color reproduction in print, you will receive 
information regarding the costs from Elsevier after receipt of your accepted article. Please 
indicate your preference for color: in print or online only. Further information on the preparation of 
electronic artwork. 
Color figures for exclusive use as cover illustration may be submitted by authors who are also 
submitting a manuscript for consideration. These figures should relate to the manuscript being 
submitted as well as the larger scope and focus of Epilepsy & Behavior. 
Illustration services  
Elsevier's WebShop offers Illustration Services to authors preparing to submit a manuscript but 
concerned about the quality of the images accompanying their article. Elsevier's expert illustrators 
can produce scientific, technical and medical-style images, as well as a full range of charts, tables 
and graphs. Image 'polishing' is also available, where our illustrators take your image(s) and 
improve them to a professional standard. Please visit the website to find out more. 
Figure captions  
Ensure that each illustration has a caption. Supply captions separately, not attached to the figure. A 
caption should comprise a brief title (not on the figure itself) and a description of the illustration. 
Keep text in the illustrations themselves to a minimum but explain all symbols and abbreviations 
used. 
Tables  
Please submit tables as editable text and not as images. Tables can be placed either next to the 
relevant text in the article, or on separate page(s) at the end. Number tables consecutively in 
accordance with their appearance in the text and place any table notes below the table body. Be 
sparing in the use of tables and ensure that the data presented in them do not duplicate results 
described elsewhere in the article. Please avoid using vertical rules and shading in table cells. 
References 
Citation in text  
Please ensure that every reference cited in the text is also present in the reference list (and vice 
versa). Any references cited in the abstract must be given in full. Unpublished results and personal 
communications are not recommended in the reference list, but may be mentioned in the text. If 
these references are included in the reference list they should follow the standard reference style of 
the journal and should include a substitution of the publication date with either 'Unpublished results' 
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or 'Personal communication'. Citation of a reference as 'in press' implies that the item has been 
accepted for publication. 
Web references  
As a minimum, the full URL should be given and the date when the reference was last accessed. 
Any further information, if known (DOI, author names, dates, reference to a source publication, 
etc.), should also be given. Web references can be listed separately (e.g., after the reference list) 
under a different heading if desired, or can be included in the reference list. 
Data references  
This journal encourages you to cite underlying or relevant datasets in your manuscript by citing 
them in your text and including a data reference in your Reference List. Data references should 
include the following elements: author name(s), dataset title, data repository, version (where 
available), year, and global persistent identifier. Add [dataset] immediately before the reference so 
we can properly identify it as a data reference. The [dataset] identifier will not appear in your 
published article. 
References in a special issue  
Please ensure that the words 'this issue' are added to any references in the list (and any citations in 
the text) to other articles in the same Special Issue. 
Reference management software  
Most Elsevier journals have their reference template available in many of the most popular 
reference management software products. These include all products that support Citation Style 
Language styles, such as Mendeley and Zotero, as well as EndNote. Using the word processor plug-
ins from these products, authors only need to select the appropriate journal template when preparing 
their article, after which citations and bibliographies will be automatically formatted in the journal's 
style. If no template is yet available for this journal, please follow the format of the sample 
references and citations as shown in this Guide. 
Users of Mendeley Desktop can easily install the reference style for this journal by clicking the 
following link: 
http://open.mendeley.com/use-citation-style/epilepsy-and-behavior 
When preparing your manuscript, you will then be able to select this style using the Mendeley plug-
ins for Microsoft Word or LibreOffice. 
Reference style  
Text: Indicate references by number(s) in square brackets in line with the text. The actual authors 
can be referred to, but the reference number(s) must always be given.  
List: Number the references (numbers in square brackets) in the list in the order in which they 
appear in the text. 
Examples:  
Reference to a journal publication:  
[1] Van der Geer J, Hanraads JAJ, Lupton RA. The art of writing a scientific article. J Sci Commun 
2010;163:51–9.  
Reference to a book:  
[2] Strunk Jr W, White EB. The elements of style. 4th ed. New York: Longman; 2000.  
Reference to a chapter in an edited book:  
[3] Mettam GR, Adams LB. How to prepare an electronic version of your article. In: Jones BS, Smith 
RZ, editors. Introduction to the electronic age, New York: E-Publishing Inc; 2009, p. 281–304.  
Reference to a website:  
[4] Cancer Research UK. Cancer statistics reports for the UK, http://www.cancerresearchuk.org/
aboutcancer/statistics/cancerstatsreport/; 2003 [accessed 13.03.03].  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Reference to a dataset:  
[dataset] [5] Oguro M, Imahiro S, Saito S, Nakashizuka T. Mortality data for Japanese oak wilt disease 
and surrounding forest compositions, Mendeley Data, v1; 2015. https://doi.org/10.17632/xwj98nb39r.1.  
Note shortened form for last page number. e.g., 51–9, and that for more than 6 authors the first 6 should 
be listed followed by 'et al.' For further details you are referred to 'Uniform Requirements for 
Manuscripts submitted to Biomedical Journals'
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Highlights 
• The present study examined the relationship between self-compassion and depression, anxiety, 
and resilience in people with epilepsy (PWE) 
• Higher self-compassion was found to predict lower depression and anxiety and higher resilience 
• These findings highlight the importance of self-compassion in improving psychological wellbeing 
in PWE 
• The study provides support for clinical interventions that target self-compassion in this population 
Abstract 
Background 
Research suggests that people with epilepsy (PWE) have a poorer quality of life and are more likely 
to experience depression and anxiety than the general population.  Given the adversity faced by 
people with the condition, resilience may an important psychological resource.  However, to date 
resilience has been largely overlooked in the epilepsy literature.  Self-compassion, and therapies 
designed to promote it, have been widely associated with improved psychological wellbeing and, to 
a lesser extent, resilience.  However, the impact of self-compassion on depression, anxiety, and 
resilience in PWE has not been examined. 
Objectives 
Using a quantitative cross-sectional survey design, the aim of the present study was to address this 
gap in the research by examining the extent to which self-compassion predicted depression, anxiety, 
and resilience when controlling for other important demographic and illness-related variables.  
Methods 
Adults with epilepsy were invited to take part in a survey online or in epilepsy or neurology clinics.  
Two-hundred and seventy participants completed the survey and data were analysed using 
hierarchical multiple regression models.   
Results 
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In this sample of PWE, self-compassion significantly predicted lower depression and anxiety and 
higher resilience when other significant sociodemographic and illness-related variables had been 
taken into account. 
Conclusions 
The findings of the present study indicate that self-compassion is an important factor in determining 
psychological outcomes for adults with epilepsy.  This study offers an important first step in the 
development of compassion-focused approaches to help improve psychological outcomes for PWE. 
Keywords 
Epilepsy; Self-Compassion; Depression; Anxiety; Resilience 
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1. Introduction 
Epilepsy is a chronic neurological condition characterised by recurrent episodes of abnormal 
electrical brain activity known as seizures which can affect sensory, motor and autonomic function, 
consciousness, emotional state, memory, cognition, and behaviour [1,2].  In England, epilepsy 
affects between 362,000 and 415,000 [3]; in Europe, the number of adults with active epilepsy is 
estimated to be 2.5 million [4]; and in the United States (US) the number of adults currently 
diagnosed with the condition is around 2.4 million [5]. 
1.1 Epilepsy and psychological wellbeing 
As a result of difficulties associated with the condition, people with epilepsy (PWE) have poorer 
quality of life (QOL) than the general population [6-10].  Depression and anxiety are also prevalent 
and contribute significantly to poorer QOL in this population [11].  Furthermore, in PWE 
depression and anxiety have been shown to significantly impair social functioning [12], and have 
been associated with poor sleep quality and suicidal ideation [13].  However, despite an increasing 
body of evidence supporting the link between epilepsy and poor psychological outcomes including 
depression and anxiety, trajectories of psychological wellbeing in PWE often do not follow the 
clinical course of the condition.  Instead, psychological wellbeing and QOL may be affected by a 
wide range of psychosocial factors including discrimination, difficulties of adjustment, personal and 
social capital, and social support [14].  Coping and engagement strategies, perceived social support, 
stress, and self-efficacy have also been identified as important [15]. 
Depression is highly prevalent in PWE [16].  It has been suggested that this high prevalence may be 
related to the frequency of seizures and the potentially depressogenic effects of some epilepsy 
medications [17].  In contrast, a 2015 review by Lacey, Salzberg, and D’Souza [18] found that, 
whilst epilepsy illness-related factors are important in predicting depression, sociodemographic 
factors including age, gender, education, employment and income predict this more consistently, 
and psychological factors including emotional aspects of recovery from seizures; social concerns 
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such as fear of injury, activity restriction, and embarrassment; and a past history of depression, 
anxiety and perceived stress were also important. 
Anxiety is also highly prevalent in PWE [19].  Perhaps unintuitively, the prevalence of anxiety in 
people whose epilepsy is well controlled does not appear to be lower than those with refractory 
epilepsy [20].  Such a high prevalence is often underestimated and it has been suggested that 
anxiety and epilepsy may share common neurobiological correlates, meaning that anxiety may both 
follow and precede epilepsy, although the evidence for this is largely derived from animal studies 
and further research is needed [21].  This perspective also fails to take into account psychological 
and social factors associated with epilepsy and anxiety, such as those identified by a recent study of 
adult epilepsy outpatients which found that a combination of psychosocial factors, including the use 
of coping strategies involving escape-avoidance and accepting greater responsibility, lower self-
efficacy, and greater self-illness enmeshment, were associated with anxiety [22].  Other social 
factors such as workplace discrimination have also been highlighted as important predictors of 
anxiety, alongside seizure control and the use of epilepsy medication [23]. 
1.2 Shame in epilepsy 
An important predictor for depression and anxiety in general population is shame [24,25].  Shame 
can be viewed as a self-focused and self-evaluative experience of being flawed or inadequate 
[26,27], or of negative aspects of the self being exposed [28,29].  In addition to self-evaluation, 
shame may relate to how we believe we exist in the minds of others or result from a process of 
internalising the “external shame” (e.g. criticism or ridicule) expressed by others [30].  Shame may 
furthermore represent a perception of self as being close to an undesired and unattractive self, rather 
than simply failing to meet ideal standards [31-33].   
Although the relationship between depression, anxiety, and shame has not been investigated directly 
in PWE, it is likely to be highly relevant to this population.  Shame has been identified in 
qualitative research into self-evaluating emotions in PWE, with participants describing the 
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condition as shameful, not wanting others to know about their diagnosis, and feeling bad about 
themselves as a result of having the condition [34].  In another study 56% of participants reported 
feelings of shame associated with their epilepsy [35].  Similar findings have been identified in 
research into children with epilepsy, with researchers observing an implicit reluctance for children 
to accept epilepsy as a part of their identity and displaying associated feelings of shame [36]. 
1.3 Self-compassion and psychological wellbeing 
The psychological impact of shame in PWE has not been well evidenced.  However, in the general 
population shame has been linked closely to self-criticism and depression in both adults and 
children [37-39].  However, there is an increasing body of evidence to suggest that self-compassion 
can help to protect against shame and lead to better mental health outcomes [40,41,42].  Self-
compassion has been defined as the act of being kind and understanding towards oneself in the face 
of difficult experiences, recognising one’s own experiences as part of the shared human condition 
rather than viewing them as isolating, and sitting mindfully with painful thoughts or feelings rather 
than over-identifying with them [43].  This conceptualisation is underpinned by Paul Gilbert’s 
evolutionary model of emotional regulation [44], which comprises three interacting 
neurophysiological systems: 
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In Gilbert’s model, individuals who are high in shame inhabit an over-activation of the drive and 
threat-based systems, whilst the soothing system is comparatively inaccessible.  In contrast, 
individuals who are higher in self-compassion are able to achieve calmness and relieve distress 
more easily through the activation of the self-soothing system [45].  In the general population, self-
compassion has been shown to predict improved psychological wellbeing including lower 
depression and anxiety, even when other variables have been accounted for [46-48].  In PWE, as 
highlighted above, if one views their condition as meaning that they are inadequate, or believe that 
others view them in this way, then they are more likely to experience feelings of shame which can 
precipitate (or be precipitated by) experiences of depression or low mood.  In contrast, those who 
are high in self-compassion should, according to Gilbert’s model and subsequent research, 
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In addition to reducing depression and anxiety, self-compassion has also been associated with 
resilience [49-51], although few studies have measured this directly and the empirical evidence to 
support this claim is currently limited.  In recent years, the concept of resilience has received 
increasing interest in the psychological literature.  Resilience has been defined simply as “an 
outcome of successful adaptation to adversity” [52].  Within this definition, two elements are seen 
as important: recovery, or how people “bounce back” from a stressful event [53]; and sustainability, 
or the capacity to continue forward in the face of adversity [54].  Resilience has been demonstrated 
as an important personal resource which is associated with improved physical and psychological 
wellbeing [55], and has been examined in a wide range of health populations including adults with 
cancer [56], diabetes, [57], and chronic pain [58].  To date, however, resilience has been largely 
overlooked in the epilepsy literature, where the focus has been on risk factors for negative 
psychological outcomes such as depression and anxiety [59].  Given the potentially significant 
psychosocial impact of the condition identified, resilience is arguably an important psychological 
resource to consider in this population. 
1.5 Rationale for the present study 
In summary, the currently available evidence for predictors of depression and anxiety in PWE 
suggests that a combination of psychosocial, illness-related, and sociodemographic factors are 
likely to be important.  However, existing research does not adequately account for variations in 
psychological outcomes, and it is possible that other factors which have not yet been investigated 
may be important.  In the general population, self-compassion has been posited as a potential 
antidote to feelings of shame and has been linked to improved psychological outcomes and 
resilience.  However, self-compassion as a predictor of reduced depression and anxiety and 
increased resilience in PWE has not been examined.  If self-compassion can help to promote 
resilience and protect against illness-related factors and shame for people with this condition, then 
this may lead to reductions in depression and anxiety.  The findings of this research may therefore 
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have potentially significant clinical implications for the psychological care of PWE, for example by 
providing evidence for interventions such as CFT as a means of increasing resilience and improving 
psychological wellbeing. 
1.6 Research aims and hypotheses 
Using a quantitative design, the aim of the study was to identify whether self-compassion predicted 
additional variance in measures of depression, anxiety, and resilience when other known predictors 
of wellbeing including socio-demographic and illness-related variables had been accounted for.  It 
was hypothesised that self-compassion would be negatively associated with depression and anxiety 




The study used a quantitative cross-sectional survey design to examine predictors of depression, 
anxiety, and resilience in PWE.  Feedback on the design was obtained from a panel of service user 
representatives from the charity Epilepsy Action (the Epilepsy Action Research Network; EARN) 
and suggested changes were incorporated into the final design. 
2.2 Participants 
A predictive power calculation for a linear multiple regression with six predictors suggested that to 
achieve power of .8 with a medium effect size of .2 (as indicated in other studies of self-compassion  
[e.g. 60]) at a probability level of p = .05 required 75 participants.  Epilepsy Action supported 
recruitment by advertising the study on their website, newsletter, and social media channels.  A total 
of 327 participants consented to take part in the study; 305 were recruited online through Facebook 
support groups and Twitter, and 22 were recruited from local NHS epilepsy services.  Of these, 270 
provided responses that could be utilised in the final study. 
2.2.1 Inclusion and exclusion criteria 
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To be eligible for inclusion participants were required to self-report a diagnosis of epilepsy, to be at 
least 18 years old, and to be able to understand English and complete a survey.  People who had 
experienced seizures but did not have an epilepsy diagnosis were excluded.  The questionnaires 
used were not all validated in other languages, therefore non-English speakers were not able to take 
part. 
2.3 Procedure 
2.3.1 Online recruitment 
Participants were recruited online and from local NHS epilepsy services.  Online recruitment took 
place between October 2016 and January 2017.  The study was posted on the Lancaster University 
Doctorate in Clinical Psychology research page (http://www.lancaster.ac.uk/shm/study /
doctoral_study/dclinpsy/research).  The research page included the participant information sheet 
(PIS) and a link to the consent form and Qualtrics survey.  An invitation and link to the research 
page were also posted on Twitter and Facebook, and on Epilepsy Action’s website and newsletter.  
Participants were asked to provide consent by reading the PIS and completing the consent form at 
the beginning of the survey.  The survey took participants approximately 10-15 minutes to 
complete.  Following this a debrief sheet including information about support organisations was 
displayed.  
2.3.2 Clinic recruitment 
A secondary recruitment avenue took place in local epilepsy clinics.  From October to December 
2016 the primary researcher attended epilepsy and neuropsychology clinics and asked patients if 
they would be willing to complete a short paper-based or online survey.  The survey was prefaced 
with a participant information sheet (PIS) containing a description of the study, its purpose, the 
inclusion and exclusion criteria, and how the data would be used.  Patients were given the option to 
complete the survey on paper in clinic or later online (via a web link provided) to give them 
sufficient time (> 24 hours) to read the information before deciding whether to take part.  
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Participants were asked to provide consent by completing a consent form provided and a debrief 
sheet was provided at the end of the survey.  Copies of the PIS, consent form, and debrief sheet are 
provided in the Research Ethics section. 
2.3.3 Data collection and measures 
Data were collected via a survey comprising questions about demographic and clinical information 
alongside standardised measures of seizure severity, self-compassion, depression, anxiety, and 
resilience.  The survey comprised electronic and paper versions of the following standardised 
measures: The Liverpool Seizure Severity Scale 2.0 (LSSS) [61]; The Neff Self-Compassion Scale 
(SCS) [62]; The Hospital Anxiety and Depression Scale (HADS) [63]; and The Brief Resilience 
Scale (BRS) [64].  In addition to standardised measures, data were collected about 
sociodemographic and illness related variables.  Details about the measures and survey questions, 
including Cronbach’s alpha coefficients reported in previous research, are provided in Appendix A.  
Electronic versions were administered using the Qualtrics platform, a web-based survey and data 
collection software licensed for use by Lancaster University staff and students.  
2.4 Analysis 
Statistical analyses were completed using IBM SPSS, Version 22.  Correlation analyses were 
completed for all of the main variables.  Those that were found to be significantly associated with 
the outcome variables were then entered into a hierarchical regression model, followed by self-
compassion as the main predictor variable of interest.  In order to input non-binary categorical 
variables into the regression model (i.e. employment status, level of education, and relationship 
status), these were recoded into binary categorical variables in SPSS (i.e. employed/unemployed, 
higher education/below higher education, in a relationship/not in a relationship).  The predictor 
variables were entered into the model in three steps: 1) Sociodemographic variables, 2) Illness-
related variables, and 3) Self-compassion (SCS).  The outcome variables were: 1) Depression 
(HADS), 2) Anxiety (HADS), and 3) Resilience (BRS). 
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2.5 Ethical Considerations 
It was not anticipated that this study would result in risks to participants or raise significant ethical 
issues.  Participant wellbeing was considered carefully, as per the study procedure outlined above.  
Data protection was also carefully considered.  For the majority of participants, anonymous, non-
identifiable, quantitative demographic and research questionnaire data was collected only.  No 
personal identifiable data was routinely collected and all data was stored securely and used only for 
the intended and advertised purpose.  Throughout the course of the study ethical considerations 
were discussed with the external supervisor, an expert working in the field of epilepsy.  Ethical and 
research governance approval to complete the research and recruit from the hospital was provided 
by an independent NHS Research Ethics Committee (REC) and the relevant Research and 
Development (R&D) department via the Health Research Authority (HRA) integrated system. 
3. Results 
A total of 327 participants consented to take part in the study.  Of these, 305 were recruited online 
and 22 from epilepsy clinics.  Independent t -Tests were carried out to compare the variable means 
of the clinical and online samples; no significant differences were identified between the two 
groups in relation to all of the main variables (p > .01), with the exception of level of education, 
which was found to be higher in the online sample (t = 3.141, p = .004).  Of the 327 survey 
responses, 59 contained missing data.  Fifty-seven were excluded from statistical analyses due to 
missing data on three or more main variables.  Many of these participants did not complete 
demographic questions, therefore it was not possible to compare those with missing data to those 
who completed the survey.  In the remaining two cases, data was imputed for missing BRS 
responses using mean substitution.  This provided a total of 270 responses that were included in 
statistical analyses.  
3.1 Sample characteristics 
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An overview of the socio-demographic and clinical characteristics of the sample are provided in 
Table 1.  Approximately 76% of the sample were female, which may not be representative of the 
general population in which females are thought to have a marginally lower risk of developing 
epilepsy than males [65].  The sample covered an age range from 18-71+, although only 8.1% of 
participants were aged over 60, which again may again not fully represent the general population in 
which the incidence of epilepsy is thought to be higher in older adults [66]; although the mode 
categorical age (31-50 years) was comparable to means of other studies [67,68].  Considering 
ethnicity, 73% of participants identified as White British, therefore other ethnic backgrounds were 
comparatively under-represented.  Approximately 40% of participants were educated to degree level 
or above, however only 6% reported having no qualifications, which suggests that people with 
lower levels of education were also comparatively under-represented in the sample. 
[Table 1 here] 
Descriptive statistics and Cronbach’s α coefficients for the standardised questionnaires are 
presented in Table 2.  The mean seizure severity score of the sample was 32.93 out of 100, which 
was marginally lower than other similar studies of epilepsy populations [69,70].  However, for 
participants who had not experienced a seizure in the last four weeks, a score of zero was indicated 
on the Liverpool Seizure Severity Scale, as per the authors’ guidelines [61].  This applied to 41% of 
the sample, lowering the overall average score of seizure severity.  The mean depression score of 
7.94 placed this above the recommended clinical cut-off score of ≥ 7 for depression in an epilepsy 
population [71]; this was higher than other similar studies [72,73].  The mean anxiety score was 
higher still at 11.01, placing this in the moderate clinical range and well above the recommended 
cut-off score of ≥ 8 in an epilepsy population [71]; this was again higher than other similar studies 
[72,73].  The α coefficients for responses observed in the present study indicated high internal 
consistency.  Alpha values ranged from 0.83 to 0.94, which were in line with those reported in 
previous research (see Appendix A). 
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[Table 2 here] 
3.2 Correlational analyses  
Normality of the distributions were checked by examining the skew and kurtosis of data.  The 
Liverpool Seizure Severity Scale was not normally distributed (see Table 3), therefore non-
parametric tests of correlation were used. 
[Table 3 here] 
Spearman’s rho correlations between all demographic, illness, and outcome variables are provided 
in Table 4.   
[Table 4 here] 
Several demographic variables were found to correlate with the outcome variables.  Employment 
status was correlated with depression (being employed was associated with lower depression; ρ = -.
183, p < .005), and resilience (being employed was associated with higher resilience; ρ = .158, p < .
01), but not anxiety.  Age was positively correlated with resilience (ρ = .138, p < .05), and 
negatively correlated with anxiety (ρ = -.197, p = .001), but not depression.  Gender, level of 
education, and relationship status were not correlated with any of the main outcome variables.  
Illness-related variables were found to be significant.  Seizure severity was positively correlated 
with depression (ρ = .255, p < .001) and anxiety (ρ = .202, p = .001), and negatively correlated with 
resilience (ρ = -.208, p = .001).  Seizure type also correlated with anxiety (generalised seizures were 
positively associated with anxiety; ρ = .142, p < .05), but not depression or resilience.  Medication 
use was not associated with any of the main outcome variables.  Self-compassion was significantly 
negatively correlated with depression (ρ = -.585, p < .001) and anxiety (ρ = -.608, p < .001), and 
positively correlated with resilience (ρ = .595, p < .001).  Self-compassion and seizure severity 
were not significantly correlated (p = .466). 
3.3 Multiple hierarchical regression analyses 
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Variables which were found to be significantly correlated with the outcome variables depression, 
anxiety, and resilience were entered as predictor variables into the regression model. 
Sociodemographic variables were entered into the first stage of the model, followed by illness-
related variables in the second stage, and self-compassion in the third and final stage as the main 
variable of interest.  The regression model was therefore structured as follows: 
1) Sociodemographic variables: age, employment status 
2) Illness-related variables: seizure severity (LSSS), seizure type 
3) Self-compassion (SCS) 
The results of the multiple hierarchical regression analyses are provided in Table 5 (a-c). 
[Tables 5 a-c here] 
The data were checked in SPSS to ensure that the main assumptions of multiple regression were 
met.  Dependent and independent variables were linearly related (indicated by scatterplots of 
predictor and dependent variables, residual terms were uncorrelated (using the Durbin-Watson test 
as a measure of autocorrelation), residuals at each level of the predictor had similar variance 
(homoscedasticity; indicated by scatterplots of residual and predictor variables), errors were 
normally distributed (indicated by histogram and P-P-Plots of residuals), and no multicollinearity 
was present (indicated by variance inflation factor (VIF) and tolerance statistics) [74].  Data were 
also checked for outliers; none were identified. 
The regression analyses for depression indicated that Steps 1 and 2 of the model accounted for 9.4% 
of the variance in the outcome.  Self-compassion was found to increase the explanatory power of 
the final model to 43.5%.  Self-compassion therefore explained 34.1% of the variance in 
depression, and the overall model was significant (F = 39.942, p < .001).  In the final model, the 
variables that were found to be significant were seizure severity (β = .252, p < .001), employment 
status (β = -.115, p < .01) and self-compassion (β = -.596, p < .001). 
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The regression analyses for anxiety indicated that Steps 1 and 2 of the model accounted for 9.5% of 
the variance in the outcome.  Self-compassion was found to increase the explanatory power of the 
final model to 41.7%.  Self-compassion therefore explained 32.2% of the variance in anxiety, and 
the overall model was significant (F = 37.127, p < .001).  In the final model, the variables that were 
found to be significant were seizure severity (β = .182, p < .001), seizure type (β = .102, p < .01) 
and self-compassion (β = -.579, p < .001). 
Finally, regression analyses for resilience indicated that Steps 1 and 2 of the model accounted for 
7.3% of the variance in the outcome.  Self-compassion was found to increase the explanatory power 
of the final model to 41%.  Self-compassion therefore explained 33.7% of the variance in resilience, 
and the final model was again significant (F = 36.150, p < .001).  In the final model, the variables 
that were found to be significant were seizure severity (β = -.176, p < .001) and self-compassion (β 
= .593, p < .001). 
4. Discussion 
The present study examined the relationship between self-compassion and depression, anxiety, and 
resilience in people with epilepsy (PWE), using a cross-sectional survey design.  Regression 
analyses of the data revealed higher self-compassion to predict lower depression and anxiety and 
higher resilience, supporting the initial study hypotheses. 
4.1 Self-compassion and psychological wellbeing in epilepsy 
Self-compassion is a concept that has received increasing interest in the psychological world in 
recent years.  Self-compassion is a multifaceted term which incorporates self-kindness, 
mindfulness, and a sense of common humanity as an alternative to negative states of self-criticism, 
isolation, and over-identification with painful emotions [43].  These are likely to be important for 
PWE due to the adversity associated with the condition.  Unsurprisingly, a common reaction to 
adversity and negative life experiences such as chronic illness is depression [75,76].  This is 
particularly relevant for PWE who often face difficulties which are complex and may persist even 
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when the condition is well-managed, including compromised physical health, cognitive impairment, 
isolation, uncertainty, fear, and discrimination [19,77,78].  Epilepsy has therefore also been 
associated with anxiety [19].  In contrast, people with higher resilience may be able to cope better 
with the adversity due to their increased capacity to bounce back from experiences of adversity 
[52].  Self-compassion may therefore be particularly important for helping alleviate depression and 
anxiety and increasing resilience for PWE. 
The findings of the present study suggest that, despite the complex nature of epilepsy and its impact 
on psychological wellbeing and QOL, for some PWE self-compassion may be associated with 
better psychological outcomes.  These findings may be explained in part by the known influence of 
self-compassion on self-criticism and shame [41], which many PWE experience as a result of their 
condition [79].  Similarly, in the general population events that are perceived to have been inflicted 
on the self (known as self-adversity), as opposed to those which are inflicted on others (other-
orientated adversity), have been shown to be more strongly associated with depression [80].  It has 
been suggested that epilepsy is often associated with self-blame, shame, and anger [81].  Therefore, 
if PWE have a low capacity for self-compassion and blame themselves for their condition, then they 
may possess a greater sense of self-adversity, which may lead to higher levels of depression.  This is 
in line with previous epilepsy research into the negative impact of self-blame on depression and 
QOL [82,83].  The impact of self-compassion on depression may also be explained in part by the 
effect of rumination, which has been found to mediate this relationship in the general population 
[84].  In contrast, if PWE are able to adopt a more compassionate view towards themselves and 
their condition, in a way which is non-blaming and avoids over-identifying with the adversity of 
their situation, then this may help to protect against feelings of depression.  Although the current 
study is cross-sectional so causality cannot be ascertained, the findings suggest that this is a 
plausible hypothesis. 
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The findings also indicate that higher levels of self-compassion are associated with lower levels of 
anxiety in this population.  This partially replicates previous findings from a study of people 
diagnosed with social anxiety, where self-compassion was found to be lower in those with a clinical 
diagnosis of social anxiety disorder; lower self-compassion was also associated with greater fear of 
evaluation from others [85].  These findings may be explained in part by the impact of self-
compassion on cognitive processing.  In the general population, the relationship between self-
compassion and anxiety has been shown to be mediated by positive and negative automatic 
thoughts [86].  Worry and rumination have similarly been found to mediate this relationship [84].  
The impact of self-compassion on worry and catastrophic thinking may therefore help to explain the 
findings of the present study.  For example, PWE who make more positive, self-compassionate, 
appraisals of their condition may feel less anxious than those who worry or make negative or 
catastrophic appraisals in relation to their condition.  
A further important finding of this study was that self-compassion predicted increased resilience.  
As previously highlighted, despite some evidence of this relationship in the general population 
[49-51], the literature to support the association between self-compassion and resilience is currently 
limited.  The present study offers a significant novel finding as it provides preliminary evidence of a 
relationship between self-compassion and resilience in PWE – a population who typically face high 
levels of adversity and for whom resilience is likely to be valuable to protect against feelings of 
depression and anxiety often associated with the condition.  It has been suggested that increased 
resilience in other populations may be explained by self-compassion acting as an adaptive 
emotional regulation strategy which protects against the activation of negative schemas triggered by 
adverse experiences [87].  Self-compassionate thoughts may also promote an acceptance of 
suffering as something that is universal, and people may therefore be less likely to feel guilty or 
attend to the negative aspects of their situation; they may instead be better able to control negative 
reactions to experiences which cause discomfort [88].  Self-compassion has also been shown to 
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reduce the tendency for harsh self-criticism [89], and to increase the capacity for optimism and 
feelings of self-efficacy [51,90,91].  Given this is a cross-sectional study, such mechanisms can only 
be tentatively suggested, however they may help to explain the findings of the present study in 
relation to higher self-compassion predicting greater resilience in this sample of PWE. 
4.2 Implications 
The findings of this study have potentially significant implications in relation to psychological care 
and public health strategies for PWE.  At a clinical level, the most significant indicator arising from 
this study is that it highlights a possible link between self-compassion and better psychological 
outcomes in PWE.  Although causation cannot be determined from the present study, these findings 
suggest that researching CFT for this population would be a useful next step in informing care for 
PWE who are less resilient or at risk of experiencing depression or anxiety.  The observed link 
between self-compassion and affect regulation systems required to feel reassured, safe, and well is 
the basis on which CFT is predicated [45].  In contrast, in people with higher levels of shame and 
self-criticism these regulation systems are less accessible; in these cases self-compassionate 
approaches have been shown to help to reduce shame and predict improved mood [92-94].  
Importantly, the present study extends the findings of previous research into self-compassion to an 
adult epilepsy population. While it is acknowledged that the current findings are cross-sectional and 
therefore do not provide an indication of causation, they suggest that interventions which directly 
target self-compassion may be helpful to consider in PWE.  Given that seizure severity and self-
compassion were found not to be correlated, the study suggests furthermore that it is possible to be 
self-compassionate even when actively experiencing epilepsy-related symptoms.  PWE are likely to 
require resilience in order to cope with the difficulties associated with the condition.  Currently the 
only psychological interventions which are recommended in clinical guidelines in the UK are 
relaxation, cognitive behavioural therapy (CBT), and biofeedback [3].  However, given the 
observed association between self-compassion and resilience, the present research suggests that it 
Running head: RESEARCH PAPER           2- !20
may also be helpful to consider compassion-focused approaches such as CFT in the psychological 
care of PWE presenting to clinical health services.  Further research into the use of CFT in this 
population is needed to determine its benefits. 
The finding that self-compassion predicts lower depression and anxiety may also be due to social 
perceptions of epilepsy, which can cause people to feel bad about themselves and conceal their 
condition from others [34], leading to poor psychosocial outcomes [79,95,96].  Therefore, at a 
public health level, more may need to be done to tackle the negative societal judgement of the 
visible aspects of epilepsy (i.e. uncontrolled seizures), and to foster a compassionate view of the 
condition by both people with and without the condition.  This could be achieved through the 
development of campaigns that model a compassionate view of the condition; this may include 
literature or advertisements that describe or explain epilepsy and seizures in compassionate 
language, via avenues that are accessible to a wide range of people such as online social media 
platforms, combatting negative misinformation that currently exists in these arenas [97]. 
4.3 Further research 
The findings of this study highlight a number of areas of further research that would be beneficial in 
advancing our understanding of psychological care for this population.  The present study provides 
evidence of the predictive capacity of self-compassion in regards to resilience, depression, and 
anxiety in PWE.  This suggests that increasing self-compassion in this population could have 
beneficial effects on wellbeing and therefore it would be useful to examine CFT in this population 
in further research.  This could be best achieved through experimental designs such as randomised 
controlled trails (RCTs) which offer a rigorous method of determining the effectiveness of clinical 
interventions [98].  Secondly, it would be useful to better understand how self-compassion is 
experienced in PWE (i.e. what makes some people in this population more likely to engage in acts 
of self-kindness than others and how can this be developed in the real world).  This may be 
explored initially through qualitative research involving samples of PWE identified as being either 
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high or low in self-compassion; interpretative phenomenological analysis (IPA) is an approach well 
suited to this type of health research [99].  This could be followed up with further quantitative 
research to examine predictors of self-compassion in PWE, incorporating longitudinal methods 
which would allow researchers to examine causal relationships between these variables [100].  
Additional research in these areas would help us to identify how self-compassion can be fostered 
and developed in PWE as a means of improving psychological wellbeing in this population in a 
preventative, rather than purely reactive way (i.e. by increasing resilience). 
4.4 Strengths and limitations 
The present study used a cross-sectional survey to gather data pertaining to variables of interest.  
This design presents a number of known limitations, including failing to address chronological 
variability [101].  The use of self-report measures is open to bias [102] and is sensitive to culture 
[103], further compromising the reliability of findings.  There were also limitations in the variables 
examined.  For example, duration of diagnosis was not included in analyses, therefore it was not 
possible to determine the potential impact of epilepsy diagnosis duration on key variables measured 
within the study (e.g. whether people who are diagnosed at a younger age or who have been 
diagnosed for longer are likely to be higher or lower in self-compassion, depression, anxiety, or 
resilience).  In previous research, duration of epilepsy diagnosis has not been reliably associated 
with depression and anxiety [104], however it is possible that inclusion of such a variable may have 
reduced the variance attributed to self-compassion in this sample.  Furthermore, whilst participants 
were recruited through epilepsy clinics, the majority of the sample was recruited online.  These 
samples were found to be comparable on key variables, however it was not possible to verify with 
certainty who the respondents to the survey were and if the sample was truly valid (i.e. that all 
respondents met the inclusion criteria).  Additionally, whilst the study was open internationally, the 
majority of participants were White British and female.  Online recruitment may also have 
inadvertently excluded people who were not computer literate or did not have access to the 
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technology necessary to access the study, which may have included older adults or those who were 
less educated; therefore the findings may not be generalisable to these populations.  Despite these 
limitations, the online recruitment also provided some of the study’s main strengths.  The benefits 
of online methodology in psychology has been recognised as it offers an effective means expanding 
the scale and scope of research [105]; this approach allowed a large sample to be recruited, 
therefore analyses were highly powered.  The use of social networking sites also provided an 
inclusive means of giving voice to a wide range of people, regardless of their ability to attend 
research clinics or even to speak to a researcher on the telephone. 
4.5 Conclusions 
The findings of the present study suggest that self-compassion may be an important factor in 
determining psychological outcomes for adults with epilepsy.  Whilst socio-demographic and 
illness-related variables have been demonstrated here and elsewhere to contribute to the wellbeing 
of people in this population, these findings suggest that other factors may also be important.  The 
present study suggests that higher self-compassion may be associated with improved psychological 
outcomes such as lower depression and anxiety, and higher resilience.  Therefore, if self-
compassion can be fostered and developed through means such as formalised clinical interventions 
(e.g. CFT), personal self-care strategies, public health interventions, or community support 
approaches, then this may be beneficial to PWE.  Further research which examines the acceptability 
and effectiveness of such approaches is needed.  However, this study offers an important first step 
in highlighting the potential importance of investigating and developing compassion-focused 
approaches to help improve psychological outcomes for PWE. 
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Table 1  




























Highest level of Education 
Degree or above 
A-Level, trade or other higher education 
GCSE or NVQ 









































White - English/Welsh/Scottish/Northern Irish/British 
White - Irish 
Any other White background 
White and Black Caribbean 
White and Black African 















Table 1  
Sociodemographic and Clinical Information (%)
Table 2  
Descriptive Statistics - Reliability Values, Means, and Standard Deviations of Main 
Variables
α M SD
1. Seizure severity 0.86 32.93 32.10
2. Self-compassion 0.94 2.61 0.68
3. Depression 0.84 7.94 4.70
4. Anxiety 0.83 11.01 4.60
5. Resilience 0.87 2.74 0.86
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Table 3  
Descriptive Statistics - Distributions of Main Variables
Statistic Std. Error
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Table 4 
Spearman’s Rho Correlations Between Variables
























































4. Resilience - -.04 .138* .
158*
*
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12. Seizure type -
* **p ≤ .01  
    *p ≤ .05
Table 4 
Spearman’s Rho Correlations Between Variables
1 2 3 4 5 6 7 8 9 10 11 12
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Table 5a  
Results of Hierarchical Multiple Regression for Depression







Age -.166 .191 -.054 -.868 .386





Age -.157 .185 -.051 -.847 .398
Employment status -1.476 .638 -.142 -2.313 .022
Seizure severity .038 .009 .263 4.277 .000




Age .212 .149 .069 1.419 .157
Employment status -1.200 .504 -.115 -2.379 .018
Seizure severity .037 .007 .252 5.186 .000
Seizure type -.040 .445 -.004 -.089 .929
Self-compassion 4.231 .344 -.596 -12.30
1
.000
* p < .01 
**p < .001
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Table 5b  
Results of Hierarchical Multiple Regression for Anxiety







Age -.652 .183 -.218 -3.561 .000





Age -.632 .179 -.211 -3.529 .000
Employment status -.575 .616 -.057 -.933 .352
Seizure severity .027 .009 .193 3.144 .002




Age -.285 .147 -.095 -1.945 .053
Employment status -.316 .495 -.031 -.638 .524
Seizure severity .026 .007 .182 3.696 .000
Seizure type .921 .437 .102 2.108 .036
Self-compassion -3.974 .338 -.579 -11.765 .000
**p < .001
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Table 5c  
Results of Hierarchical Multiple Regression for Resilience







Age .095 .035 .169 2.751 .006





Age .093 .034 .165 2.729 .007
Employment status .201 .118 .106 1.706 .089
Seizure severity -.005 .002 -.187 -3.008 .003




Age .026 .028 .047 .947 .345
Employment status .151 .094 .079 1.604 .110
Seizure severity -.005 .001 -.176 -3.546 .000
Seizure type -.051 .083 -.030 -.612 .541
Self-compassion .767 .064 .593 11.972 .000
**p ≤ .001
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Appendices 
Appendix A. Details of Measures and Questions Included in the Survey 
Appendix A. 
Details of Measures and Questions Included in the Survey
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1. Main findings 
1.1 Literature review 
The systematic literature review of correlates of stigma in people with epilepsy (PWE) identified, 
appraised, and synthesised a large body of empirical evidence from 33 papers reporting findings 
from 25 quantitative research studies.  The findings suggested a complicated combination of 
potential predictors and outcomes.  Predictors were found to be influenced by country of origin and 
included demographic, illness-related, and psychosocial variables.  Being married, higher income, 
and higher age were found to predict lower levels of stigma.  In contrast, being diagnosed younger, 
having a greater number or more frequent seizures, and sustaining greater injuries from seizures 
were found to predict higher stigma.  Higher stigma was also predicted by psychological factors 
including lower self-efficacy, social anxiety, future concerns or negative expectations about the 
condition, and beliefs that the condition is genetically determined.  Avoidant coping strategies such 
as concealing the condition from others, or disengaging from managing it, were also associated with 
higher stigma.  Stigma was also higher when PWE did not have access to understandable 
information about the condition.  Social support, in contrast, was found to predict lower stigma.  
Outcomes from stigma were more uniform; those who felt stigmatised reported lower self-efficacy 
and motivation, and unsurprisingly reported poorer physical wellbeing and condition management, 
characterised by lower medication adherence and increased seizure severity.  Poorer psychological 
outcomes were also identified for those with higher stigma, including higher depression and anxiety 
and lower quality of life. 
1.2 Research paper 
The empirical research paper was underpinned by the theory that self-compassion, and therapies 
which promote growth in people’s individual capacity to be self-compassionate, can aid self-
soothing in the face of adversity, and therefore improve psychological wellbeing [1,2].  The existing 
self-compassion research across populations has primarily focused on outcomes of depression and 
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anxiety [3-5], and to a lesser extent resilience [6].  The aim of the study was to take the established 
phenomenon and apply it to a specific health population, namely PWE, to ascertain whether these 
concepts are transferable to people with a complex neurological condition.  In a quantitative study 
of a sample of adults with epilepsy, the findings of the study indicated that self-compassion can play 
a significant role in predicting improved psychological outcomes in this population - specifically 
lower depression and anxiety and increased resilience.  The most significant implication of these 
findings was providing preliminary evidence that compassion-focused interventions such as 
compassion focused therapy (CFT) may be beneficial in the psychological care of PWE. 
2. Research decisions, challenges, and professional issues 
Throughout the course of the thesis a large number of important decisions were presented by the 
development of both the literature review and empirical research study.  These decisions 
fundamentally shaped the thesis content, process, and outcomes.  They also underpinned the 
relative strengths and limitations of the research in terms of its methodology and value in the wider 
psychological literature.  Some of the key decisions, challenges, and professional issues are 
discussed here, with reference to strengths and limitations they precipitated in the thesis. 
2.1 Literature review 
2.1.1 Scope 
An important consideration early on in the thesis was the focus of the literature review.  I had 
already decided what the focus of the empirical paper would be, therefore in the literature review I 
was initially interested in examining the main research variable, self-compassion, more closely.  I 
was specifically interested in the relationship between self-compassion and shame, as this is 
something that I had come across in the literature [7,8].  However, through initial scoping searches 
it became apparent that the research was heterogenous and it would be difficult to create a 
meaningful and focused narrative.  This brought me closer to the subject of stigma in epilepsy, 
which had already come up literature searches and was highly applicable to my research study.  In 
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consultation with my research supervisor I decided to look at correlates of stigma in epilepsy.  This 
produced a large number of results which seemed unmanageable, and again too heterogenous, to 
easily draw together.  I was therefore required to narrow the search to focus my research aims.  
During this process, I had to make decisions about cut-off criteria, for example deciding whether or 
not to include Western and Non-Western research, older and newer studies, and child and adult 
populations.  Overall, I feel that focusing only on Western, adult populations, published since the 
year 2000 provided a focused review of current literature.  However, despite limiting the cultural 
and geographical scope of the review, the sample was less homogenous than I had envisaged, and 
there were significant differences identified across countries.  This highlights the complex nature of 
stigma in PWE and warrants further research.  However, the sample was also still arguably less 
heterogeneous than if non-Western populations had been included; again this warrants a separate 
review. 
I also had to carefully consider alternative search terms, for example terms associated with stigma, 
such as “shame” and “misconceptions”, and truncated words such as “*”, to include terms such as 
stigmatising and stigmatised.  These iterations were rejected in the final list of search terms, which 
was kept relatively simple in order to ensure that the search remained focused.  These decisions 
were made pragmatically and with the knowledge that no search is perfect.  In order to produce a 
focused and robust search strategy, I liaised with the academic librarian for guidance who made a 
number of suggestions, such as using thesaurus search terms in databases; I believe that these steps 
led to a comprehensive review of the literature and represented a strength of the research. 
2.1.2 Methodological appraisal 
Once I had completed my searches and identified relevant studies, a further key decision was how 
best to critically appraise the methodological quality of the papers included in the literature review.  
Having had previous experience of using quality appraisal tools, I have learned that the process can 
be time-consuming, subjective, and can seem like an unhelpful process.  I have previously used 
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long checklists such as the STROBE [9]; however, this has been criticised for inappropriate use as a 
methodological quality assessment tool [10].  For the thesis, I was keen to use a shorter tool that 
focused on the main issues of reporting and methodology.  I therefore considered a range of 
different options before deciding to use the quality appraisal tool for observational studies adapted 
from the Agency for Healthcare Research and Quality [11].  This tool was chosen as the items were 
highly relevant to the cross-sectional survey design used in the majority of research papers in the 
review.  Peer inter-rating helped to ensure that the process was as objective as possible and to 
identify areas of error or bias. 
2.2 Research paper 
2.2.1 Measurement and survey design 
In the early development of the empirical study, one of the most important decisions was which 
standardised variable measures to use.  There were several choices for measures of depression, 
anxiety, resilience, and self-compassion, and each presented compromises.  These decisions were 
informed largely by previous studies in the field.  For example, the Hospital Anxiety and 
Depression Scale (HADS [12]) is widely used in epilepsy populations as it is designed for clinical 
samples due to fewer somatic items than some other measures of depression and anxiety [13].  
Whilst epilepsy specific measures of depression exist, I was advised by my field supervisor that 
these were less well established than the HADS, therefore these were avoided.  Another important 
consideration was the demand that the survey may place on participants.  Whilst it was desirable to 
gain a comprehensive dataset that would allow for nuanced and meaningful analyses, it was 
important to balance this with the time and demand placed on participants; it was also possible that 
longer questionnaires would lead to higher attrition rates.  I decided that as the main variable of 
interest it was important to have a comprehensive measure of self-compassion, therefore the 26-
item Neff Self Compassion Scale (SCS; [14]) was used.  However, to ensure that the survey did not 
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become too long, shorter measures, such as the six-item Brief Resilience Scale (BRS; [15]), were 
used to measure other variables in the study. 
Despite the careful consideration given to measures, there was evidence that some aspects of the 
survey may have been challenging or undesirable to participants, and this may represent a limitation 
of the study design.  The data suggests that some participants discontinued their responses when 
presented with questions from the SCS.  Although missing data in questionnaire surveys is 
inevitable [16], some participants in the clinic appeared to find some of the more convoluted 
questions difficult to answer, which may help to explain some of the attrition identified in the online 
sample.  The SCS has come under increasing scrutiny for its psychometric properties [17,18], 
although it has been validated as a measure of self-compassion [19] and is presently the most 
widely relied upon tool for this purpose [20].  The measure was therefore was considered to be the 
best available at the time of the undertaking the research study. 
Once the variable measures had been chosen, there were decisions to make around how the survey 
would operate using the Qualtrics software.  One such example was whether or not to force 
responses so that a question cannot be answered until responses have been given to all previous 
questions.  The dilemma in this issue was that forcing responses would lead to complete datasets 
but would likely result in higher levels of attrition and would not give participants the option to skip 
difficult or emotive questions, however not forcing responses would likely result in missing data, 
which would present further difficulty later in managing data analysis.  I decided that it was more 
important to give participants the option to complete only the questions they felt able to, as this was 
ethically more desirable and would likely result in more participants completing the survey as a 
whole, albeit perhaps with some missing data.  The outcome of this appeared generally favourable: 
the majority of participants completed all or the majority of questions and the fraction of missing 
data was small. 
2.2.2 Recruitment and data collection 
CRITICAL APPRAISAL 3- !7
Ethical issues in relation to recruitment and data collection were also identified.  An important 
ethical challenge identified during the recruitment phase was that of identifying potential 
participants in clinic in an ethical and practical way.  In consultation with my supervisors, I 
considered a number of different approaches including obtaining patient names from clinic staff, 
sending out participant information sheet by post in advance, and opportunistically approaching 
patients in the waiting room.  A further related issue was that of informed consent.  Whilst 
recruiting in clinic it was pragmatic for patients to be approached and asked if they would be 
interested and willing to take part in the study.  However, the recommended norm is to give 
potential participants in excess of 24 hours to decide whether or not to take part [21], therefore it 
was unclear whether they could reasonably complete a paper copy of the survey on the day they 
were approached in clinic.  In order to ascertain the best approach to addressing these issues, I 
consulted HRA guidance, spoke to my supervisors, and then contacted the REC who had provided 
approval for the study.  I was advised that it is acceptable and pragmatic to give people the option to 
complete the study survey on the day of clinic, as long as they have the option to take is away and 
think if needed; this was supported by up-to-date research guidance [22].  Given this advice, I 
decided to ask nurses and consultants if they could identify participants at the end of consultations 
and direct them to me if they were interested in hearing about the study and potentially taking part.  
This was in line with my approved ethics application, was non-intrusive, did not put much work 
onto clinical staff, and was practically effective. 
2.2.3 Sample 
Despite the careful consideration given to recruitment, a limitation of the study was clearly 
identifying a sample of adults with a diagnosis of epilepsy.  I was advised by my field supervisor 
early on in the research process that some people may believe that they have epilepsy when they 
have not in fact received a medical diagnosis.  Whilst we could establish for certain that participants 
recruited from outpatient clinics had received a diagnosis, this was not possible for those recruited 
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online; this was open to anyone who stated that they had received a diagnosis.  However, there was 
no way to confirm that this was accurate.  Furthermore, the manager of the video telemetry (VT) 
clinic advised that even some patients who have received a diagnosis of epilepsy may not actually 
have the condition.  Part of the work of this clinic is identifying the nature of seizure activity, and it 
is possible that some seizures may be better accounted for by the psychiatric diagnosis of non-
epileptic attack disorder (NEAD).  In order to provide an indication of this possible bias, the clinical 
and online samples were compared using a series of t-tests; these were found to be largely 
comparable.  The sample was also unintentionally homogenous, with a disproportionately high 
number of White British females, under the age of 60; although the ethnic make-up was reasonably 
typical of the UK population [23].  This was likely due largely to the fact that the study was 
primarily advertised on online social media sites, including Facebook support groups and Twitter, 
supported by a UK epilepsy charity.  This limited the generalisability of the study and prevents us 
from making assertions that apply beyond this.  For example, it is possible that self-compassion is a 
culturally dependent construct in this context, however this was beyond the scope of the present 
study.   
3. Future research 
Given the significance of the finding that self-compassion can significantly predict higher resilience 
and lower depression and anxiety in PWE, it would be valuable to  understand more about the role 
of self-compassion in other areas of health.  It would be particularly valuable to extend these 
findings to other long-term neurological health conditions in order to gain a greater understanding 
of how broad-reaching the benefits of self-compassion may be and if there are any negative effects 
of utilising approaches such as CFT in neurological populations.  Potentially valuable research 
could be carried out in areas such as Parkinson’s disease, multiple sclerosis, Huntington’s disease, 
and motor neurone disease, amongst others.  This would allow us to better understand whether these 
findings are generalisable or whether there are certain factors specific to an epilepsy population 
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which make this a particularly important psychological construct.  One such example is stigma, 
which was identified in the literature review as particularly important for PWE.  The findings may 
also be relevant to some other neurological populations; for example there has been preliminary 
evidence for the use of CFT in people suffering from acquired brain injury [24]. 
A further area of potential future research is to extend the scope of research into self-compassion in 
PWE to different populations.  As noted above, the sample obtained in the study was homogenous 
and findings were particularly applicable to a White British population; future studies could 
therefore examine self-compassion in PWE in other specific countries or cultures to determine 
whether or not findings could be replicated and generalised. 
4. Personal reflections 
Prior to undertaking this research, I understood logically that PWE can face a range of difficulties 
on a day-to-day basis, and that self-compassion may be able to help protect against some of these.  
The findings of the thesis supported these hypotheses.  However, over-and-above the findings 
obtained from the review and empirical study, my understanding of the importance of these areas 
was enhanced through personal reflection and engagement with the research area throughout the 
thesis process.  Through researching stigma whilst completing the systematic literature review, and 
through speaking to PWE (and people who care for PWE) during the design and data collection of 
the empirical study, I feel that I gained a much greater understanding of just how challenging the 
condition and its impact can be.   
During the course of the study, I became immersed in the interesting, and to me previously largely 
unknown, world of epilepsy.  This exposure helped me to better understand the difficulties faced by 
people with this condition and the resilience that they demonstrate publicly to others.  This was 
particularly true of the welcome into the epilepsy community I was fortunate to be given online.  
For example, in order to recruit participants on Twitter I “followed” a number of epilepsy charities 
and groups, and for several months my Twitter feed was filled with information about the condition 
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and the experiences of those diagnosed with it.  This provided illuminating insights into the types of 
issues faced by PWE on a daily basis.  Similarly, I also had the opportunity to attend an epilepsy 
surgery meeting where clinical decisions are made about patients’ condition and their suitability for 
surgical or medical interventions.  This helped me to gain an appreciation of the medical nature of 
epilepsy, the difficult decisions that some patients face, and the impact that this might have 
psychologically and socially.  I feel that these experiences were valuable; they complemented the 
research I was doing and helped me, as a researcher, to better understand the subject and ground my 
findings in a wider body of knowledge. 
This connection to the research material was particularly important to me.  I initially undertook the 
study due to a personal connection with the subject; I do not have a diagnosis of epilepsy, however I 
have experienced two isolated seizures, ten years apart from one another, the most recent of which 
was in 2014, immediately prior to starting my clinical psychology doctorate.  This experience gave 
me an insight into what it might be like to live with seizures over a longer period of time, and the 
impact that this could have on the lives of people with the condition.  I experienced feelings of 
anxiety, uncertainty, and powerlessness as a result of these, relatively minor, isolated but 
uncontrollable events.  I was unable to drive for six months, which impacted my work and social 
life.  I was also faced with questions about how these events arose and what they meant, and was 
left with some sense of felt, if not enacted, stigma.  Revisiting the subject two years later felt 
empowering as it allowed me to better understand the psychological and social processes involved, 
and to approach the area in a more positive way.  It also motivated me to do something to help 
people who have to live with epilepsy on a daily basis.  Since I last experienced a seizure, I have 
become much more familiar with third wave cognitive behavioural therapy (CBT) approaches such 
as mindfulness and CFT, both personally and professionally.  To apply this knowledge to a 
condition to which I felt some affiliation felt like a valuable and humbling pursuit.  Whilst my 
personal experiences were by no means essential to completing the work, I believe that they 
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provided motivation and, I hope, allowed me to approach the study with the compassion I was 
attempting to measure in those who agreed to participate. 
5. Conclusions 
Overall, I feel that this thesis was successful in gaining valuable insights in relation to the 
psychological nature of epilepsy, including improving our understanding of the impact of the 
condition, and identifying ways in which some people are able to cope with the adversity associated 
with it.  The systematic literature review highlighted and examined an important challenge faced by 
this population - stigma -  and the empirical research study a specific psychological attribute - self-
compassion - which was found to predict increased resilience to such challenges.  I believe that 
these two individual papers therefore complimented each other to provide a cohesive and well-
balanced narrative of important psychological factors in this population.  The findings could be 
summarised very broadly as this: PWE face significant challenges as a result of their condition and 
the perceptions of themselves and others in relation to it; however, it appears that approaching the 
challenges in a kind, understanding, and empathic way may help in some way to protect PWE 
against this adversity, and perhaps resolve some of it altogether.   
In addition to identifying negative outcomes of physical health conditions, clinical psychologists’ 
role includes identifying protective factors and approaches that support or promote positive 
psychological outcomes as part of the development of comprehensive clinical formulations [25].  I 
therefore feel that it was important to consider resilience as an outcome in the study as well as 
examining depression and anxiety.  I believe that findings from the study in relation to resilience 
were some of the most unique and interesting in advancing our understanding of how PWE may be 
able to cope with the adversity associated with living with the condition.  These findings, along 
with those of the rest of the thesis, may be particularly relevant to PWE, their carers, and the 
services involved in their care; however, they may apply more broadly beyond this population and 
condition.  Stigma and self-compassion are arguably concepts that are important to us all, and 
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further research will help us to determine the extent of their relative significance.  However I hope, 
and believe, that this thesis has provided a small yet significant contribution to our growing 
understanding of these psychological phenomena in a specific population by examining the nature 
of stigma and self-compassion in the context of epilepsy.  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A5-2. Is this application linked to a previous study or another current application?
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 2. OVERVIEW OF THE RESEARCH  
 
To provide all the information required by review bodies and research information systems, we ask a number of
specific questions. This section invites you to give an overview using language comprehensible to lay reviewers and
members of the public. Please read the guidance notes for advice on this section.
A6-1. Summary of the study.   Please provide a brief summary of the research (maximum 300 words) using language
easily understood by lay reviewers and members of the public. Where the research is reviewed by a REC within the UK
Health Departments’ Research Ethics Service, this summary will be published on the Health Research Authority (HRA)
website following the ethical review. Please refer to the question specific guidance for this question.
This will be a quantitative study examining self-compassion as a predictor of depression, anxiety, and resilience in
people with epilepsy (PWE). The study will use a cross-sectional survey design targeting adults with epilepsy recruited
through local NHS services and online avenues. Data will be collected via a survey comprising questions about
demographic information alongside standardised measures of seizure severity, self-compassion, depression, anxiety,
resilience, and stigma. We will use a hierarchical regression model to control for known predictors of depression and
then add in self-compassion as the variable of interest to ascertain whether this is a significant additional predictor. It
is hypothesised that self-compassion will be negatively associated with depression and anxiety, and positively
associated with resilience, even when other known variables are accounted for, as this may help in some way to
protect against the effects of illness-related factors and shame and stigma associated with epilepsy.






A6-2. Summary of main issues. Please summarise the main ethical, legal, or management issues arising from your study
and say how you have addressed them.
Not all studies raise significant issues. Some studies may have straightforward ethical or other issues that can be identified
and managed routinely. Others may present significant issues requiring further consideration by a REC, R&D office or other
review body (as appropriate to the issue). Studies that present a minimal risk to participants may raise complex
organisational or legal issues. You should try to consider all the types of issues that the different reviewers may need to
consider.
It is anticipated that issues relating to this study are likely to be minimal. Participants will be required to provide
informed consent before taking part. The study will be supervised by clinical psychologists with expertise in the field of
epilepsy and clinical research. The study will also be completed in consultation with the charity Epilepsy Action who
have been involved in the design of the research. At the end of the survey a debrief sheet will be provided to
participants with information about organisations they can contact for additional support if needed.
 3. PURPOSE AND DESIGN OF THE RESEARCH
A7. Select the appropriate methodology description for this research. Please tick all that apply:
 Case series/ case note review
 Case control
 Cohort observation








 Questionnaire, interview or observation study
 Randomised controlled trial
 Other (please specify)
A10. What is the principal research question/objective? Please put this in language comprehensible to a lay person.
Using a quantitative design, the study will aim to address the following research question:
Does self-compassion predict reduced depression and anxiety and increased resilience when other known predictors
of wellbeing including socio-demographic variables (age, gender, relationship status, education, and employment)
and illness-related variables (seizure frequency, seizure severity, time since diagnosis) have been accounted for?
A11. What are the secondary research questions/objectives if applicable? Please put this in language comprehensible to
a lay person.
As a secondary research question, we are also interested in whether epilepsy-related stigma is linked to self-
compassion.
A12. What is the scientific justification for the research? Please put this in language comprehensible to a lay person.
Research suggests that people with epilepsy (PWE) have poorer quality of life (QOL) and higher levels of depression
and anxiety than the general population. The currently available evidence for predictors of QOL and depression in PWE






suggests that a combination of psychosocial, illness-related, and socio-demographic factors are likely to be
important.   Existing research, however, does not adequately account for variations in psychological outcomes, and it is
possible that other factors which have not yet been investigated may also be of importance.
Self-compassion is the act of being kind and understanding towards oneself in the face of difficult experiences;
recognising ones own experiences as part of the shared human condition rather than viewing them as isolating; and
sitting mindfully with painful thoughts or feelings rather than over-identifying with them. Even when other variables have
been accounted for, self-compassion has been shown to predict improved psychological health including lower levels
of depression. Self-compassion has also been associated with resilience.
In PWE, depression, anxiety, and poor QOL may be linked to self-criticism resulting from shame and stigma
associated with the condition. However, self-compassion as a predictor of depression, anxiety, and resilience in
people with epilepsy has not been explored.
It is hypothesised that self-compassion will be negatively associated with depression and anxiety and positively
associated with resilience even when other known variables are accounted for, as this may help in some way to
protect against the effects of illness-related factors and shame and stigma associated with epilepsy.
The findings of this research may have potentially significant clinical implications for the psychological care of people
with epilepsy, for example by providing evidence for treatment approaches such as Compassion Focused Therapy
(CFT) in improving psychological resilience and mood-related outcomes.
A13. Please summarise your design and methodology. It should be clear exactly what will happen to the research
participant, how many times and in what order. Please complete this section in language comprehensible to the lay person.
Do not simply reproduce or refer to the protocol. Further guidance is available in the guidance notes.
Participants will be recruited from local NHS epilepsy services and via an online survey. The chief investigator or clinic
staff will provide information about the study to patients in epilepsy clinics to consider if they would like to take part.
Patients will be provided with a participant information sheet (PIS) outlining the study, its purpose, and how the data
will be used. They will be able to take this information away to consider whether they would like to participate before
providing informed consent by completing a consent form and completing the survey. Participants will be able to
complete the survey electronically or on paper in the clinic or online. A debrief sheet with a list of support organisations
will be provided at the end of the survey.
A secondary recruitment avenue will use online platforms including social media and the Epilepsy Action website. An
invitation to the study will be posted online with a link to the participant information sheet (PIS), consent form, and the
Qualtrics survey. This will be contained within the Lancaster University Doctorate in Clinical Psychology website.
Data will be collected via a survey comprising questions about demographic information alongside standardised
measures of seizure severity, self-compassion, anxiety, depression, resilience, and stigma. We will also ask for
participants to provide their nationality and ethnicity, although this will not be included as a variable in regression
analyses. The survey will take around 15 minutes to complete.
A14-1. In which aspects of the research process have you actively involved, or will you involve, patients, service users,
and/or their carers, or members of the public?
 Design of the research
 Management of the research
 Undertaking the research
 Analysis of results
 Dissemination of findings
 None of the above
 
Give details of involvement, or if none please justify the absence of involvement.
The design of the study was developed in consultation with a panel of service users from the Epilepsy Action
Research Network (EARN). Epilepsy Action have also provided consultation on the PIS to make this more reader-
friendly for a lay audience. The findings of the study will be disseminated to service users via the charity.
 4. RISKS AND ETHICAL ISSUES







A15. What is the sample group or cohort to be studied in this research?









 Generic Health Relevance
 Infection
 Inflammatory and Immune System
 Injuries and Accidents
 Mental Health
 Metabolic and Endocrine
 Musculoskeletal
 Neurological
 Oral and Gastrointestinal
 Paediatrics
 Renal and Urogenital




Gender:  Male and female participants
Lower age limit:  18  Years
Upper age limit:   No upper age limit
A17-1. Please list the principal inclusion criteria (list the most important, max 5000 characters).
Participants must have a diagnosis of epilepsy, be at least 18 years old, and be able to understand English.
A17-2. Please list the principal exclusion criteria (list the most important, max 5000 characters).
People with no diagnosis of epilepsy, even if they have experienced seizures. People who are unable to complete a
survey e.g. non-English speakers.
 RESEARCH PROCEDURES, RISKS AND BENEFITS  






A18. Give details of all non-clinical intervention(s) or procedure(s) that will be received by participants as part of the
research protocol. These include seeking consent, interviews, non-clinical observations and use of questionnaires.
Please complete the columns for each intervention/procedure as follows:
1. Total number of interventions/procedures to be received by each participant as part of the research protocol.
2. If this intervention/procedure would be routinely given to participants as part of their care outside the research,
how many of the total would be routine?
3. Average time taken per intervention/procedure (minutes, hours or days)
4. Details of who will conduct the intervention/procedure, and where it will take place.
Intervention or procedure 1 2 3 4
Provide informed consent.
Participants will be given
information about the study and
asked to tick a box to indicate
consent.
1 5 Written information will be provided at the start of the survey in the
form of the participant information sheet (PIS). Consent will be
obtained in paper or electronic form by a member of the research
team present in an epilepsy clinic or accessed independently by
participants online.
Complete survey 1 15 The survey will be provided to participants to complete independently,
either in an epilepsy clinic or online.
A21. How long do you expect each participant to be in the study in total?
Each participant will be asked to read the participant information sheet (PIS) and to complete a short survey which will
take approximately 15 minutes.
A22. What are the potential risks and burdens for research participants and how will you minimise them?
For all studies, describe any potential adverse effects, pain, discomfort, distress, intrusion, inconvenience or changes
to lifestyle. Only describe risks or burdens that could occur as a result of participation in the research. Say what steps
would be taken to minimise risks and burdens as far as possible.
The risks of taking part in this study are minimal. Participants will be asked to answer questions about their epilepsy,
symptoms of depression and anxiety, and factors associated with resilience, stigma, and self-compassion. We will
not be targeting a clinical mental health population and it is not anticipated that participants are likely to be in a state
of distress when taking part in the study. 
Participants will be asked to complete a short survey only and the information requested is not of a sensitive nature.
Participants will be given an information sheet outlining the nature of the study before being asked to provide
informed consent by completing the consent form. They will be given time to consider whether or not they want to take
part in the study. A list of support organisations will be provided to participants in a debrief sheet at the end of the
survey.
A23. Will interviews/ questionnaires or group discussions include topics that might be sensitive, embarrassing or
upsetting, or is it possible that criminal or other disclosures requiring action could occur during the study?
 Yes       No
A24. What is the potential for benefit to research participants?
Participants are unlikely to benefit directly. However, they will be informing our understanding of self-compassion in
people with epilepsy (PWE).
A26. What are the potential risks for the researchers themselves? (if any)
None identified.
 RECRUITMENT AND INFORMED CONSENT






 In this section we ask you to describe the recruitment procedures for the study. Please give separate details fordifferent study groups where appropriate.
A27-1. How will potential participants, records or samples be identified? Who will carry this out and what resources
will be used?For example, identification may involve a disease register, computerised search of social care or GP records,
or review of medical records. Indicate whether this will be done by the direct care team or by researchers acting under
arrangements with the responsible care organisation(s).
Potential participants will be identified in two ways:
1) Patients in local NHS epilepsy or neurology/neuropsychology clinics will be approached and asked if they would be
willing to take part by completing a short survey either on paper or electronically using equipment provided, or
independently online.
2) The survey will be advertised online via Epilepsy Action, Twitter, Facebook, and the Lancaster University website. A
link will be provided to complete the survey electronically.
A27-2. Will the identification of potential participants involve reviewing or screening the identifiable personal
information of patients, service users or any other person?
 Yes       No
Please give details below:
No patient records or other identifiable information will be accessed and identification of the sample will be
opportunistic.
A28. Will any participants be recruited by publicity through posters, leaflets, adverts or websites?
 Yes       No
If Yes, please give details of how and where publicity will be conducted, and enclose copy of all advertising material
(with version numbers and dates).
The study will be advertised online through social media and the Epilepsy Action and Lancaster University websites.
A29. How and by whom will potential participants first be approached?
Potential participants online will be able to click on a link which provides information about the study via the participant
information sheet (PIS). They will then be given a link to the consent form which will require them to provide consent
via ticking the relevant boxes, following which they will be taken to the survey itself.
Potential participants in epilepsy clinics will be given the participant information sheet (PIS) and offered the opportunity
to take part. Participants will be able to take the study information away to decide whether or not they want to take part.
No participants will be asked to come into clinic to complete the survey - only those already in attendance will be
approached.
A30-1. Will you obtain informed consent from or on behalf of research participants?
 Yes       No
If you will be obtaining consent from adult participants, please give details of who will take consent and how it will be
done, with details of any steps to provide information (a written information sheet, videos, or interactive material).
Arrangements for adults unable to consent for themselves should be described separately in Part B Section 6, and for
children in Part B Section 7.
If you plan to seek informed consent from vulnerable groups, say how you will ensure that consent is voluntary and
fully informed.
A description of the purpose and nature of the study will be provided to potential participants to read in the form of the
participant information sheet (PIS). Participants will be directed to the consent form to complete either in electronic or
paper form and asked to indicate that they consent to taking part by ticking the relevant boxes.







If you are not obtaining consent, please explain why not.
Please enclose a copy of the information sheet(s) and consent form(s).
A30-2. Will you record informed consent (or advice from consultees) in writing?
 Yes       No
A31. How long will you allow potential participants to decide whether or not to take part?
Participants can take as long as they want within the duration of the recruitment phase of study to decide whether or
not to take part. A link to the survey will remain available online for the duration of the recruitment phase of the study. 
Participants approached in clinic will be able to take the study information away before completing the survey in the
clinic or online via a webpage link provided.
A33-1. What arrangements have been made for persons who might not adequately understand verbal explanations or
written information given in English, or who have special communication needs?(e.g. translation, use of interpreters)
The questionnaires being used are not necessarily validated in other languages therefore non-English speakers will
not be invited to take part in the study. People with communication or learning difficulties which would make it difficult
to complete a survey will also be excluded from the study for practical reasons. It is not anticipated that this should
significantly limit the scope of the research.
A35. What steps would you take if a participant, who has given informed consent, loses capacity to consent during the
study?  Tick one option only.
 The participant and all identifiable data or tissue collected would be withdrawn from the study. Data or tissue which
is not identifiable to the research team may be retained.
 The participant would be withdrawn from the study. Identifiable data or tissue already collected with consent would
be retained and used in the study. No further data or tissue would be collected or any other research procedures carried
out on or in relation to the participant.
 The participant would continue to be included in the study.
 Not applicable – informed consent will not be sought from any participants in this research.




 CONFIDENTIALITY  
 In this section, personal data means any data relating to a participant who could potentially be identified. It includespseudonymised data capable of being linked to a participant through a unique code number.
 Storage and use of personal data during the study
A36. Will you be undertaking any of the following activities at any stage (including in the identification of potential
participants)?(Tick as appropriate)
 Access to medical records by those outside the direct healthcare team
 Access to social care records by those outside the direct social care team






 Electronic transfer by magnetic or optical media, email or computer networks
 Sharing of personal data with other organisations
 Export of personal data outside the EEA
 Use of personal addresses, postcodes, faxes, emails or telephone numbers
 Publication of direct quotations from respondents
 Publication of data that might allow identification of individuals
 Use of audio/visual recording devices
 Storage of personal data on any of the following:
   
 Manual files (includes paper or film)
 NHS computers
 Social Care Service computers
 Home or other personal computers
 University computers
 Private company computers
 Laptop computers
Further details:
Personal identifiable data will not be collected from participants. Anonymous, non-identifiable, quantitative
demographic and research questionnaire data will be collected only, other than in the circumstance described below.
Personal addresses, postcodes, faxes, emails or telephone numbers will only be used if participants request paper
copies of study information (e.g. surveys) to be sent out to them. Once sent out, this data will be deleted and will not be
held or used for any other purpose. Personal data will not be linked to anonymous survey responses.
A37. Please describe the physical security arrangements for storage of personal data during the study?
Data will be stored electronically on the Qualtrics web based survey and data collection tool licensed for use by
Lancaster University. Paper copies of surveys will be inputted into the electronic Qualtrics system and then
immediately securely destroyed. If required, personal data may be held for a short period of time on the secure and
encrypted server system used by Lancaster University. This will be destroyed as soon as the relevant information has
been sent out to potential participants.
A38. How will you ensure the confidentiality of personal data?Please provide a general statement of the policy and
procedures for ensuring confidentiality, e.g. anonymisation or pseudonymisation of data.
No personal data will be routinely gathered from participants, other than in the circumstances outlined above.
A40. Who will have access to participants' personal data during the study? Where access is by individuals outside the
direct care team, please justify and say whether consent will be sought.
No personal data will be routinely obtained. Where potential participants provide contact information in requests for
paper copies of survey information this will be accessible only by the research team.
 Storage and use of data after the end of the study
A41. Where will the data generated by the study be analysed and by whom?
Data will be analysed by the Chief Investigator under supervision of the Academic Supervisor. Analysis will be
completed at the home of the Chief Investigator and at Lancaster University.
A42. Who will have control of and act as the custodian for the data generated by the study?






     
 Title  Forename/Initials  SurnameProf Bill  Sellwood
Post Programme Director, Lancaster University Doctorate in Clinical Psychology
Qualifications
Work Address Doctorate in Clinical Psychology, Furness College
 Faculty of Health and Medicine
 Lancaster University, Lancaster




A43. How long will personal data be stored or accessed after the study has ended?
 Less than 3 months
 3 – 6 months
 6 – 12 months
 12 months – 3 years
 Over 3 years
A44. For how long will you store research data generated by the study?
Years: 10 
Months:  
A45. Please give details of the long term arrangements for storage of research data after the study has ended.Say
where data will be stored, who will have access and the arrangements to ensure security.
Data will be stored by the Lancaster Doctorate in Clinical Psychology on the secure Lancaster University network (or
other location deemed by the university to meet the same security standards) and will be accessible to the PI,
supervisors, data custodian, research or programme director or administrative staff on the programme.
 INCENTIVES AND PAYMENTS
A46. Will research participants receive any payments, reimbursement of expenses or any other benefits or incentives
for taking part in this research?
 Yes       No
A47. Will individual researchers receive any personal payment over and above normal salary, or any other benefits or
incentives, for taking part in this research?
 Yes       No
A48. Does the Chief Investigator or any other investigator/collaborator have any direct personal involvement (e.g.






financial, share holding, personal relationship etc.) in the organisations sponsoring or funding the research that may
give rise to a possible conflict of interest?
 Yes       No
 NOTIFICATION OF OTHER PROFESSIONALS
A49-1. Will you inform the participants’ General Practitioners (and/or any other health or care professional responsible
for their care) that they are taking part in the study?
 Yes       No
If Yes, please enclose a copy of the information sheet/letter for the GP/health professional with a version number and date.
 PUBLICATION AND DISSEMINATION
A50-1. Will the research be registered on a public database?
 Yes       No
Please give details, or justify if not registering the research.
The research will be listed as trainee research on the Lancaster University website at
http://www.lancaster.ac.uk/shm/study/doctoral_study/dclinpsy/rese arch/
The study will also be listed on the Epilepsy Action website.
Registration of research studies is encouraged wherever possible.
You may be able to register your study through your NHS organisation or a register run by a medical research charity,
or publish your protocol through an open access publisher. If you are aware of a suitable register or other method of
publication, please give details. If not, you may indicate that no suitable register exists. Please ensure that you have
entered registry reference number(s) in question A5-1.
A51. How do you intend to report and disseminate the results of the study?Tick as appropriate:
 Peer reviewed scientific journals
 Internal report
 Conference presentation
 Publication on website
 Other publication
 Submission to regulatory authorities
 Access to raw data and right to publish freely by all investigators in study or by Independent Steering Committee
on behalf of all investigators
 No plans to report or disseminate the results
 Other (please specify)
A52. If you will be using identifiable personal data, how will you ensure that anonymity will be maintained when
publishing the results?
N/A
A53. Will you inform participants of the results?






 Yes       No
Please give details of how you will inform participants or justify if not doing so.
Participants will not be informed of the results directly. However, it is hoped that findings will be made available via
Epilepsy Action publications which are freely available and accessible within the epilepsy community. Participants will
be directed to the Lancaster University Research website and Epilepsy Action website for updates on the findings of
the study.
 5. Scientific and Statistical Review
A54-1. How has the scientific quality of the research been assessed?Tick as appropriate:
 Independent external review
 Review within a company
 Review within a multi−centre research group
 Review within the Chief Investigator's institution or host organisation
 Review within the research team
 Review by educational supervisor
 Other
Justify and describe the review process and outcome. If the review has been undertaken but not seen by the
researcher, give details of the body which has undertaken the review:
The research has been developed by the Chief Investigator as part of a doctoral thesis for the Doctorate in Clinical
Psychology (DClinPsy) at Lancaster University. As such, the project is supervised by an experienced researcher
(Academic Supervisor) and a practising clinical neuropsychologist in the field of epilepsy (External/Field Supervisor). 
A research proposal was developed and approved by the Chair of the Exam Board on behalf of the DClinPsy
programme. Throughout the project, the research team will liaise regularly to discuss the process in order to maintain
high levels of scientific standards in line with doctorate level academic research. Consultation on the design of the
study has also been provided by the charity Epilepsy Action.
For all studies except non-doctoral student research, please enclose a copy of any available scientific critique reports,
together with any related correspondence.
For non-doctoral student research, please enclose a copy of the assessment from your educational supervisor/ institution.
A56. How have the statistical aspects of the research been reviewed?Tick as appropriate:
 Review by independent statistician commissioned by funder or sponsor
 Other review by independent statistician
 Review by company statistician
 Review by a statistician within the Chief Investigator’s institution
 Review by a statistician within the research team or multi−centre group
 Review by educational supervisor
 Other review by individual with relevant statistical expertise
 No review necessary as only frequencies and associations will be assessed – details of statistical input not
required
In all cases please give details below of the individual responsible for reviewing the statistical aspects. If advice has
been provided in confidence, give details of the department and institution concerned.
     






 Title  Forename/Initials  Surname  
Department Doctorate in Clinical Psychology, Faculty of Health and Medicine
Institution Lancaster University
Work Address C37 Furness College
 Doctorate in Clinical Psychology, Lancaster University
 Lancaster, Lancashire





Please enclose a copy of any available comments or reports from a statistician.
A57. What is the primary outcome measure for the study?
The Hospital Anxiety and Depression Scale (HADS) as a measure of depression and anxiety (Zigmond, A.S., & Snaith,
R. P. (1983). The hospital anxiety and depression scale. Acta Psychiatrica Scandinavica 67 (6): 361–370.
doi:10.1111/j.1600-0447.1983.tb09716.x. PMID 6880820); and the Brief Resilience Scale (BRS) as a measure of
resilience (Smith, B. W., Dalen, J., Wiggins, K., Tooley, E., Christopher, P., & Bernard, J. (2008). The brief resilience
scale: assessing the ability to bounce back. International journal of behavioral medicine, 15(3), 194-200).
A58. What are the secondary outcome measures?(if any)
We may conduct further regression analyses to measure the effect of felt or enacted stigma on self-compassion. To
measure stigma we will use The Stigma Scale for Chronic Illnesses 8-item version (SSCI-8) (Molina, Y., Choi, S.,
Cella, D., & Rao, D. (2013). The Stigma Scale for Chronic Illnesses 8-Item Version (SSCI-8): Development, Validation
and Use Across Neurological Conditions. International Journal Of Behavioral Medicine, 20(3), 450-460.
doi:10.1007/s12529-012-9243-4).
A59. What is the sample size for the research?  How many participants/samples/data records do you plan to study in
total? If there is more than one group, please give further details below.
Total UK sample size: 75 
Total international sample size (including UK): 75 
Total in European Economic Area: 75 
Further details:
This figure is an estimate of the minimum number of participants needed to address the research question using the
proposed form of analysis.
A60. How was the sample size decided upon?  If a formal sample size calculation was used, indicate how this was done,
giving sufficient information to justify and reproduce the calculation.
A predictive power calculation for a linear multiple regression with 6 predictors suggests that to achieve power of .8
with a medium effect size of .2 (as indicated in other studies of self-compassion e.g. Soysa, C. K., & Wilcomb, C. J.
(2015). Mindfulness, self-compassion, self-efficacy, and gender as predictors of depression, anxiety, stress, and well-
being. Mindfulness, 6(2), 217-226.) at a probability level of p =.05 requires 75 participants.   We will therefore aim to
recruit approximately 75-100 participants.
A61-1. Will participants be allocated to groups at random?
 Yes       No






A62. Please describe the methods of analysis (statistical or other appropriate methods, e.g. for qualitative research) by
which the data will be evaluated to meet the study objectives.
We will use a hierarchical regression model to control for known predictors of depression and anxiety and then add in
self-compassion as the variable of interest to ascertain whether this is a significant additional predictor.   The following
variables will be used:
Predictor variables:
1.Socio-demographic variables: age, gender, relationship status, education, employment
2.Illness-related variables: seizure frequency and severity (LSSS), time since diagnosis





As a secondary research question, we may use a similar regression model to measure the effect of stigma on self-
compassion, as stigma has been highlighted as potentially important in the literature.   
Demographic data and outcomes of correlational and regression analyses will be provided in tables, and findings will
be discussed. 
Where data is missing and surveys are only partially completed, available data may still be included e.g. if there are
complete sets of some but not all predictor or dependent variables.
 6. MANAGEMENT OF THE RESEARCH
A63. Other key investigators/collaborators. Please include all grant co−applicants, protocol co−authors and other key
members of the Chief Investigator’s team, including non-doctoral student researchers.
 
 Title  Forename/Initials  SurnameDr  Helen  Caswell
Post Consultant Clinical Neuropsychologist
Qualifications Chartered Clinical Psychologist
Employer Salford Royal NHS Foundation Trust
Work Address Dept of Neuropsychology
 Clinical Science Building, Salford Royal Hospital
 Stott Lane, Salford





 A64. Details of research sponsor(s)
A64-1. Sponsor  
Lead Sponsor





Status:  NHS or HSC care organisation
 Academic
 Pharmaceutical industry
 Medical device industry
 Local Authority
 Other social care provider (including voluntary sector or private
organisation)
 Other
If Other, please specify:  




Name of organisation Lancaster University, Research Services
Given name Diane
Family name Hopkins
Address Room B14 Furness College, Lancaster University
Town/city Lancaster
Post code LA1 4YT




Is the sponsor based outside the UK?
 Yes       No
Under the Research Governance Framework for Health and Social Care, a sponsor outside the UK must appoint a
legal representative established in the UK. Please consult the guidance notes.
A65. Has external funding for the research been secured?
 Funding secured from one or more funders
 External funding application to one or more funders in progress
 No application for external funding will be made
What type of research project is this?
 Standalone project
 Project that is part of a programme grant
 Project that is part of a Centre grant
 Project that is part of a fellowship/ personal award/ research training award
 Other
Other – please state: 






A66. Has responsibility for any specific research activities or procedures been delegated to a subcontractor (other
than a co-sponsor listed in A64-1) ?  Please give details of subcontractors if applicable.
 Yes       No
A67. Has this or a similar application been previously rejected by a Research Ethics Committee in the UK or another
country?
 Yes       No
Please provide a copy of the unfavourable opinion letter(s). You should explain in your answer to question A6-2 how the
reasons for the unfavourable opinion have been addressed in this application.
A68-1. Give details of the lead NHS R&D contact for this research:
     
 Title  Forename/Initials  SurnameMs  Natalie  Garratt
Organisation Research and Development
Address Salford Royal NHS Foundation Trust
 Stott Lane
 Salford





Details can be obtained from the NHS R&D Forum website: http://www.rdforum.nhs.uk
A69-1. How long do you expect the study to last in the UK?
Planned start date: 01/08/2016
Planned end date: 28/02/2017
Total duration:  
Years: 0 Months: 6 Days: 28 
A71-1. Is this study?
 Single centre
 Multicentre





 Other countries in European Economic Area






Total UK sites in study 1
Does this trial involve countries outside the EU?
 Yes       No
 USA
 Other international (please specify)
The research will take place in England. The study will be advertised online, therefore whilst we anticipate the majority
of participants to be UK residents, the scope of the research is international.
A72. Which organisations in the UK will host the research?Please indicate the type of organisation by ticking the box and
give approximate numbers if known:
 NHS organisations in England 1 
 NHS organisations in Wales  
 NHS organisations in Scotland  
 HSC organisations in Northern Ireland  
 GP practices in England  
 GP practices in Wales  
 GP practices in Scotland  
 GP practices in Northern Ireland  
 Joint health and social care agencies (eg
community mental health teams)
 
 Local authorities  
 Phase 1 trial units  
 Prison establishments  
 Probation areas  
 Independent (private or voluntary sector)
organisations
 
 Educational establishments 1 
 Independent research units  
 Other (give details)  
  
Total UK sites in study: 2
A73-1. Will potential participants be identified through any organisations other than the research sites listed above?
 Yes       No
A73-2. If yes, will any of these organisations be NHS organisations?
 Yes       No
If yes, details should be given in Part C.
A74. What arrangements are in place for monitoring and auditing the conduct of the research?
The Chief Investigator will complete the research under the supervision of the Academic Supervisor at Lancaster






University and the External Supervisor who is an expert in epilepsy research and working in the field. Regular
supervision meetings will take place to ensure that the research is completed to a high standard.
 A76. Insurance/ indemnity to meet potential legal liabilities  
 Note: in this question to NHS indemnity schemes include equivalent schemes provided by Health and Social Care(HSC) in Northern Ireland
A76-1. What arrangements will be made for insurance and/or indemnity to meet the potential legal liability of the
sponsor(s) for harm to participants arising from the management of the research?  Please tick box(es) as applicable.
Note: Where a NHS organisation has agreed to act as sponsor or co-sponsor, indemnity is provided through NHS schemes.
Indicate if this applies (there is no need to provide documentary evidence). For all other sponsors, please describe the
arrangements and provide evidence.
 NHS indemnity scheme will apply (NHS sponsors only)
 Other insurance or indemnity arrangements will apply (give details below)
Lancaster University legal liability cover will apply.
Please enclose a copy of relevant documents.
A76-2. What arrangements will be made for insurance and/ or indemnity to meet the potential legal liability of the
sponsor(s) or employer(s) for harm to participants arising from the design of the research?  Please tick box(es) as
applicable.
Note: Where researchers with substantive NHS employment contracts have designed the research, indemnity is provided
through NHS schemes. Indicate if this applies (there is no need to provide documentary evidence). For other protocol
authors (e.g. company employees, university members), please describe the arrangements and provide evidence.
 NHS indemnity scheme will apply (protocol authors with NHS contracts only)
 Other insurance or indemnity arrangements will apply (give details below)
Lancaster University legal liability cover will apply.
Please enclose a copy of relevant documents.
A76-3. What arrangements will be made for insurance and/ or indemnity to meet the potential legal liability of
investigators/collaborators arising from harm to participants in the conduct of the research? 
Note: Where the participants are NHS patients, indemnity is provided through the NHS schemes or through professional
indemnity. Indicate if this applies to the whole study (there is no need to provide documentary evidence). Where non-NHS
sites are to be included in the research, including private practices, please describe the arrangements which will be made at
these sites and provide evidence.
 NHS indemnity scheme or professional indemnity will apply (participants recruited at NHS sites only)
 Research includes non-NHS sites (give details of insurance/ indemnity arrangements for these sites below)
Lancaster University legal liability cover will apply.
Please enclose a copy of relevant documents.
A78. Could the research lead to the development of a new product/process or the generation of intellectual property?
 Yes  No  Not sure






 PART C: Overview of research sites  
Please enter details of the host organisations (Local Authority, NHS or other) in the UK that will be responsible for the
research sites.   For further information please refer to guidance.
Investigator
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2. Research protocol 
 
Research Protocol 
 Version number: 1 
Date: 25/07/16 
IRAS ID: 205444 
Title: What is the Relationship Between Self-Compassion and Depression, Anxiety, and Resilience 
in Adults with Epilepsy? 
Applicant: David Baker 
Lancaster University, Doctorate in Clinical Psychology 
Research Supervisor: Dr Fiona Eccles 
Field Supervisor: Dr Helen Caswell 
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Introduction 
Background 
 People with epilepsy (PWE) have poorer quality of life (QOL) than the general population 
(Strine, Kobau, Chapman, Thurman, Price & Balluz, 2002; Tellez-Zenteno, Matijevic & Wiebe, 
2005; Wiebe, Bellhouse, Fallahay & Eliasziw, 1999; Kobau, Zahran, Grant, Thurman, Price & 
Zack, 2003; Santhouse, Carrier, Arya, Fowler & Duncan, 2007).  Epilepsy is also significantly 
associated with depression (Fiest et al., 2013), and depression predicts poor QOL (Boylan, Flint, 
Labovitz, Jackson, Starner & Devinsky, 2004).  Anxiety is also highly prevalent in this population 
(Beyenberg, Mitchell, Schmidt, Elger, & Reuber, 2005).   
QOL trajectories in PWE often do not follow the clinical course of epilepsy, but instead may 
be affected by a wide range of psychosocial factors including experienced stigma and 
discrimination, difficulties of adjustment, personal and social capital, and social support (Jacoby & 
Baker, 2008).  Coping and engagement strategies, perceived social support, stress, and self-efficacy 
have also been identified as important (Gandy, Sharpe & Perry, 2012).  In a recent review by Lacey, 
Salzberg & D’Souza (2015), epilepsy illness-related factors including seizure frequency, and to a 
lesser extent seizure recency, were found to predict depression in PWE.  However, 
sociodemographic factors including age, gender, education, employment and income were found to 
predict depression more consistently; and psychological factors including emotional aspects of 
recovery from seizures; social concerns such as fear of injury, activity restriction, and 
embarrassment; and a past history of depression, anxiety, perceived stress, and stigma were also 
found to be important.   
The currently available evidence for predictors of QOL and depression in PWE suggests that 
a combination of psychosocial, illness-related, and socio-demographic factors are likely to be 
influential.  Existing research, however, does not adequately account for variations in psychological 
outcomes, and it is possible that other factors which have not yet been investigated may also be 
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important.  Stigma has been highlighted as a potentially significant factor in precipitating or 
exacerbating poor QOL in PWE (Antonak & Livneh, 1992; Jacoby, 2002; Baker, Jacoby, Buck, 
Stalgis, & Monnet, 1997; Beyenburg et al., 2005; Hesdorffer and Lee, 2009; Lambert & Robertson, 
1999; Marsh & Rao, 2002).  There is also evidence that even where stigma is not enacted externally, 
this may be ‘felt’ by PWE (Jacobi & Austin, 2007), and some may feel less valuable, adaptable, 
dependable, mature, stable, able to cope, successful and well-adjusted than people without the 
condition (Collings, 1990).  Health-related stigma, including stigma in epilepsy, has been related to 
shame (Scambler, 2009).  In the general population, shame has been linked to self-criticism and 
depression (Gilbert & Miles, 2000).  In contrast, there is an increasing body of evidence to suggest 
that across a range of contexts, self-compassion may protect against shame and lead to better mental 
health outcomes (Johnson & O’Brien, 2013; Ferreira, Pinto-Gouveia, & Duarte, 2013; Leary, Tate, 
& Adams et al., 2007). 
 Self-compassion is the act of being kind and understanding towards oneself in the face of 
difficult experiences; recognising one’s own experiences as part of the shared human condition 
rather than viewing them as isolating; and sitting mindfully with painful thoughts or feelings rather 
than over-identifying with them (Neff, 2003).  Even when other variables have been accounted for, 
self-compassion has been shown to predict improved psychological health including lower levels of 
depression and anxiety (Neff & Faso, 2015; Soysa & Wilcomb, 2015; Van Dam, Sheppard, Forsyth 
& Earleywine, 2011).  Self-compassion has also been associated with resilience (Kemper, Mo & 
Khayat, 2015; Neff & McGehee, 2010; Smeets, Neff, Alberts & Peters, 2014), although few studies 
have measured this directly.  Resilience may help to protect against illness-related factors affecting 
mood and QOL.  It is possible that in PWE, depression and anxiety (and thus poor QOL) may be 
linked to self-criticism resulting from shame and stigma associated with the condition.  However, 
self-compassion as a predictor of psychological wellbeing and resilience in people with epilepsy has 
not been examined.   
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It is hypothesised that self-compassion will be negatively associated with depression and 
anxiety and positively associated with resilience even when other known variables are accounted 
for.  The findings of this research may have potentially significant clinical implications for the 
psychological care of people with epilepsy, for example by providing evidence for treatment 
approaches such as Compassion Focused Therapy (CFT) in improving psychological wellbeing and 
resilience. 
Research Aims 
 Using a quantitative design, the study will aim to address the following research question: 
Does self-compassion predict reduced depression and anxiety and increased resilience when other 
known predictors of wellbeing including socio-demographic variables (age, gender, relationship 
status, education, and employment) and illness-related variables (seizure frequency, seizure 
severity) have been accounted for?  As a secondary research question, we are also interested in 
whether epilepsy-related stigma is linked to self-compassion. 
Method 
Design 
 The study will use a quantitative cross-sectional survey design to examine predictors of 
depression, anxiety, and resilience in people with epilepsy.  The design was developed in 
consultation with research and external supervisors with relevant expertise.  Feedback was also 
obtained from a panel of service user representatives from the Epilepsy Action Research Network 
(EARN) and suggested changes were incorporated into the final design.  Epilepsy Action also 
commented on the participant information sheet to make this more readable for a lay audience. 
Participants 
 A predictive power calculation for a linear multiple regression with 6 predictors suggests 
that to achieve power of .8 with a medium effect size of .2 (as indicated in other studies of self-
compassion e.g. Soysa & Wilcomb, 2015) at a probability level of p =.05 requires 75 participants.  
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We will therefore aim to recruit approximately 75-100 participants through local NHS epilepsy 
services and online avenues including social media including Facebook support groups and Twitter 
using #epilepsy.  It is hoped that the charity, Epilepsy Action will also support recruitment.  This 
may include advertising on their website, forum (Forum4e, an online community of people with 
epilepsy and carers), social media (Facebook and Twitter), publications (Epilepsy Today and 
Epilepsy Professional), local branches, groups and events.  
 Inclusion criteria: 
To be eligible for inclusion, participants must: 
• Have a diagnosis of epilepsy 
• Be at least 18 years old 
• Be able to understand English 
 Exclusion criteria: 
Participants will be excluded if they: 
• Do not have a diagnosis of epilepsy (even if they have experienced seizures) 
• Are unable to complete a survey e.g. non-English speakers 
Materials 
 Electronic and paper versions of the following standardised measures will be used in the 
survey: Liverpool Seizure Severity Scale 2.0 (LSSS) (Scott-Lennox, Bryant-Comstock, Lennox, & 
Baker, 2001); Neff Self-Compassion Scale (Neff, 2003); Hospital Anxiety and Depression Scale 
(Zigmond, & Snaith, 1983); Brief Resilience Scale (BRS) (Smith, Dalen, Wiggins, Tooley, 
Christopher, & Bernard, 2008); and The Stigma Scale for Chronic Illnesses 8-item version (SSCI-8) 
(Molina, Choi, Cella, & Rao, 2013).  Further information about measures is provided in Appendix 
1.  Electronic versions will be delivered using Qualtrics web-based survey and data collection 
software licensed for use by Lancaster University staff and students.  If participants wish to 
complete the survey electronically in the epilepsy clinic, computer equipment will be provided. 
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Procedure 
 Recruitment.  Participants will be recruited from local NHS epilepsy services and online.  
The primary researcher will attend clinics and ask patients if they would be willing to complete a 
short survey either on a computer tablet or on paper.  The survey will be prefaced with a participant 
information sheet (PIS) containing a description of the study, its purpose, and how the data will be 
used.  Patients approached in clinic will be able to take the study information away before 
completing the survey in the clinic or online via a webpage link provided.  Patients will be asked to 
provide consent by completing a consent form provided (again this could be electronic or on paper).  
The survey will take a total of approximately 15 minutes to complete.  A secondary recruitment 
avenue will use online platforms including social media and the Epilepsy Action website.  An 
invitation to the study will be posted on the Lancaster University Doctorate in Clinical Psychology 
research page (http://www.lancaster.ac.uk/shm/study/doctoral_study/dclinpsy/research) with a link 
to the participant information sheet (PIS), the consent form, and the Qualtrics survey. 
 Data Collection.  Data will be collected via a survey comprising questions about 
demographic information (age, gender, nationality, ethnicity, relationship status, highest level of 
education, employment hours per week, therapy offered/received) and illness-related information 
(age at epilepsy onset/diagnosis, seizure type (if known), medication) alongside standardised 
measures of seizure severity, self-compassion, depression, anxiety, resilience, and stigma. 
 Personal identifiable data will not routinely be collected from participants.  Anonymous, 
non-identifiable, quantitative demographic and research questionnaire data will be collected only.  
Personal addresses, postcodes, faxes, emails or telephone numbers will only be used if participants 
request paper copies of study information (e.g. surveys) to be sent out to them.  If required, personal 
data may be held for a short period of time on the secure and encrypted server system used by 
Lancaster University.  This data will be destroyed as soon as the relevant information has been sent 
out to potential participants and will not be used for any other purpose.  Personal data will not be 
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linked to anonymous survey responses.  Data will be stored electronically on the Qualtrics web 
based survey and data collection tool licensed for use by Lancaster University.  Paper copies of 
surveys will be inputted into the electronic Qualtrics system and then immediately securely 
destroyed.  Anonymous survey data will be held securely for a period of 10 years in line with 
university procedures and then destroyed. 
Analysis 
 We will use a hierarchical regression model to control for known predictors of depression 
and anxiety and then add in self-compassion as the variable of interest to ascertain whether this is a 
significant additional predictor.  The following variables will be used: 
Predictor variables: 
1. Socio-demographic variables: age, gender, relationship status, education, employment 
2. Illness-related variables: seizure severity (LSSS), time since diagnosis 
3. Self-compassion (Neff Self-Compassion Scale) 
Outcome variables: 
1. Depression (HADS) 
2. Anxiety (HADS) 
3. Resilience (BRS) 
 As a secondary analysis we intend to use a similar regression model to assess whether felt or 
enacted stigma predicts self-compassion when other variables have been controlled for. 
Dissemination 
 It is anticipated that findings will be submitted for publication in a relevant peer reviewed 
academic journal.  It is hoped that findings will also be disseminated to the epilepsy community 
through Epilepsy Action publications. 
Practical Issues 
Costs 
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  Licenses for all measures have been obtained as necessary and associated costs have been 
covered by Lancaster University. 
Potential Limitations 
 The study will use a quantitative survey design and as such we will not be able to gain 
detailed qualitative information from participants about their experiences.  Given the proposed 
sample size and analysis it will not be possible to determine mediating or moderating effects.  The 
sample will be obtained in part from local NHS services, therefore this may represent a limited 
demographic and findings may not be generalisable more widely. 
Ethical considerations 
 It is not anticipated that this study will result in significant risks to participants or raise 
significant ethical issues.  Participants will be free to withdraw from the study at any time.  At the 
beginning of the study participants will be provided with a brief outline of the study in the form of 
the participant information sheet (PIS).  At the end of the survey participants will be presented with 
a list of available resources/organisations to contact should they require any additional support.  
Any ethical issues arising during the course of the study will be discussed with the Field Supervisor 
who is a Consultant Clinical Neuropsychologist with significant expertise working in the field of 
epilepsy.  Ethical approval will be sought from a Research Ethics Committee (REC) and research 
governance approval from Trust Research and Development (R&D) departments via the Integrated 
Research Application System (IRAS) prior to commencing data collection. 
Service-user involvement 
 The design of the study and materials were developed in consultation with a panel of service 
user representatives from the Epilepsy Action charity’s research network (EARN). 
Estimated Timescale 
August 2016 
Start data collection 
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December 2016 
End data collection 
January-March 2017 
Analyse and write-up data 
April-May 2017 
Complete final version of research paper  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Flow Chart of Thesis Research Protocol 
 Version number: 1 
Date: 25/07/16 







Potential participants are asked to provide informed consent by completing a consent 
form. 
Epilepsy clinic patients are asked if they are interested in taking part in a study by 
completing a short survey OR adults with epilepsy are invited to take part in a survey 
online.
Potential participants are provided with a participant information sheet (PIS) containing 
a description of the study, its purpose, and how the data will be used. They can take as 
long as they need during the recruitment phase of the study to consider whether or not 
they want to take part.
Once informed consent has been obtained, participants complete the survey 
(approximately 15 minutes).
Once all data has been collected, this is analysed by the Chief Investigator with support 
from the Academic Supervisor.
Findings are written-up and disseminated.
Following completion of the survey, participants are provided with a debrief sheet 
including information about support organisations and resources. They are advised that 
the study findings will be made available online.
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Ground Floor 
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07 September 2016 
 
Mr David Baker 
Doctorate in Clinical Psychology, Furness College 
Faculty of Health and Medicine 




Dear Mr Baker 
 
Study title: What is the Relationship Between Self-Compassion and 
Depression, Anxiety, and Resilience in Adults with 
Epilepsy? 
REC reference: 16/LO/1554 
IRAS project ID: 205444 
 
Thank you for your letter of 7th September 2016, responding to the Proportionate Review  
Sub-Committee’s request for changes to the documentation for the above study. 
 
The revised documentation has been reviewed and approved by the sub-committee. 
 
We plan to publish your research summary wording for the above study on the HRA website, 
together with your contact details. Publication will be no earlier than three months from the 
date of this favourable opinion letter.  The expectation is that this information will be published 
for all studies that receive an ethical opinion but should you wish to provide a substitute 
contact point, wish to make a request to defer, or require further information, please contact 
Please note:  This is the 
favourable opinion of the 
REC only and does not allow 
you to start your study at NHS 
sites in England until you 
receive HRA Approval  
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the REC Manager Ms Julie Kidd, nrescommittee.london-stanmore@nhs.net. Under very 
limited circumstances (e.g. for student research which has received an unfavourable opinion), 
it may be possible to grant an exemption to the publication of the study. 
Confirmation of ethical opinion 
 
On behalf of the Committee, I am pleased to confirm a favourable ethical opinion for the above 
research on the basis described in the application form, protocol and supporting documentation 
as revised. 
 
Conditions of the favourable opinion 
 
The REC favourable opinion is subject to the following conditions being met prior to the start of 
the study. 
 
1. Add a version number and date to the consent form.  
 
You should notify the REC once all conditions have been met (except for site approvals 
from host organisations) and provide copies of any revised documentation with updated 
version numbers. Revised documents should be submitted to the REC electronically 
from IRAS. The REC will acknowledge receipt and provide a final list of the approved 
documentation for the study, which you can make available to host organisations to 
facilitate their permission for the study. Failure to provide the final versions to the REC 
may cause delay in obtaining permissions. 
 
Management permission must be obtained from each host organisation prior to the start of the 
study at the site concerned. 
 
Management permission should be sought from all NHS organisations involved in the study in 
accordance with NHS research governance arrangements. Each NHS organisation must 
confirm through the signing of agreements and/or other documents that it has given permission 
for the research to proceed (except where explicitly specified otherwise).  
Guidance on applying for HRA Approval (England)/ NHS permission for research is available in 
the Integrated Research Application System, www.hra.nhs.uk or at http://www.rdforum.nhs.uk.  
 
Where a NHS organisation’s role in the study is limited to identifying and referring potential 
participants to research sites (“participant identification centre”), guidance should be sought 
from the R&D office on the information it requires to give permission for this activity. 
 
For non-NHS sites, site management permission should be obtained in accordance with the 
procedures of the relevant host organisation. 
 
Sponsors are not required to notify the Committee of management permissions from host 
organisations.  
 
Registration of Clinical Trials 
 
All clinical trials (defined as the first four categories on the IRAS filter page) must be registered 
on a publically accessible database. This should be before the first participant is recruited but no 
later than 6 weeks after recruitment of the first participant. 
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There is no requirement to separately notify the REC but you should do so at the earliest 
opportunity e.g. when submitting an amendment.  We will audit the registration details as part of 
the annual progress reporting process. 
  
To ensure transparency in research, we strongly recommend that all research is registered but 
for non-clinical trials this is not currently mandatory. 
  
If a sponsor wishes to request a deferral for study registration within the required timeframe, 
they should contact hra.studyregistration@nhs.net. The expectation is that all clinical trials will 
be registered, however, in exceptional circumstances non registration may be permissible with 
prior agreement from the HRA. Guidance on where to register is provided on the HRA website. 
 
It is the responsibility of the sponsor to ensure that all the conditions are complied with 
before the start of the study or its initiation at a particular site (as applicable). 
 
Ethical review of research sites 
 
The favourable opinion applies to all NHS sites taking part in the study, subject to management 
permission being obtained from the NHS/HSC R&D office prior to the start of the study (see 




The documents reviewed and approved by the Committee are: 
 
Document   Version   Date   
Copies of advertisement materials for research participants [Social 
media advertising posts]  
1  25 July 2016  
Covering letter on headed paper [Covering letter on headed paper]  1  25 July 2016  
Covering letter on headed paper      
Evidence of Sponsor insurance or indemnity (non NHS Sponsors 
only)  
    
Evidence of Sponsor insurance or indemnity (non NHS Sponsors 
only) [Lancaster university professional indemnity insurance]  
1  25 July 2016  
IRAS Application Form [IRAS_Form_04082016]    04 August 2016  
IRAS Application Form XML file [IRAS_Form_04082016]    04 August 2016  
IRAS Checklist XML [Checklist_04082016]    04 August 2016  
Letter from sponsor [Lancaster university sponsorship letter]  1  25 July 2016  
Other [Liverpool Seizure Severity Scale]      
Other [Participant debrief sheet]  1  25 July 2016  
Other [Lancaster university public liability insurance]  1  25 July 2016  
Other [Lancaster university employers liability insurance]  1  25 July 2016  
Other [Zurich]      
Participant consent form      
Participant consent form [Participant consent form]  1  25 July 2016  
Participant information sheet (PIS) [Participant information sheet 
(PIS)]  
1  25 July 2016  
Research protocol or project proposal [Research protocol]  1  25 July 2016  
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Summary CV for Chief Investigator (CI) [CV for chief investigator]  1  25 July 2016  
Summary CV for supervisor (student research) [CV for academic 
supervisor]  
1  25 July 2016  
Summary, synopsis or diagram (flowchart) of protocol in non 
technical language [Research protocol flow chart]  
1  25 July 2016  
Validated questionnaire [Hospital anxiety and depression scale 
(HADS)]  
1  25 July 2016  
Validated questionnaire [Neff self compassion scale]  1  25 July 2016  
Validated questionnaire [Brief resilience scale]  1  25 July 2016  
Validated questionnaire [Liverpool seizure severity scale]  1  25 July 2016  
Validated questionnaire [Stigma scale for chronic illnesses 8 item]  1  25 July 2016  
 
Statement of compliance 
 
The Committee is constituted in accordance with the Governance Arrangements for Research 
Ethics Committees and complies fully with the Standard Operating Procedures for Research 
Ethics Committees in the UK. 
 




The attached document “After ethical review – guidance for researchers” gives detailed 
guidance on reporting requirements for studies with a favourable opinion, including: 
 
 Notifying substantial amendments 
 Adding new sites and investigators 
 Notification of serious breaches of the protocol 
 Progress and safety reports 
 Notifying the end of the study 
 
The HRA website also provides guidance on these topics, which is updated in the light of 




You are invited to give your view of the service that you have received from the National 
Research Ethics Service and the application procedure.  If you wish to make your views known 
please use the feedback form available on the HRA website: 
http://www.hra.nhs.uk/about-the-hra/governance/quality-assurance  
 
We are pleased to welcome researchers and R & D staff at our NRES committee members’ 
training days – see details at http://www.hra.nhs.uk/hra-training/  
 




















Enclosures:    “After ethical review – guidance for researchers”  










London - Stanmore Research Ethics Committee 
Ground Floor 
NRES/HRA 



















08 September 2016 
 
Mr David Baker 
Doctorate in Clinical Psychology, Furness College 
Faculty of Health and Medicine 




Dear Mr Baker 
 
Study title: What is the Relationship Between Self-Compassion and 
Depression, Anxiety, and Resilience in Adults with 
Epilepsy? 
REC reference: 16/LO/1554 
IRAS project ID: 205444 
 
Thank you for your email of the 7th September. I can confirm the REC has received the 
documents listed below and that these comply with the approval conditions detailed in our letter 






Please note:  This is an 
acknowledgement letter from 
the REC only and does not 
allow you to start your study 
at NHS sites in England until 
you receive HRA Approval  
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Documents received 
 
The documents received were as follows: 
 
Document   Version   Date   
Other [Participant de brief sheet]  1  13 July 2016  




The final list of approved documentation for the study is therefore as follows: 
 
Document   Version   Date   
Copies of advertisement materials for research participants [Social 
media advertising posts]  
1  25 July 2016  
Covering letter on headed paper [Covering letter on headed paper]  1  25 July 2016  
Evidence of Sponsor insurance or indemnity (non NHS Sponsors 
only)  
    
Evidence of Sponsor insurance or indemnity (non NHS Sponsors 
only) [Lancaster university professional indemnity insurance]  
1  25 July 2016  
IRAS Application Form [IRAS_Form_04082016]    04 August 2016  
IRAS Application Form XML file [IRAS_Form_04082016]    04 August 2016  
IRAS Checklist XML [Checklist_04082016]    04 August 2016  
Letter from sponsor [Lancaster university sponsorship letter]  1  25 July 2016  
Other [Liverpool Seizure Severity Scale]      
Other [Lancaster university public liability insurance]  1  25 July 2016  
Other [Lancaster university employers liability insurance]  1  25 July 2016  
Other [Zurich]      
Other [Participant de brief sheet]  1  13 July 2016  
Participant consent form  2  01 September 2016  
Participant information sheet (PIS) [Participant information sheet 
(PIS)]  
1  25 July 2016  
Research protocol or project proposal [Research protocol]  1  25 July 2016  
Summary CV for Chief Investigator (CI) [CV for chief investigator]  1  25 July 2016  
Summary CV for supervisor (student research) [CV for academic 
supervisor]  
1  25 July 2016  
Summary, synopsis or diagram (flowchart) of protocol in non- 
technical language [Research protocol flow chart]  
1  25 July 2016  
Validated questionnaire [Hospital anxiety and depression scale 
(HADS)]  
1  25 July 2016  
Validated questionnaire [Neff self-compassion scale]  1  25 July 2016  
Validated questionnaire [Brief resilience scale]  1  25 July 2016  
Validated questionnaire [Liverpool seizure severity scale]  1  25 July 2016  
Validated questionnaire [Stigma scale for chronic illnesses 8 item]  1  25 July 2016  
 
You should ensure that the sponsor has a copy of the final documentation for the study.  It is 
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the sponsor's responsibility to ensure that the documentation is made available to R&D offices 
at all participating sites. 
 












E-mail: nrescommittee.london-stanmore@nhs.net  
 
Copy to: Dr Diane Hopkins 


















Re: What is the Relationship Between Self-Compassion and Depression, Anxiety, 
and Resilience in Adults with Epilepsy? 
 
The University of Lancaster undertakes to perform the role of sponsor in the matter 
of the work described in the accompanying grant application.  As sponsor we assume 
responsibility for monitoring and enforcement of research governance.  As principal 
investigator you will confirm that the institution’s obligations are met by ensuring 
that, before the research commences and during the full term of the grant, all the 
necessary legal and regulatory requirements are met in order to conduct the 
research, and all the necessary licenses and approvals have been obtained. The 
Institution has in place formal procedures for managing the process for obtaining 
any necessary or appropriate ethical approval for this grant. Full ethical approval 
must be in place before the research commences and should be reviewed at all 






PP Professor Roger Pickup 
Associate Dean for Research 
Chair Faculty of Health and Medicine Research Ethics Committee. 
 
CC Dr Diane Hopkins, Secretary to FHMREC 
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Mr David Baker 
Doctorate in Clinical Psychology, Furness College 
Faculty of Health and Medicine 





23 September 2016 
 
Dear Mr Baker, 
 
 
Study title: What is the Relationship Between Self-Compassion and 
Depression, Anxiety, and Resilience in Adults with Epilepsy? 
IRAS project ID: 205444  
REC reference: 16/LO/1554  
Sponsor Lancaster University, Research Services 
 
I am pleased to confirm that HRA Approval has been given for the above referenced study, on the 
basis described in the application form, protocol, supporting documentation and any clarifications 
noted in this letter.  
 
Participation of NHS Organisations in England  
The sponsor should now provide a copy of this letter to all participating NHS organisations in England.  
 
Appendix B provides important information for sponsors and participating NHS organisations in 
England for arranging and confirming capacity and capability. Please read Appendix B carefully, in 
particular the following sections: 
 Participating NHS organisations in England – this clarifies the types of participating 
organisations in the study and whether or not all organisations will be undertaking the same 
activities 
 Confirmation of capacity and capability - this confirms whether or not each type of participating 
NHS organisation in England is expected to give formal confirmation of capacity and capability. 
Where formal confirmation is not expected, the section also provides details on the time limit 
given to participating organisations to opt out of the study, or request additional time, before 
their participation is assumed. 
 Allocation of responsibilities and rights are agreed and documented (4.1 of HRA assessment 
criteria) - this provides detail on the form of agreement to be used in the study to confirm 
capacity and capability, where applicable. 
Further information on funding, HR processes, and compliance with HRA criteria and standards is also 
provided. 
 
It is critical that you involve both the research management function (e.g. R&D office) supporting each 
organisation and the local research team (where there is one) in setting up your study. Contact details 
Letter of HRA Approval 
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IRAS project ID 205444 
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and further information about working with the research management function for each organisation 
can be accessed from www.hra.nhs.uk/hra-approval.  
 
Appendices 
The HRA Approval letter contains the following appendices: 
 A – List of documents reviewed during HRA assessment 
 B – Summary of HRA assessment 
 
After HRA Approval 
The document “After Ethical Review – guidance for sponsors and investigators”, issued with your REC 
favourable opinion, gives detailed guidance on reporting expectations for studies, including:  
 Registration of research 
 Notifying amendments 
 Notifying the end of the study 
The HRA website also provides guidance on these topics, and is updated in the light of changes in 
reporting expectations or procedures. 
 
In addition to the guidance in the above, please note the following: 
 HRA Approval applies for the duration of your REC favourable opinion, unless otherwise 
notified in writing by the HRA. 
 Substantial amendments should be submitted directly to the Research Ethics Committee, as 
detailed in the After Ethical Review document. Non-substantial amendments should be 
submitted for review by the HRA using the form provided on the HRA website, and emailed to 
hra.amendments@nhs.net.  
 The HRA will categorise amendments (substantial and non-substantial) and issue confirmation 
of continued HRA Approval. Further details can be found on the HRA website. 
Scope  
HRA Approval provides an approval for research involving patients or staff in NHS organisations in 
England.  
 
If your study involves NHS organisations in other countries in the UK, please contact the relevant 
national coordinating functions for support and advice. Further information can be found at 
http://www.hra.nhs.uk/resources/applying-for-reviews/nhs-hsc-rd-review/. 
  
If there are participating non-NHS organisations, local agreement should be obtained in accordance 
with the procedures of the local participating non-NHS organisation. 
 
User Feedback 
The Health Research Authority is continually striving to provide a high quality service to all applicants 
and sponsors. You are invited to give your view of the service you have received and the application 
procedure. If you wish to make your views known please email the HRA at hra.approval@nhs.net. 
Additionally, one of our staff would be happy to call and discuss your experience of HRA Approval.  
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HRA Training 
We are pleased to welcome researchers and research management staff at our training days – see 
details at http://www.hra.nhs.uk/hra-training/  
 




Miss Lauren Allen 
Assessor 
 




Copy to: Dr Diane Hopkins (Sponsor contact) 
, Research and Development (Lead NHS R&D contact) 
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Appendix A - List of Documents 
 
The final document set assessed and approved by HRA Approval is listed below.   
 
 Document   Version   Date   
Copies of advertisement materials for research participants [Social 
media advertising posts]  
1  25 July 2016  
Covering letter on headed paper [Covering letter on headed paper]  1  25 July 2016  
Evidence of Sponsor insurance or indemnity (non NHS Sponsors 
only)  
    
Evidence of Sponsor insurance or indemnity (non NHS Sponsors 
only) [Lancaster university professional indemnity insurance]  
1  25 July 2016  
IRAS Application Form [IRAS_Form_04082016]    04 August 2016  
Letter from sponsor [Lancaster university sponsorship letter]  1  25 July 2016  
Other [Liverpool Seizure Severity Scale]      
Other [Lancaster university public liability insurance]  1  25 July 2016  
Other [Lancaster university employers liability insurance]  1  25 July 2016  
Other [Zurich]      
Other [Participant de brief sheet]  1  13 July 2016  
Other [Statement of Activities]  1  23 September 2016  
Other [Schedule of Events]  1  23 September 2016  
Participant consent form  2  01 September 2016  
Participant information sheet (PIS) [Participant information sheet 
(PIS)]  
1  25 July 2016  
Research protocol or project proposal [Research protocol]  1  25 July 2016  
Summary CV for Chief Investigator (CI) [CV for chief investigator]  1  25 July 2016  
Summary CV for supervisor (student research) [CV for academic 
supervisor]  
1  25 July 2016  
Summary, synopsis or diagram (flowchart) of protocol in non 
technical language [Research protocol flow chart]  
1  25 July 2016  
Validated questionnaire [Hospital anxiety and depression scale 
(HADS)]  
1  25 July 2016  
Validated questionnaire [Neff self compassion scale]  1  25 July 2016  
Validated questionnaire [Brief resilience scale]  1  25 July 2016  
Validated questionnaire [Liverpool seizure severity scale]  1  25 July 2016  
Validated questionnaire [Stigma scale for chronic illnesses 8 item]  1  25 July 2016  
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Appendix B - Summary of HRA Assessment 
 
This appendix provides assurance to you, the sponsor and the NHS in England that the study, as 
reviewed for HRA Approval, is compliant with relevant standards. It also provides information and 
clarification, where appropriate, to participating NHS organisations in England to assist in assessing 
and arranging capacity and capability. 
For information on how the sponsor should be working with participating NHS organisations in 
England, please refer to the, participating NHS organisations, capacity and capability and 
Allocation of responsibilities and rights are agreed and documented (4.1 of HRA assessment 
criteria) sections in this appendix.  
The following person is the sponsor contact for the purpose of addressing participating organisation 
questions relating to the study: Dr Diane Hopkins (ethics@lancaster.ac.uk, 01524592838).  
 
HRA assessment criteria  
Section HRA Assessment Criteria Compliant with 
Standards 
Comments 
1.1 IRAS application completed 
correctly 
Yes No comments 
  
    
2.1 Participant information/consent 
documents and consent 
process 
Yes No comments 
    
3.1 Protocol assessment 
 
Yes No comments 
    
4.1 Allocation of responsibilities 
and rights are agreed and 
documented  
Yes The Statement of Activities and 
Schedule of Events will act as the 
agreement between the sponsor and 





Yes Where applicable, independent 
contractors (e.g. General Practitioners) 
should ensure that the professional 
indemnity provided by their medical 
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Section HRA Assessment Criteria Compliant with 
Standards 
Comments 
defence organisation covers the 
activities expected of them for this 
research study 
4.3 Financial arrangements 
assessed  
Yes No funding will be provided to the 
participating NHS organisation.  
    
5.1 Compliance with the Data 
Protection Act and data 
security issues assessed 
Yes No comments 
5.2 CTIMPS – Arrangements for 
compliance with the Clinical 
Trials Regulations assessed 
Not Applicable No comments 
5.3 Compliance with any 
applicable laws or regulations 
Yes No comments 
    
6.1 NHS Research Ethics 
Committee favourable opinion 




6.2 CTIMPS – Clinical Trials 
Authorisation (CTA) letter 
received 
Not Applicable No comments 
6.3 Devices – MHRA notice of no 
objection received 
Not Applicable No comments 
6.4 Other regulatory approvals 
and authorisations received 
Yes No comments 
 
Participating NHS Organisations in England 
This provides detail on the types of participating NHS organisations in the study and a statement as to whether 
the activities at all organisations are the same or different.  
There is one site type. Local clinic staff will be required to assist with the identification of participants.    
Participants can complete the survey in clinic or online.  
 
Some participants may also be recruited outside the NHS. HRA Approval does not cover activity 
outside the NHS. Before recruiting outside the NHS the research team must follow the procedures 
and governance arrangements of responsible organisations.  
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The Chief Investigator or sponsor should share relevant study documents with participating NHS 
organisations in England in order to put arrangements in place to deliver the study. The documents 
should be sent to both the local study team, where applicable, and the office providing the research 
management function at the participating organisation. For NIHR CRN Portfolio studies, the Local 
LCRN contact should also be copied into this correspondence.  For further guidance on working with 
participating NHS organisations please see the HRA website. 
 
If chief investigators, sponsors or principal investigators are asked to complete site level forms for 
participating NHS organisations in England which are not provided in IRAS or on the HRA website, 
the chief investigator, sponsor or principal investigator should notify the HRA immediately at 
hra.approval@nhs.net. The HRA will work with these organisations to achieve a consistent approach 
to information provision.  
 
Confirmation of Capacity and Capability  
This describes whether formal confirmation of capacity and capability is expected from participating NHS 
organisations in England. 
Participating NHS organisations in England will be expected to formally confirm their capacity 
and capability to host this research.  
 Following issue of this letter, participating NHS organisations in England may now confirm to 
the sponsor their capacity and capability to host this research, when ready to do so. How 
capacity and capacity will be confirmed is detailed in the Allocation of responsibilities and 
rights are agreed and documented (4.1 of HRA assessment criteria) section of this appendix.  
 The Assessing, Arranging, and Confirming document on the HRA website provides further 
information for the sponsor and NHS organisations on assessing, arranging and confirming 
capacity and capability. 
 
 
Principal Investigator Suitability 
This confirms whether the sponsor position on whether a PI, LC or neither should be in place is correct for each 
type of participating NHS organisation in England and the minimum expectations for education, training and 
experience that PIs should meet (where applicable). 
A Local collaborator will be required at the participating NHS organisation to facilitate access 
arrangements for the research team where needed.  
 
GCP training is not a generic training expectation, in line with the HRA statement on training 
expectations. 
 
HR Good Practice Resource Pack Expectations 
This confirms the HR Good Practice Resource Pack expectations for the study and the pre-engagement checks 
that should and should not be undertaken 
Members of the research team who do not have a contractual relationship with the participating NHS 
organisation will require a Letter of Access to conduct study activity on NHS premises. Disclosure 
and Barring Service and Occupational Health checks will be required where a Letter of Access is 
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Other Information to Aid Study Set-up  
This details any other information that may be helpful to sponsors and participating NHS organisations in 
England to aid study set-up. 








RE: IRAS Confirmation of Capacity and Capability at  Trust
Full Study Title: What is the Relationship Between Self-Compassion 
and Depression, Anxiety, and Resilience in Adults with Epilepsy?
REC: 16/LO/1554
This email confirms that  Trust has the capacity and capability to deliver 
the above referenced study.
We agree to start this study on 1st October 2016 as per the Statement of 
Activities and the first participant should be recruited into this study by no 
later than 2nd December 2016.  If there are difficulties in meeting this 
target, please do not hesitate to contact us at  where we can offer 
advice and support.
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 Participant Information Sheet 
Version number: 1 
Date: 25/07/16 
IRAS ID: 205444 
Study Title: What is the Relationship Between Self-Compassion and Depression, 
Anxiety, and Resilience in Adults with Epilepsy? 
My name is David Baker. I am conducting this research as part of a doctoral 
programme in clinical psychology at Lancaster University. 
What is the purpose of the study? 
Research suggests that some people with epilepsy may experience depression and 
anxiety as a result of their condition.  
We would like to ask adults with epilepsy to complete a short survey about 
epilepsy, self-compassion, depression, anxiety, resilience and stigma. We want to 
find out whether self-compassion (the act of being kind to oneself) can: 
• Help to reduce depression and anxiety in people with epilepsy 
• Increase resilience in people with epilepsy 
We are also interested in whether epilepsy-related stigma is linked to self-
compassion. We hope that this will help to improve psychological care for people 
with epilepsy in the future. 
Can I take part? 
We would like to invite you to take part if you: 
• Are aged 18 or above 
• Have been diagnosed with epilepsy 
• Are able to understand English 
Do I have to take part? 
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No. Your involvement in this study is entirely voluntary. You are free to withdraw at 
any time up until you complete the survey. Once you have completed the survey it 
will not be possible to withdraw your answers, because they will be anonymous. 
What will happen if I decide to take part? 
At the beginning of the survey, we will ask you to give your consent to take part.  
We will then ask you to answer some questions about epilepsy, self-compassion, 
depression, anxiety, resilience and stigma. All your answers will be anonymous, 
and it should take around 15 minutes to complete. 
How do I take part? 
You can access the survey via the link at the bottom of this page. You may ask a 
family member, friend or carer to help you to complete the survey if needed. 
Alternatively, to receive a paper copy of the survey and a pre-paid return 
envelope, please contact David Baker: 
Email: d.baker1@lancaster.ac.uk  
Tel: on 07xxxxxxxxx (insert research phone number once known) 
Will my data be confidential? 
All data provided by you will entirely anonymous. Nobody will have access to any 
personal information that identifies you. 
Lancaster University will store the electronic survey data securely for up to 10 
years. We will input the answers from paper surveys on to our electronic survey 
software and destroy the paper copies immediately. 
What will happen to my data? 
We will analyse the survey data you provide. The results will be written up and 
submitted as part of a thesis within the Lancaster Doctorate in Clinical Psychology 
programme.  
Our findings will be shared with the charity Epilepsy Action to ensure that they are 
accessible to people with epilepsy. We also hope that the findings will be written 
up into a brief paper for submission in a relevant academic journal. 
What are the possible benefits or risks of taking part? 
We cannot guarantee any direct benefits of taking part. However, completing our 
survey may help you to reflect on your experiences. You will also be helping to 
inform our understanding of psychological care for people with epilepsy in the 
future.  
We do not anticipate any risks in taking part in this study. However, if you 
experience any distress, during or after your involvement in the research, you 
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should contact someone for support. Information on available resources can be 
found at the end of the survey. 
What if I have a complaint? 
If you have any complaints about this research, please contact the primary 
researcher, David Baker: 
Tel: 07xxxxxxxxx  
Email: d.baker1@lancaster.ac.uk 
Alternatively, to make a complaint to Lancaster University, you can contact: 
Dr Bill Sellwood, the Research Director: 
Tel: 01524 593 998 
Or 
Prof Bruce Hollingsworth, the Head of Division: 
Tel: 01524 594 154.  
For independent advice, please contact: 
Prof Roger Pickup, Associate Dean for Research: 
Tel: 01524 593 746 
Email: r.pickup@lancaster.ac.uk 
Who is involved in this research? 
The study will be undertaken by the Primary Researcher, David Baker (Trainee 
Clinical Psychologist, Doctorate in Clinical Psychology, Lancaster University, Tel: 
07xxxxxxxxx).  
The study will be supervised by the Academic Supervisor, Dr Fiona Eccles (Lecturer 
in Research Methods, Lancaster Doctorate in Clinical Psychology, Tel: 01524 
592807), and the Field Supervisor, Dr Helen Caswell (Consultant Clinical 
Neuropsychologist, Department of Clinical Neuropsychology, Salford Royal NHS 
Foundation Trust, Tel: 0161 206 2029). 
Thank you for taking the time to consider taking part in our study.  
If you would like to take part, please click on the link below to provide consent 
and take the survey: 
(LINK TO CONSENT FORM) 
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 CONSENT FORM  
Version number: 2 
Date: 01/09/16 
IRAS ID: 205444 
Title of Project:  What is the Relationship Between Self Compassion and Depression, Anxiety, and Resilience in 
Adults with Epilepsy? 
We are asking if you would like to take part in a research project about self compassion and depression, anxi-
ety and resilience in epilepsy. We are also interested in stigma in people with epilepsy. 
Before you consent to participating in the study we ask that you read the participant information sheet and 
mark each box below with your initials if you agree.  If you have any questions or queries before signing the 
consent form please speak to the principal investigator, David Baker. 
Please tick all boxes 
1. I confirm that I have read the information sheet and fully understand what is expected of 
me within this study. 
2. I confirm that I have had the opportunity to ask any questions and to have them answered. 
3. I understand that my participation is entirely voluntary and I am free to withdraw at any 
time up until I complete the survey, without my medical care or legal rights being affected. 
I understand that once I have completed the survey it will not be possible to withdraw my 
data. 
4. I understand that my responses to the survey will be anonymous and I consent for this data 
to be used for the purposes of research outlined in the participant information sheet. 
5. I consent to take part in the above study. 
            
Name of Participant  Date    Signature 
                                
            
Name of Researcher  Date    Signature 
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Participant Debrief Sheet 
Version number: 1 
Date: 13/07/16 
IRAS ID: 205444 
Thank you for taking the time to complete our survey. 
The findings of this study will be available on the Lancaster University Research website 
and on the Epilepsy Action website. 
If you feel you would benefit from any support, the following services may be able to 
help you: 
• For information about NHS therapy and counselling, or details of private therapy 
and charities, visit nhs.uk/conditions/stress-anxiety-depression/pages/free-
therapy-or-counselling.aspx 
• To speak to someone at any time, the Samaritans helpline is available 24 hours a 
day, 365 days a year: 
Tel: 08457 90 90 90 
Website: samaritans.org 
• For information and support around mental health, contact Mind: 
Tel: 0300 123 3393 (9am to 6pm, Monday to Friday (except for bank holidays)  
Website: mind.org.uk 
• For advice and information about epilepsy contact Epilepsy Action: 
Freephone: 0808 800 5050 
Website: epilepsy.org.uk 
If, at any time, you experience suicidal thoughts or thoughts of wanting to harm yourself 
or someone else, visit your GP or attend A&E.
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HOW I TYPICALLY ACT TOWARDS MYSELF IN DIFFICULT TIMES 
 
Please read each statement carefully before answering. To the left of each item, indicate how 
often you behave in the stated manner, using the following scale: 
  
     Almost                                                                                               Almost 
      never                                                                                                 always 
          1                         2                         3                         4                         5 
 
 
_____ 1.  I’m disapproving and judgmental about my own flaws and inadequacies. 
_____ 2.  When I’m feeling down I tend to obsess and fixate on everything that’s wrong. 
_____ 3.  When things are going badly for me, I see the difficulties as part of life that everyone 
goes through. 
_____ 4.  When I think about my inadequacies, it tends to make me feel more separate and cut 
off from the rest of the world. 
_____ 5.  I try to be loving towards myself when I’m feeling emotional pain. 
_____ 6.  When I fail at something important to me I become consumed by feelings of 
inadequacy. 
_____ 7. When I'm down and out, I remind myself that there are lots of other people in the world 
feeling like I am. 
_____ 8.  When times are really difficult, I tend to be tough on myself. 
_____ 9.  When something upsets me I try to keep my emotions in balance.   
_____ 10. When I feel inadequate in some way, I try to remind myself that feelings of 
inadequacy are shared by most people. 
_____ 11. I’m intolerant and impatient towards those aspects of my personality I don't like. 
_____ 12. When I’m going through a very hard time, I give myself the caring and tenderness I 
need. 
_____ 13. When I’m feeling down, I tend to feel like most other people are probably happier 
than I am. 
_____ 14. When something painful happens I try to take a balanced view of the situation. 
_____ 15. I try to see my failings as part of the human condition. 
_____ 16. When I see aspects of myself that I don’t like, I get down on myself. 
_____ 17. When I fail at something important to me I try to keep things in perspective. 
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 _____ 18. When I’m really struggling, I tend to feel like other people must be having an easier 
time of it. 
_____ 19. I’m kind to myself when I’m experiencing suffering. 
_____ 20. When something upsets me I get carried away with my feelings. 
_____ 21. I can be a bit cold-hearted towards myself when I'm experiencing suffering. 
_____ 22. When I'm feeling down I try to approach my feelings with curiosity and openness. 
_____ 23. I’m tolerant of my own flaws and inadequacies. 
_____ 24. When something painful happens I tend to blow the incident out of proportion. 
_____ 25. When I fail at something that's important to me, I tend to feel alone in my failure. 





Brief Resilience Scale (BRS) 
 
   
Please respond to each item by 
marking one box per row 
Strongly 



















I have a hard time making it through 













It does not take me long to recover 













It is hard for me to snap back when 













I usually come through difficult times 













I tend to take a long time to get over 












Scoring: Add the responses varying from 1-5 for all six items giving a range from 6-30. Divide the total 
sum by the total number of questions answered.  
 







Smith, B. W., Dalen, J., Wiggins, K., Tooley, E., Christopher, P., & Bernard, J. (2008). The brief resilience 
scale: assessing the ability to bounce back. International journal of behavioral medicine, 15(3), 194-200. 
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These findings support the validity and reliabil-
ity of using a most severe seizure scoring for data
collected with the original LSSS (a version that
collects data on major and minor seizures). To
replicate the recommended scoring procedure, re-
searchers must ask patients to report the number
of major and minor seizures experienced during
each recall period so that patients without seizures
can be assigned a severity of 0 for their LSSS
seizure severity scores.
In conclusion, our findings indicate that mea-
surement of seizure severity is an important end-
point in the clinical study of epilepsy. We propose
a modification of the LSSS and a revised scoring
system that assesses the most severe seizures that
the patient experienced during a recall period
without specifically differentiating between major
and minor seizures. Use of the revised LSSS ‘most
severe seizure’ promises to provide reliable and
responsive assessments of the impact of
antiepileptic pharmacotherapy on seizure severity.
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Appendix A
Liverpool Seizure Severity Scale 2.0
So we can better understand the severity of your seizures, please complete the following questionnaire
thinking about the most se6ere seizure you experienced during the past 4 weeks. (This may be different
for each individual, but is based on your most severe seizures over the past 4 weeks.) Your responses are
a very important part of this study and will be kept strictly CONFIDENTIAL. No one but the research
staff will see your responses. If results of this study are published, only aggregate data will be used; names
and any other identifying information will not be reported.
How many seizures have Note: Please enter ‘0’ if you have not experienced
you experienced during the any seizures in the last 4 weeks and do not com-
– – – – – –seizurespast 4 weeks? plete the remainder of the questionnaire. If you
cannot remember the exact number of seizures
you’ve experienced, please estimate based on the
number you usually had during a single day or
week.
Copyright notice: All copyrights for the Liverpool Seizure Severity Scale 2.0 are in the public domain.
Researchers and clinicians may duplicate and use this instrument as printed without restriction, except no
part of the instrument may be altered or incorporated in another measure protected by separate
copyright. The Liverpool Seizure Severity Scale 2.0 may be replicated and used without modification by
anyone without express permission of the developers. If the instrument is modified or changed from that
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Please answer each question based on the most severe seizure you have experienced in the past 4 weeks.
Circle only one answer for each question.




I never 0I blank out 32. Most com- 1 I blank I blank out for2 I blank out 4
blank out:for less thanmonly when I out for for between more than 5
1 minute between 1 3 and 5 min- lose con-minutesblank out:lose
sciousnessand 2consciousness: utes
minutes








I feel very4. After my most 0 I feel 1 I feel slightly 2 I do not feel 3
confused at allfairly con- confusedsevere confused
fusedseizures:
3 1 to 2 hoursLess than 1 41 Between 1 More than I never5. After my most 2 0Between 6 5
severe seizures minute feel con-and 5 minutes and 2 hours
my confusion fused1 hourminutes
lasts for:
3I always fall 0 I usually 16. When I have I sometimes 2 I never fall to
my most to the fall to the fall to the the ground
severe ground ground ground
seizures:
I usuallyI always 07. After my most 1 I sometimes 2 I never have a 3
have ahave a headachehave asevere
headache headacheheadacheseizures:
3I always feel 0 I usually 18. After my most I sometimes 2 I never feel
sleepysevere feel sleepy sleepyfeel sleepy
seizures:
I sometimes9. After my most I always 0 I usually 3I never find21
that I have wetfind that find that Ifind that Isevere
myselfhave wet my-seizures: have wet I have
selfmyself wet my-
self
I always 2 I never find0 I usually 310. After my 1 I sometimes
find that Imost severe that I have bit-find that find that I
I havehave bittenseizures: ten my tonguehave bitten
bitten my my tonguemy tongue
tongue
I never find111. After my I always 20 I usually 3I sometimes
find that Ifind thatfind that Imost severe that I have in-
jured myselfseizures: I have in-have injured have injured
myself (othermyself jured my- (other than bit-
self (other ing my tongue)than biting(other than
than bit- my tongue)biting my
tongue) ing my
tongue)
More than32 1 to 2 hours12. After my Less than 1 0 Between 1 41 Between 6
minutes andand 5most severe minute 2 hours
minutes 1 hourseizures I can
usually return




*The Hospital Anxiety and Depression Scale has not been included here as this is a licensed 
product. 
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